AUDOIN Bertrand
Medical Doctor (MD)
Professor (MD, PhD)
at AMU and at AP-HMPhysician in neurology department MICeME (Maladie Inflammatoire du Cerveau et de la Moelle Epinière), University Hospital of Marseille, AP-HM
Medical Doctor (MD)
Professor (MD, PhD)
Detailed Activities
Current Research Interest:
– Structural, metabolic and functional brain and spinal cord MRI to follow patients with multiple sclerosis (MS)
– Application of Ultra High Field (7T) MRI in MS
– Therapeutic approaches in MS
Research Projects
Publications :
180164
AUDOIN
1
harvard-cite-them-right-no-et-al
50
date
desc
year
2616
https://crmbm.univ-amu.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A100%2C%22request_next%22%3A50%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22J9GHBINL%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Guttieres%20et%20al.%22%2C%22parsedDate%22%3A%222025-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGuttieres%2C%20L.%2C%20Vannelli%2C%20L.%2C%20Demortiere%2C%20S.%2C%20Perriguey%2C%20M.%2C%20Elziere%2C%20M.%2C%20Durozard%2C%20P.%2C%20Boutiere%2C%20C.%2C%20Rico%2C%20A.%2C%20Hilezian%2C%20F.%2C%20Stellmann%2C%20J.-P.%2C%20Pelletier%2C%20J.%2C%20Maarouf%2C%20A.%2C%20Stolowy%2C%20N.%20and%20Audoin%2C%20B.%20%282025%29%20%26%23x2018%3BFluorescein%20Angiography%20as%20a%20Surrogate%20Marker%20of%20Disease%20Activity%20in%20Susac%20Syndrome%26%23x2019%3B%2C%20%3Ci%3ENeurology%28R%29%20Neuroimmunology%20%26amp%3B%20Neuroinflammation%3C%5C%2Fi%3E%2C%2012%282%29%2C%20p.%20e200379.%20Available%20at%3A%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200379%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200379%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Fluorescein%20Angiography%20as%20a%20Surrogate%20Marker%20of%20Disease%20Activity%20in%20Susac%20Syndrome%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%22%2C%22lastName%22%3A%22Guttieres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lea%22%2C%22lastName%22%3A%22Vannelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demortiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Perriguey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maya%22%2C%22lastName%22%3A%22Elziere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Durozard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clemence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Hilezian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan-Patrick%22%2C%22lastName%22%3A%22Stellmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Natacha%22%2C%22lastName%22%3A%22Stolowy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVES%3A%20To%20evaluate%20the%20sensitivity%20of%20fluorescein%20angiography%20%28FA%29%20in%20detecting%20disease%20activity%20in%20Susac%20syndrome.%5CnMETHODS%3A%20We%20conducted%20a%20blinded%20analysis%20of%20all%20FA%2C%20brain%20MRI%2C%20and%20audiogram%20examinations%20performed%20throughout%20the%20follow-up%20of%20patients%20with%20Susac%20syndrome.%5CnRESULTS%3A%20A%20total%20of%2079%20FA%20examinations%2C%2085%20brain%20MRI%20scans%2C%20and%2049%20audiograms%20were%20analyzed%20from%209%20patients%20followed%20for%20a%20mean%20%28SD%29%20period%20of%206%20%284%29%20years.%20Disease%20activity%20was%20detected%20in%2041.5%25%20of%20FA%20examinations%2C%2010.5%25%20of%20MRI%20scans%2C%20and%2025%25%20of%20audiograms%20%28FA%20vs%20MRI%2C%20p%20%3C%200.0001%3B%20FA%20vs%20audiogram%2C%20p%20%3D%200.06%3B%20audiogram%20vs%20MRI%2C%20p%20%3C%200.05%29.%20Within%203%20months%20of%20clinical%20relapses%2C%20activity%20was%20observed%20in%2057%25%2C%2024%25%2C%20and%2027%25%20of%20FA%2C%20MRI%2C%20and%20audiogram%20examinations%2C%20respectively%20%28FA%20vs%20MRI%2C%20p%20%3C%200.05%3B%20FA%20vs%20audiogram%2C%20p%20%3D%200.09%3B%20audiogram%20vs%20MRI%2C%20p%20%3D%201%29.%20Quantitative%20analysis%20of%20FA%20showed%20a%20mean%20%28SD%29%20of%202.5%20%282.5%29%20leakages%20%28both%20eyes%29%20during%20relapses%20compared%20with%201.2%20%281.4%29%20during%20remission%20%28p%20%3C%200.05%29.%5CnDISCUSSION%3A%20FA%2C%20particularly%20arterial%20leakage%2C%20demonstrated%20the%20highest%20sensitivity%20in%20detecting%20disease%20activity%20and%20may%20be%20a%20valuable%20tool%20for%20treatment%20management%20in%20Susac%20syndrome.%20Future%20studies%20with%20larger%20samples%20should%20aim%20to%20identify%20the%20optimal%20threshold%20of%20FA%20changes%20associated%20with%20an%20increased%20risk%20of%20relapse.%22%2C%22date%22%3A%222025-03%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FNXI.0000000000200379%22%2C%22ISSN%22%3A%222332-7812%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%2C%229L2KHJ5X%22%5D%2C%22dateModified%22%3A%222025-02-06T08%3A21%3A59Z%22%7D%7D%2C%7B%22key%22%3A%22PR8HZX9E%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Villacieros-%5Cu00c1lvarez%20et%20al.%22%2C%22parsedDate%22%3A%222025-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EVillacieros-%26%23xC1%3Blvarez%2C%20J.%2C%20Espejo%2C%20C.%2C%20Arrambide%2C%20G.%2C%20Dinoto%2C%20A.%2C%20Mulero%2C%20P.%2C%20Rubio-Flores%2C%20L.%2C%20Nieto%2C%20P.%2C%20Alcal%26%23xE1%3B%2C%20C.%2C%20Meca-Lallana%2C%20J.E.%2C%20Millan-Pascual%2C%20J.%2C%20Mart%26%23xED%3Bnez-Garc%26%23xED%3Ba%2C%20P.%2C%20Bernard-Valnet%2C%20R.%2C%20Gonz%26%23xE1%3Blez-Su%26%23xE1%3Brez%2C%20I.%2C%20Orviz%2C%20A.%2C%20T%26%23xE9%3Bllez%2C%20R.%2C%20Navarro%20Cant%26%23xF3%3B%2C%20L.%2C%20Presas-Rodr%26%23xED%3Bguez%2C%20S.%2C%20Mart%26%23xED%3Bnez-Y%26%23xE9%3Blamos%2C%20S.%2C%20Cuello%2C%20J.P.%2C%20Alonso%2C%20A.%2C%20Pi%26%23xF1%3Bar%20Morales%2C%20R.%2C%20%26%23xC1%3Blvarez%20Bravo%2C%20G.%2C%20Benyahya%2C%20L.%2C%20Trouillet-Assant%2C%20S.%2C%20Dyon-Tafan%2C%20V.%2C%20Froment%20Tilikete%2C%20C.%2C%20Ruet%2C%20A.%2C%20Bourre%2C%20B.%2C%20Deschamps%2C%20R.%2C%20Papeix%2C%20C.%2C%20Maillart%2C%20E.%2C%20Kerschen%2C%20P.%2C%20Ayrignac%2C%20X.%2C%20Rovira%2C%20%26%23xC0%3B.%2C%20Auger%2C%20C.%2C%20Audoin%2C%20B.%2C%20Montalban%2C%20X.%2C%20Tintore%2C%20M.%2C%20Mariotto%2C%20S.%2C%20Cobo-Calvo%2C%20A.%20and%20Marignier%2C%20R.%20%282025%29%20%26%23x2018%3BProfile%20and%20Usefulness%20of%20Serum%20Cytokines%20to%20Predict%20Prognosis%20in%20Myelin%20Oligodendrocyte%20Glycoprotein%20Antibody-Associated%20Disease%26%23x2019%3B%2C%20%3Ci%3ENeurology%28R%29%20Neuroimmunology%20%26amp%3B%20Neuroinflammation%3C%5C%2Fi%3E%2C%2012%282%29%2C%20p.%20e200362.%20Available%20at%3A%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200362%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200362%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Profile%20and%20Usefulness%20of%20Serum%20Cytokines%20to%20Predict%20Prognosis%20in%20Myelin%20Oligodendrocyte%20Glycoprotein%20Antibody-Associated%20Disease%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Javier%22%2C%22lastName%22%3A%22Villacieros-%5Cu00c1lvarez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carmen%22%2C%22lastName%22%3A%22Espejo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Georgina%22%2C%22lastName%22%3A%22Arrambide%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alessandro%22%2C%22lastName%22%3A%22Dinoto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patricia%22%2C%22lastName%22%3A%22Mulero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%22%2C%22lastName%22%3A%22Rubio-Flores%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pablo%22%2C%22lastName%22%3A%22Nieto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carmen%22%2C%22lastName%22%3A%22Alcal%5Cu00e1%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%20E.%22%2C%22lastName%22%3A%22Meca-Lallana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jorge%22%2C%22lastName%22%3A%22Millan-Pascual%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pedro%22%2C%22lastName%22%3A%22Mart%5Cu00ednez-Garc%5Cu00eda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raphael%22%2C%22lastName%22%3A%22Bernard-Valnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22In%5Cu00e9s%22%2C%22lastName%22%3A%22Gonz%5Cu00e1lez-Su%5Cu00e1rez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%5Cu00edda%22%2C%22lastName%22%3A%22Orviz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raquel%22%2C%22lastName%22%3A%22T%5Cu00e9llez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%22%2C%22lastName%22%3A%22Navarro%20Cant%5Cu00f3%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Silvia%22%2C%22lastName%22%3A%22Presas-Rodr%5Cu00edguez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sergio%22%2C%22lastName%22%3A%22Mart%5Cu00ednez-Y%5Cu00e9lamos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20Pablo%22%2C%22lastName%22%3A%22Cuello%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ana%22%2C%22lastName%22%3A%22Alonso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raquel%22%2C%22lastName%22%3A%22Pi%5Cu00f1ar%20Morales%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gary%22%2C%22lastName%22%3A%22%5Cu00c1lvarez%20Bravo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lakhdar%22%2C%22lastName%22%3A%22Benyahya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Trouillet-Assant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Dyon-Tafan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Froment%20Tilikete%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Ruet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Deschamps%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Papeix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Kerschen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Ayrignac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%5Cu00c0lex%22%2C%22lastName%22%3A%22Rovira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cristina%22%2C%22lastName%22%3A%22Auger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Montalban%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mar%22%2C%22lastName%22%3A%22Tintore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sara%22%2C%22lastName%22%3A%22Mariotto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alvaro%22%2C%22lastName%22%3A%22Cobo-Calvo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Marignier%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVES%3A%20To%20characterize%20the%20serum%20cytokine%20profile%20in%20myelin%20oligodendrocyte%20glycoprotein%20antibody-associated%20disease%20%28MOGAD%29%20at%20onset%20and%20during%20follow-up%20and%20assess%20their%20utility%20for%20predicting%20relapses%20and%20disability.%5CnMETHODS%3A%20This%20retrospective%20multicentric%20cohort%20study%20included%20patients%20aged%2016%20years%20and%20older%20meeting%20MOGAD%202023%20criteria%2C%20with%20serum%20samples%20collected%20at%20baseline%20%28%5Cu22643%20months%20from%20disease%20onset%29%20and%20follow-up%20%28%5Cu22656%20months%20from%20the%20baseline%29%2C%20and%20age-matched%20and%20time%20to%20sampling-matched%20patients%20with%20multiple%20sclerosis%20%28MS%29.%20Eleven%20cytokines%20were%20assessed%20using%20the%20ELLA%20system.%20Data%20comparisons%20and%20statistical%20analyses%20between%20cytokine%20levels%20and%20clinical%20outcomes%20were%20performed.%5CnRESULTS%3A%20Eighty-eight%20patients%20with%20MOGAD%20and%2032%20patients%20with%20MS%20were%20included.%20Patients%20with%20MOGAD%20showed%20higher%20IL6%20%28p%20%3D%200.036%29%2C%20IL8%20%28p%20%3D%200.012%29%2C%20and%20IL18%20%28p%20%3D%200.026%29%20baseline%20levels%20compared%20with%20those%20with%20MS%2C%20in%20non-optic%20neuritis%20%28ON%29%20presentations.%20BAFF%20values%20increased%20over%20time%2C%20especially%20in%20patients%20with%20MOGAD%20treated%20with%20anti-CD20%20%28p%20%3D%200.002%29.%20Baseline%20BAFF%2C%20CXCL10%2C%20IL10%2C%20and%20IL8%20levels%20correlated%20with%20disease%20severity%20at%20MOGAD%20onset%20%28all%20p%20%3C%200.05%29.%20Finally%2C%20higher%20baseline%20BAFF%20levels%20predicted%20lower%20risk%20of%20relapses%20%28hazard%20ratio%200.41%20%5B0.19%3B%200.89%5D%2C%20p%20%3D%200.024%29.%5CnDISCUSSION%3A%20This%20study%20suggests%20a%20proinflammatory%20Th17-dominant%20profile%20in%20non-ON%20MOGAD%20patients%2C%20with%20a%20novel%20finding%20of%20a%20potential%20protective%20role%20of%20BAFF%20on%20relapses.%20These%20results%20shed%20new%20light%20on%20the%20pathogenesis%20of%20MOGAD%2C%20potentially%20guiding%20therapeutic%20decisions.%22%2C%22date%22%3A%222025-03%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FNXI.0000000000200362%22%2C%22ISSN%22%3A%222332-7812%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226KPLZTET%22%5D%2C%22dateModified%22%3A%222025-01-06T08%3A55%3A53Z%22%7D%7D%2C%7B%22key%22%3A%22N4FVE92U%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ramdani%20et%20al.%22%2C%22parsedDate%22%3A%222025-01-15%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ERamdani%2C%20R.%2C%20Pique%2C%20J.%2C%20Deschamps%2C%20R.%2C%20Ciron%2C%20J.%2C%20Maillart%2C%20E.%2C%20Audoin%2C%20B.%2C%20Cohen%2C%20M.%2C%20Zephir%2C%20H.%2C%20Laplaud%2C%20D.%2C%20Ayrignac%2C%20X.%2C%20Collongues%2C%20N.%2C%20Ruet%2C%20A.%2C%20Thouvenot%2C%20E.%2C%20Bourre%2C%20B.%2C%20Papeix%2C%20C.%2C%20Benyahya%2C%20L.%2C%20Marignier%2C%20R.%20and%20NOMADMUS%20Study%20Group%20%282025%29%20%26%23x2018%3BEvaluation%20of%20the%20predictive%20value%20of%20CSF-restricted%20oligoclonal%20bands%20on%20residual%20disability%20and%20risk%20of%20relapse%20in%20adult%20patients%20with%20MOGAD%3A%20MOGADOC%20study%26%23x2019%3B%2C%20%3Ci%3EMultiple%20Sclerosis%20%28Houndmills%2C%20Basingstoke%2C%20England%29%3C%5C%2Fi%3E%2C%20p.%2013524585241311436.%20Available%20at%3A%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F13524585241311435%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F13524585241311435%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Evaluation%20of%20the%20predictive%20value%20of%20CSF-restricted%20oligoclonal%20bands%20on%20residual%20disability%20and%20risk%20of%20relapse%20in%20adult%20patients%20with%20MOGAD%3A%20MOGADOC%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ryan%22%2C%22lastName%22%3A%22Ramdani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Pique%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Deschamps%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikael%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Zephir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Laplaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Ayrignac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Collongues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Ruet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Thouvenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Papeix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lakhdar%22%2C%22lastName%22%3A%22Benyahya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Marignier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22NOMADMUS%20Study%20Group%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20clinical%20course%20of%20myelin%20oligodendrocyte%20glycoprotein%20%28MOG%29%20antibody-associated%20disease%20%28MOGAD%29%20is%20variable.%20However%2C%20robust%20markers%20of%20poor%20outcome%20and%5C%2For%20relapse%20risk%20are%20still%20missing.%5CnOBJECTIVE%3A%20To%20evaluate%20the%20frequency%20of%20cerebrospinal%20fluid-restricted%20oligoclonal%20bands%20%28CSF-OCB%29%20in%20a%20national%20cohort%20of%20adult%20MOGAD%20patients%20and%20to%20assess%20their%20prognostic%20value%20for%20the%20risk%20of%20relapse%20and%20severity.%5CnMETHODS%3A%20We%20included%20MOGAD%20adult%20patients%20fulfilling%20the%20MOGAD%202023%20criteria%20who%20underwent%20CSF%20analysis%20at%20maximum%203%20months%20from%20onset.%5CnRESULTS%3A%20Data%20from%20190%20patients%20were%20collected.%20We%20found%20the%20presence%20of%20CSF-OCB%20in%2032%20patients%20%2816.8%25%29.%20Positive%20and%20negative%20CSF-OCB%20patients%20were%20similar%20for%20median%20age%20at%20onset%2C%20sex%2C%20clinical%20presentation%2C%20severity%20at%20onset%2C%20and%20residual%20disability.%20Relapses%20were%20more%20frequent%20in%20the%20CSF-OCB%2B%20group%20%28p%20%3D%200.049%29%2C%20particularly%20within%20the%20first%20year%20of%20follow-up%20%28p%20%3D%200.007%29.%20Although%20CSF-OCB%2B%20was%20more%20frequently%20associated%20with%20imaging%20features%20suggestive%20of%20multiple%20sclerosis%20%28MS%29%20%28p%20%3D%200.014%29%2C%2078%25%20of%20these%20patients%20fulfilled%20the%202023%20supportive%20features%20and%2065%25%20experienced%20lesion%20vanishing%20at%20follow-up%20magnetic%20resonance%20imaging%20%28MRI%29.%5CnCONCLUSION%3A%20We%20found%20a%20higher%20risk%20of%20relapse%20in%20MOGAD%20with%20CSF-OCB%20particularly%20during%20the%20first%20year.%20Close%20attention%20is%20recommended%20regarding%20the%20risk%20of%20misdiagnosis%20with%20MS.%22%2C%22date%22%3A%222025-01-15%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1177%5C%2F13524585241311435%22%2C%22ISSN%22%3A%221477-0970%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226KPLZTET%22%5D%2C%22dateModified%22%3A%222025-01-16T13%3A54%3A16Z%22%7D%7D%2C%7B%22key%22%3A%22F2ENYVDV%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Androdias%20et%20al.%22%2C%22parsedDate%22%3A%222024-12-21%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EAndrodias%2C%20G.%2C%20L%26%23xFC%3Bnemann%2C%20J.D.%2C%20Maillart%2C%20E.%2C%20Amato%2C%20M.P.%2C%20Audoin%2C%20B.%2C%20Bruijstens%2C%20A.L.%2C%20Bsteh%2C%20G.%2C%20Butzkueven%2C%20H.%2C%20Ciccarelli%2C%20O.%2C%20Cobo-Calvo%2C%20A.%2C%20Derfuss%2C%20T.%2C%20Di%20Pauli%2C%20F.%2C%20Edan%2C%20G.%2C%20Enzinger%2C%20C.%2C%20Geraldes%2C%20R.%2C%20Granziera%2C%20C.%2C%20Hacohen%2C%20Y.%2C%20Hartung%2C%20H.-P.%2C%20Hynes%2C%20S.%2C%20Inglese%2C%20M.%2C%20Kappos%2C%20L.%2C%20Kuusisto%2C%20H.%2C%20Langer-Gould%2C%20A.%2C%20Magyari%2C%20M.%2C%20Marignier%2C%20R.%2C%20Montalban%2C%20X.%2C%20Mycko%2C%20M.P.%2C%20Nourbakhsh%2C%20B.%2C%20Oh%2C%20J.%2C%20Oreja-Guevara%2C%20C.%2C%20Piehl%2C%20F.%2C%20Prosperini%2C%20L.%2C%20Sastre-Garriga%2C%20J.%2C%20Sellebjerg%2C%20F.%2C%20Selmaj%2C%20K.%2C%20Siva%2C%20A.%2C%20Tallantyre%2C%20E.%2C%20van%20Pesch%2C%20V.%2C%20Vukusic%2C%20S.%2C%20Weinstock-Guttman%2C%20B.%2C%20Zipp%2C%20F.%2C%20Tintor%26%23xE9%3B%2C%20M.%2C%20Iacobaeus%2C%20E.%20and%20Stankoff%2C%20B.%20%282024%29%20%26%23x2018%3BDe-escalating%20and%20discontinuing%20disease-modifying%20therapies%20in%20multiple%20sclerosis%26%23x2019%3B%2C%20%3Ci%3EBrain%3C%5C%2Fi%3E%2C%20p.%20awae409.%20Available%20at%3A%20%3Ca%20class%3D%27zp-ItemURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fbrain%5C%2Fawae409%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fbrain%5C%2Fawae409%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22De-escalating%20and%20discontinuing%20disease-modifying%20therapies%20in%20multiple%20sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%5Cu00e9raldine%22%2C%22lastName%22%3A%22Androdias%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan%20D%22%2C%22lastName%22%3A%22L%5Cu00fcnemann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20Pia%22%2C%22lastName%22%3A%22Amato%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arlette%20L%22%2C%22lastName%22%3A%22Bruijstens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriel%22%2C%22lastName%22%3A%22Bsteh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helmut%22%2C%22lastName%22%3A%22Butzkueven%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olga%22%2C%22lastName%22%3A%22Ciccarelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alvaro%22%2C%22lastName%22%3A%22Cobo-Calvo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tobias%22%2C%22lastName%22%3A%22Derfuss%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franziska%22%2C%22lastName%22%3A%22Di%20Pauli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Edan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Enzinger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ruth%22%2C%22lastName%22%3A%22Geraldes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cristina%22%2C%22lastName%22%3A%22Granziera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yael%22%2C%22lastName%22%3A%22Hacohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hans-Peter%22%2C%22lastName%22%3A%22Hartung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sin%5Cu00e9ad%22%2C%22lastName%22%3A%22Hynes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matilde%22%2C%22lastName%22%3A%22Inglese%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ludwig%22%2C%22lastName%22%3A%22Kappos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hanna%22%2C%22lastName%22%3A%22Kuusisto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Annette%22%2C%22lastName%22%3A%22Langer-Gould%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Melinda%22%2C%22lastName%22%3A%22Magyari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Marignier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Montalban%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcin%20P%22%2C%22lastName%22%3A%22Mycko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bardia%22%2C%22lastName%22%3A%22Nourbakhsh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jiwon%22%2C%22lastName%22%3A%22Oh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Celia%22%2C%22lastName%22%3A%22Oreja-Guevara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fredrik%22%2C%22lastName%22%3A%22Piehl%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luca%22%2C%22lastName%22%3A%22Prosperini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jaume%22%2C%22lastName%22%3A%22Sastre-Garriga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Finn%22%2C%22lastName%22%3A%22Sellebjerg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Krzysztof%22%2C%22lastName%22%3A%22Selmaj%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aksel%22%2C%22lastName%22%3A%22Siva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emma%22%2C%22lastName%22%3A%22Tallantyre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22van%20Pesch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bianca%22%2C%22lastName%22%3A%22Weinstock-Guttman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frauke%22%2C%22lastName%22%3A%22Zipp%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mar%22%2C%22lastName%22%3A%22Tintor%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ellen%22%2C%22lastName%22%3A%22Iacobaeus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Stankoff%22%7D%5D%2C%22abstractNote%22%3A%22The%20development%20of%20disease-modifying%20therapies%20%28DMTs%29%20for%20the%20treatment%20of%20multiple%20sclerosis%20%28MS%29%20has%20been%20highly%20successful%20in%20recent%20decades.%20It%20is%20now%20widely%20accepted%20that%20early%20initiation%20of%20DMTs%20after%20disease%20onset%20is%20associated%20with%20a%20better%20long-term%20prognosis.%20However%2C%20the%20question%20of%20when%20and%20how%20to%20de-escalate%20or%20discontinue%20DMTs%20remains%20open%20and%20critical.%20This%20topic%20was%20discussed%20during%20an%20international%20focused%20workshop%20organized%20by%20the%20European%20Committee%20for%20Treatment%20and%20Research%20in%20Multiple%20Sclerosis%20%28ECTRIMS%29%20in%202023.%20The%20aim%20was%20to%20review%20the%20current%20evidence%20on%20the%20rationale%20for%2C%20but%20also%20the%20potential%20pitfalls%20of%2C%20treatment%20de-escalation%20in%20MS.%20Several%20clinical%20scenarios%20emerged%2C%20mainly%20driven%20by%20a%20change%20in%20the%20benefit-risk%20ratio%20of%20DMTs%20over%20the%20course%20of%20the%20disease%20and%20with%20aging.%20The%20workshop%20also%20addressed%20the%20issue%20of%20de-escalation%20by%20the%20type%20of%20DMT%20used%20and%20in%20specific%20situations%20including%20pregnancy%20and%20paediatric%20onset%20MS.%20Finally%2C%20we%20provide%20practical%20guidelines%20for%20selecting%20appropriate%20patients%2C%20defining%20de-escalation%20and%20monitoring%20modalities%2C%20and%20outline%20unmet%20needs%20in%20this%20field.%22%2C%22date%22%3A%222024-12-21%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Fbrain%5C%2Fawae409%22%2C%22ISSN%22%3A%220006-8950%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fbrain%5C%2Fawae409%22%2C%22collections%22%3A%5B%226KPLZTET%22%5D%2C%22dateModified%22%3A%222025-01-16T14%3A01%3A13Z%22%7D%7D%2C%7B%22key%22%3A%22CHX847WV%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Durozard%20et%20al.%22%2C%22parsedDate%22%3A%222024-11%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDurozard%2C%20P.%2C%20Maarouf%2C%20A.%2C%20Zaaraoui%2C%20W.%2C%20Stellmann%2C%20J.-P.%2C%20Bouti%26%23xE8%3Bre%2C%20C.%2C%20Rico%2C%20A.%2C%20Demorti%26%23xE8%3Bre%2C%20S.%2C%20Guye%2C%20M.%2C%20Le%20Troter%2C%20A.%2C%20Dary%2C%20H.%2C%20Ranjeva%2C%20J.-P.%2C%20Audoin%2C%20B.%20and%20Pelletier%2C%20J.%20%282024%29%20%26%23x2018%3BCortical%20Lesions%20as%20an%20Early%20Hallmark%20of%20Multiple%20Sclerosis%3A%20Visualization%20by%207%20T%20MRI%26%23x2019%3B%2C%20%3Ci%3EInvestigative%20Radiology%3C%5C%2Fi%3E%2C%2059%2811%29%2C%20p.%20747.%20Available%20at%3A%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FRLI.0000000000001082%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FRLI.0000000000001082%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cortical%20Lesions%20as%20an%20Early%20Hallmark%20of%20Multiple%20Sclerosis%3A%20Visualization%20by%207%20T%20MRI%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Durozard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wafaa%22%2C%22lastName%22%3A%22Zaaraoui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan-Patrick%22%2C%22lastName%22%3A%22Stellmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mence%22%2C%22lastName%22%3A%22Bouti%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demorti%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Guye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Le%20Troter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hugo%22%2C%22lastName%22%3A%22Dary%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Ranjeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%5D%2C%22abstractNote%22%3A%22Objectives%5Cu00a0%5Cn%20%20%20%20%20%20%20%20%20%20Compelling%20evidence%20indicates%20a%20significant%20involvement%20of%20cortical%20lesions%20in%20the%20progressive%20phase%20of%20multiple%20sclerosis%20%28MS%29%2C%20significantly%20contributing%20to%20late-stage%20disability.%20Despite%20the%20promise%20of%20ultra-high-field%20magnetic%20resonance%20imaging%20%28MRI%29%20in%20detecting%20cortical%20lesions%2C%20current%20evidence%20falls%20short%20in%20providing%20insights%20into%20the%20existence%20of%20such%20lesions%20during%20the%20early%20stages%20of%20MS%20or%20their%20underlying%20cause.%20This%20study%20delineated%2C%20at%20the%20early%20stage%20of%20MS%2C%20%281%29%20the%20prevalence%20and%20spatial%20distribution%20of%20cortical%20lesions%20identified%20by%207%20T%20MRI%2C%20%282%29%20their%20relationship%20with%20white%20matter%20lesions%2C%20and%20%283%29%20their%20clinical%20implications.%5Cn%20%20%20%20%20%20%20%20%20%20Materials%20and%20Methods%5Cu00a0%5Cn%20%20%20%20%20%20%20%20%20%20Twenty%20individuals%20with%20early-stage%20relapsing-remitting%20MS%20%28disease%20duration%20%3C1%20year%29%20underwent%20a%207%20T%20MRI%20session%20involving%20T1-weighted%20MP2RAGE%2C%20T2%2A-weighted%20multiGRE%2C%20and%20T2-weighted%20FLAIR%20sequences%20for%20cortical%20and%20white%20matter%20segmentation.%20Disability%20assessments%20included%20the%20Expanded%20Disability%20Status%20Scale%2C%20the%20Multiple%20Sclerosis%20Functional%20Composite%2C%20and%20an%20extensive%20evaluation%20of%20cognitive%20function.%5Cn%20%20%20%20%20%20%20%20%20%20Results%5Cu00a0%5Cn%20%20%20%20%20%20%20%20%20%20Cortical%20lesions%20were%20detected%20in%2015%20of%2020%20patients%20%2875%25%29.%20MP2RAGE%20revealed%20a%20total%20of%20190%20intracortical%20lesions%20%28median%2C%204%20lesions%5C%2Fcase%20%5Brange%2C%200%5Cu201344%5D%29%20and%20216%20leukocortical%20lesions%20%28median%2C%202%20lesions%5C%2Fcase%20%5Brange%2C%200%5Cu201375%5D%29.%20Although%20the%20number%20of%20white%20matter%20lesions%20correlated%20with%20the%20total%20number%20of%20leukocortical%20lesions%20%28r%20%3D%200.91%2C%20P%20%3C%200.001%29%2C%20no%20correlation%20was%20observed%20between%20the%20number%20of%20white%20matter%20or%20leukocortical%20lesions%20and%20the%20number%20of%20intracortical%20lesions.%20Furthermore%2C%20the%20number%20of%20leukocortical%20lesions%20but%20not%20intracortical%20or%20white-matter%20lesions%20was%20significantly%20correlated%20with%20cognitive%20impairment%20%28r%20%3D%200.63%2C%20P%20%3D%200.04%2C%20corrected%20for%20multiple%20comparisons%29.%5Cn%20%20%20%20%20%20%20%20%20%20Conclusions%5Cu00a0%5Cn%20%20%20%20%20%20%20%20%20%20This%20study%20highlights%20the%20notable%20prevalence%20of%20cortical%20lesions%20at%20the%20early%20stage%20of%20MS%20identified%20by%207%20T%20MRI.%20There%20may%20be%20a%20potential%20divergence%20in%20the%20underlying%20pathophysiological%20mechanisms%20driving%20distinct%20lesion%20types%2C%20notably%20between%20intracortical%20lesions%20and%20white%20matter%5C%2Fleukocortical%20lesions.%20Moreover%2C%20during%20the%20early%20disease%20phase%2C%20leukocortical%20lesions%20more%20effectively%20accounted%20for%20cognitive%20deficits.%22%2C%22date%22%3A%22November%202024%22%2C%22language%22%3A%22en-US%22%2C%22DOI%22%3A%2210.1097%5C%2FRLI.0000000000001082%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fjournals.lww.com%5C%2Finvestigativeradiology%5C%2Fabstract%5C%2F2024%5C%2F11000%5C%2Fcortical_lesions_as_an_early_hallmark_of_multiple.1.aspx%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22UP3H3ICX%22%2C%22B4EWFM7E%22%2C%225P5FWCR9%22%2C%226KPLZTET%22%2C%229L2KHJ5X%22%2C%22XTA6KS7L%22%5D%2C%22dateModified%22%3A%222025-01-15T08%3A57%3A51Z%22%7D%7D%2C%7B%22key%22%3A%22EFR2IKPY%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Maarouf%20et%20al.%22%2C%22parsedDate%22%3A%222024-05-06%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMaarouf%2C%20A.%2C%20Stellmann%2C%20J.P.%2C%20Rico%2C%20A.%2C%20Boutiere%2C%20C.%2C%20Demortiere%2C%20S.%2C%20Durozard%2C%20P.%2C%20Zaaraoui%2C%20W.%2C%20Ranjeva%2C%20J.-P.%2C%20Pelletier%2C%20J.%20and%20Audoin%2C%20B.%20%282024%29%20%26%23x2018%3BActive%20and%20non-active%20progression%20independent%20of%20relapse%20activity%20within%20the%20first%2020%20years%20of%20relapsing%20multiple%20sclerosis%26%23x2019%3B%2C%20%3Ci%3EJournal%20of%20Neurology%2C%20Neurosurgery%2C%20and%20Psychiatry%3C%5C%2Fi%3E%2C%20p.%20jnnp-2024-333597.%20Available%20at%3A%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fjnnp-2024-333597%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fjnnp-2024-333597%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Active%20and%20non-active%20progression%20independent%20of%20relapse%20activity%20within%20the%20first%2020%20years%20of%20relapsing%20multiple%20sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan%20Patrick%22%2C%22lastName%22%3A%22Stellmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clemence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demortiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Durozard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wafaa%22%2C%22lastName%22%3A%22Zaaraoui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Ranjeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Progression%20independent%20of%20relapse%20activity%20%28PIRA%29%20has%20been%20described%20since%20the%20early%20stage%20of%20relapsing%20multiple%20sclerosis%20%28RMS%29.%20However%2C%20little%20is%20known%20about%20the%20relation%20between%20PIRA%20and%20inflammatory%20activity%20that%20is%20particularly%20important%20at%20this%20stage%20of%20the%20disease.%5CnMETHOD%3A%20We%20included%20110%20patients%20in%20a%20prospective%20study%20within%2018%20months%20of%20RMS%20onset.%20MRI%20examinations%20and%20clinical%20visits%20were%20scheduled%20on%20the%20same%20day%20for%20months%200%2C%206%2C%2012%2C%2024%2C%2036%2C%2060%2C%2084%2C%20120%2C%20180%20and%20240.%5CnRESULTS%3A%20The%20mean%20%28SD%29%20age%20of%20patients%20was%2030%20%286.7%29%20years%20at%20inclusion%20and%20median%20%28range%29%20follow-up%2015%20%289-20%29%20years.%20Analysis%20of%201118%20between-visit%20intervals%20revealed%2093%20confirmed%20disability%20accumulation%20events%20in%2068%20%2862%25%29%20patients%3A%2050%20%2854%25%29%20events%20related%20to%20relapse%20activity%20worsening%20and%2043%20%2846%25%29%20PIRA%20events%2C%20including%2017%20%2818%25%29%20with%20MRI%20activity.%20The%20risk%20of%20PIRA%20between%20two%20visits%20%28stable%20event%20as%20the%20reference%20category%29%20was%20associated%20with%20Expanded%20Disability%20Status%20Scale%20%28EDSS%29%20score%20%28HR%3A%201.41%3B%2095%25%20CI%3A%201.18%20to%201.69%3B%20p%3C0.001%29%2C%20disease%20duration%20%28HR%3A%200.75%3B%2095%25%5Cu2009CI%3A%200.62%20to%200.90%3B%20p%3C0.005%29%20and%20new%20lesions%20between%20the%20visits%20%28HR%3A%201.09%20per%20lesion%3B%2095%25%5Cu2009CI%3A%201.01%20to%201.17%3B%20p%3C0.05%29.%20As%20compared%20with%20PIRA%20events%20with%20MRI%20activity%2C%20PIRA%20events%20without%20such%20activity%20occurred%20in%20patients%20with%20more%20disability%20%28mean%20EDSS%20score%203%2C%20p%3C0.05%29%2C%20longer%20disease%20duration%20%28mean%2011%20years%2C%20p%3C0.001%29%20and%20greater%20number%20of%20T2-weighted%20lesions%20%28p%3C0.05%29.%5CnCONCLUSION%3A%20This%20study%20evidenced%20that%20inflammatory%20activity%20increases%20the%20risk%20of%20PIRA%20in%20early%20RMS%2C%20arguing%20that%20a%20significant%20part%20of%20PIRA%20is%20accessible%20to%20treatment%20targeting%20inflammation%20in%20these%20patients.%22%2C%22date%22%3A%222024-05-06%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1136%5C%2Fjnnp-2024-333597%22%2C%22ISSN%22%3A%221468-330X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22UP3H3ICX%22%2C%22B4EWFM7E%22%2C%22P66W67T8%22%2C%226KPLZTET%22%2C%229L2KHJ5X%22%5D%2C%22dateModified%22%3A%222025-01-15T08%3A57%3A53Z%22%7D%7D%2C%7B%22key%22%3A%225G3SGMDG%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Graille-Avy%20et%20al.%22%2C%22parsedDate%22%3A%222024-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGraille-Avy%2C%20L.%2C%20Boutiere%2C%20C.%2C%20Rigollet%2C%20C.%2C%20Perriguey%2C%20M.%2C%20Rico%2C%20A.%2C%20Demortiere%2C%20S.%2C%20Durozard%2C%20P.%2C%20Hilezian%2C%20F.%2C%20Vely%2C%20F.%2C%20Bertault-Peres%2C%20P.%2C%20Pelletier%2C%20J.%2C%20Maarouf%2C%20A.%20and%20Audoin%2C%20B.%20%282024%29%20%26%23x2018%3BEffect%20of%20Prior%20Treatment%20With%20Fingolimod%20on%20Early%20and%20Late%20Response%20to%20Rituximab%5C%2FOcrelizumab%20in%20Patients%20With%20Multiple%20Sclerosis%26%23x2019%3B%2C%20%3Ci%3ENeurology%28R%29%20Neuroimmunology%20%26amp%3B%20Neuroinflammation%3C%5C%2Fi%3E%2C%2011%283%29%2C%20p.%20e200231.%20Available%20at%3A%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200231%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200231%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Effect%20of%20Prior%20Treatment%20With%20Fingolimod%20on%20Early%20and%20Late%20Response%20to%20Rituximab%5C%2FOcrelizumab%20in%20Patients%20With%20Multiple%20Sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lisa%22%2C%22lastName%22%3A%22Graille-Avy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clemence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Rigollet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Perriguey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demortiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Durozard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Hilezian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Vely%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Bertault-Peres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20OBJECTIVES%3A%20Real-life%20studies%20noted%20that%20the%20risk%20of%20disease%20activity%20in%20multiple%20sclerosis%20%28MS%29%20after%20switching%20to%20rituximab%20%28RTX%29%20or%20ocrelizumab%20%28OCR%29%20may%20be%20unequal%20depending%20on%20prior%20disease-modifying%20therapy%20%28DMT%29%2C%20with%20a%20higher%20risk%20associated%20with%20fingolimod%20%28FING%29.%5CnMETHODS%3A%20We%20performed%20a%20retrospective%20analysis%20of%20a%20structured%20prospective%20data%20collection%20including%20all%20consecutive%20patients%20with%20relapsing%20MS%20who%20were%20prescribed%20RTX%5C%2FOCR%20in%20the%20MS%20center%20of%20Marseille.%20Cox%20proportional%20hazards%20models%20were%20applied%20to%20clinical%20and%20MRI%20outcomes.%5CnRESULTS%3A%20We%20included%20321%20patients%20with%20a%20median%20%28interquartile%20range%20%5BIQR%5D%29%20follow-up%20of%203.5%20years%20%281.5-5%29%20after%20RTX%5C%2FOCR%20initiation.%20At%20the%20first%20RTX%5C%2FOCR%20infusion%2C%20the%20mean%20%28SD%29%20age%20of%20patients%20was%2037%20%2810%29%20years%2C%20and%20the%20median%20%28IQR%29%20disease%20duration%20was%208%20years%20%283-15%29%3A%2068%20patients%20did%20not%20receive%20treatment%20before%20RTX%5C%2FOCR%20and%20108%20switched%20from%20FING%2C%2047%20from%20low%20efficacy%20therapy%2C%20and%2098%20from%20natalizumab.%20For%20statistical%20analysis%2C%20the%20group%20%5C%22FING%5C%22%20was%20divided%20into%20%5C%22short-FING%5C%22%20and%20%5C%22long-FING%5C%22%20groups%20according%20to%20the%20median%20value%20of%20the%20group%27s%20washout%20period%20%2827%20days%29.%20On%20Cox%20proportional%20hazards%20analysis%2C%20for%20only%20the%20%5C%22long-FING%5C%22%20group%2C%20the%20risk%20of%20relapse%20within%20the%20first%206%20months%20of%20RTX%5C%2FOCR%20was%20increased%20as%20compared%20with%20patients%20without%20previous%20DMT%20%28hazard%20ratio%20%5BHR%5D%3A%208.78%3B%2095%25%20CI%201.72-44.86%3B%20p%20%3C%200.01%29.%20Previous%20DMT%20and%20washout%20period%20duration%20of%20FING%20had%20no%20effect%20on%20B-cell%20levels%20at%206%20months.%20Beyond%20the%20first%206%20months%20of%20RTX%5C%2FOCR%2C%20age%20%3C40%20years%20was%20associated%20with%20increased%20risk%20of%20relapse%20%28HR%3A%203.93%3B%2095%25%20CI%201.30-11.89%3B%20p%20%3D%200.01%29%2C%20male%20sex%20with%20increased%20risk%20of%20new%20T2%20lesions%20%28HR%3A%202.26%3B%2095%25%20CI%201.08-4.74%3B%20p%20%3D%200.03%29%2C%20and%20EDSS%20%5Cu22652%20with%20increased%20risk%20of%20disability%20accumulation%20%28HR%3A%203.01%3B%2095%25%20CI%201.34-6.74%3B%20p%20%3C%200.01%29.%20Previous%20DMT%20had%20no%20effect%20on%20the%20effectiveness%20of%20RTX%5C%2FOCR%20beyond%206%20months%20after%20initiation.%5CnDISCUSSION%3A%20For%20patients%20switching%20from%20FING%20to%20RTX%5C%2FOCR%2C%20the%20risk%20of%20disease%20reactivation%20within%20the%20first%206%20months%20of%20treatment%20was%20increased%20as%20compared%20with%20patients%20with%20other%20DMT%20or%20no%20previous%20DMT%20only%20when%20the%20washout%20period%20exceeded%2026%20days.%20Neither%20FING%20nor%20other%20previous%20DMT%20reduced%20the%20effectiveness%20of%20RTX%5C%2FOCR%20beyond%20the%20first%206%20months%20of%20treatment.%22%2C%22date%22%3A%222024-05%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FNXI.0000000000200231%22%2C%22ISSN%22%3A%222332-7812%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%5D%2C%22dateModified%22%3A%222024-04-22T09%3A30%3A59Z%22%7D%7D%2C%7B%22key%22%3A%22NMDESKDG%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Demortiere%20et%20al.%22%2C%22parsedDate%22%3A%222024-04-23%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDemortiere%2C%20S.%2C%20Joubert%2C%20B.%2C%20Benaiteau%2C%20M.%2C%20Hilezian%2C%20F.%2C%20Boutiere%2C%20C.%2C%20Rico%2C%20A.%2C%20Stolowy%2C%20N.%2C%20Dubois%2C%20V.%2C%20Audoin%2C%20B.%2C%20Maarouf%2C%20A.%20and%20Pelletier%2C%20J.%20%282024%29%20%26%23x2018%3BAnti-IgLON5%20Disease%20With%20Inaugural%20Bilateral%20Neuropapillitis%26%23x2019%3B%2C%20%3Ci%3ENeurology%3C%5C%2Fi%3E%2C%20102%288%29%2C%20p.%20e209284.%20Available%20at%3A%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FWNL.0000000000209284%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FWNL.0000000000209284%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Anti-IgLON5%20Disease%20With%20Inaugural%20Bilateral%20Neuropapillitis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demortiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bastien%22%2C%22lastName%22%3A%22Joubert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Benaiteau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Hilezian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clemence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Natacha%22%2C%22lastName%22%3A%22Stolowy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valerie%22%2C%22lastName%22%3A%22Dubois%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222024-04-23%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FWNL.0000000000209284%22%2C%22ISSN%22%3A%221526-632X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%5D%2C%22dateModified%22%3A%222024-03-29T08%3A57%3A08Z%22%7D%7D%2C%7B%22key%22%3A%22JVQG8Z5Y%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Cruz%20et%20al.%22%2C%22parsedDate%22%3A%222024-03-26%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ECruz%2C%20E.S.%2C%20Fortanier%2C%20E.%2C%20Hilezian%2C%20F.%2C%20Maarouf%2C%20A.%2C%20Bouti%26%23xE8%3Bre%2C%20C.%2C%20Demorti%26%23xE8%3Bre%2C%20S.%2C%20Rico%2C%20A.%2C%20Delmont%2C%20E.%2C%20Pelletier%2C%20J.%2C%20Attarian%2C%20S.%20and%20Audoin%2C%20B.%20%282024%29%20%26%23x2018%3BFactors%20affecting%20the%20topography%20of%20nitrous%20oxide-induced%20neurological%20complications%26%23x2019%3B%2C%20%3Ci%3EEuropean%20Journal%20of%20Neurology%3C%5C%2Fi%3E%2C%20p.%20e16291.%20Available%20at%3A%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fene.16291%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fene.16291%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Factors%20affecting%20the%20topography%20of%20nitrous%20oxide-induced%20neurological%20complications%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eva%20Sole%22%2C%22lastName%22%3A%22Cruz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Fortanier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Hilezian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mence%22%2C%22lastName%22%3A%22Bouti%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demorti%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilien%22%2C%22lastName%22%3A%22Delmont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shahram%22%2C%22lastName%22%3A%22Attarian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20factors%20underlying%20the%20topography%20of%20nitrous%20oxide%20%28N2O%29-induced%20neurological%20complications%20are%20unknown.%5CnMETHODS%3A%20We%20included%20all%20consecutive%20patients%20admitted%20to%20the%20university%20hospital%20of%20Marseille%20for%20N2O-induced%20neurological%20complications%20in%20a%20prospective%20observational%20study.%20Patients%20underwent%20neurological%20examination%2C%20spinal%20cord%20magnetic%20resonance%20imaging%2C%20and%20nerve%20conduction%20studies%20within%20the%20first%204%5Cu2009weeks%20after%20admission.%5CnRESULTS%3A%20In%20total%2C%2061%20patients%20were%20included%3A%2045%25%20with%20myeloneuropathy%2C%2034%25%20with%20isolated%20myelopathy%2C%20and%2021%25%20with%20isolated%20neuropathy.%20On%20multivariable%20analysis%2C%20the%20odds%20of%20myelopathy%20were%20associated%20with%20the%20amount%20of%20weekly%20N2O%20consumption%20%28~600%5Cu2009g%20cylinder%20per%20week%2C%20odds%20ratio%20%5BOR%5D%20%3D%5Cu20091.11%2C%2095%25%20confidence%20interval%20%5BCI%5D%20%3D%5Cu20091.001-1.24%29.%20The%20extent%20of%20the%20myelopathy%20%28number%20of%20vertebral%20segments%29%20was%20correlated%20with%20the%20number%20of%20~600-g%20cylinders%20consumed%20weekly%20%28%5Cu03c1%5Cu2009%3D%5Cu20090.40%2C%20p%5Cu2009%3C%5Cu20090.005%29.%20The%20odds%20of%20neuropathy%20were%20associated%20with%20the%20duration%20of%20consumption%20%28per%20month%3B%20OR%5Cu2009%3D%5Cu20091.29%2C%2095%25%20CI%5Cu2009%3D%5Cu20091.05-1.58%29.%20Mean%20lower-limb%20motor%20nerve%20amplitude%20was%20correlated%20with%20the%20duration%20of%20consumption%20%28in%20months%3B%20%5Cu03c1%5Cu2009%3D%5Cu2009-0.34%2C%20p%5Cu2009%3C%5Cu20090.05%29.%5CnCONCLUSIONS%3A%20The%20odds%20of%20myelopathy%20increased%20with%20the%20amount%20of%20N2O%20consumption%2C%20and%20the%20odds%20of%20neuropathy%20increased%20with%20the%20duration%20of%20N2O%20exposure%2C%20which%20suggests%20distinct%20pathophysiological%20mechanisms%20underlying%20these%20two%20neurological%20complications.%22%2C%22date%22%3A%222024-03-26%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1111%5C%2Fene.16291%22%2C%22ISSN%22%3A%221468-1331%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%5D%2C%22dateModified%22%3A%222024-03-29T08%3A57%3A33Z%22%7D%7D%2C%7B%22key%22%3A%225YSAXHXM%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Sole%20Cruz%20et%20al.%22%2C%22parsedDate%22%3A%222024-03-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ESole%20Cruz%2C%20E.%2C%20Stolowy%2C%20N.%2C%20Attia%2C%20R.%2C%20Audoin%2C%20B.%20and%20Demorti%26%23xE8%3Bre%2C%20S.%20%282024%29%20%26%23x2018%3BAcute%20posterior%20ischemic%20optic%20neuropathy%20associated%20with%20a%20hypertensive%20crisis%26%23x2019%3B%2C%20%3Ci%3ERevue%20Neurologique%3C%5C%2Fi%3E%2C%20180%283%29%2C%20pp.%20218%26%23x2013%3B219.%20Available%20at%3A%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.neurol.2023.12.002%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.neurol.2023.12.002%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Acute%20posterior%20ischemic%20optic%20neuropathy%20associated%20with%20a%20hypertensive%20crisis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Sole%20Cruz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Stolowy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Attia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Demorti%5Cu00e8re%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222024-03-01%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.neurol.2023.12.002%22%2C%22ISSN%22%3A%220035-3787%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.sciencedirect.com%5C%2Fscience%5C%2Farticle%5C%2Fpii%5C%2FS0035378723011529%22%2C%22collections%22%3A%5B%226KPLZTET%22%5D%2C%22dateModified%22%3A%222024-03-21T13%3A25%3A04Z%22%7D%7D%2C%7B%22key%22%3A%226X8XQFEJ%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Collongues%20et%20al.%22%2C%22parsedDate%22%3A%222024-02-15%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ECollongues%2C%20N.%2C%20Durand-Dubief%2C%20F.%2C%20Lebrun-Frenay%2C%20C.%2C%20Audoin%2C%20B.%2C%20Ayrignac%2C%20X.%2C%20Bensa%2C%20C.%2C%20Bigaut%2C%20K.%2C%20Bourre%2C%20B.%2C%20Carra-Dalli%26%23xE8%3Bre%2C%20C.%2C%20Ciron%2C%20J.%2C%20Defer%2C%20G.%2C%20Kwiatkowski%2C%20A.%2C%20Leray%2C%20E.%2C%20Maillart%2C%20E.%2C%20Marignier%2C%20R.%2C%20Mathey%2C%20G.%2C%20Morel%2C%20N.%2C%20Thouvenot%2C%20E.%2C%20Z%26%23xE9%3Bphir%2C%20H.%2C%20Boucher%2C%20J.%2C%20Bouti%26%23xE8%3Bre%2C%20C.%2C%20Branger%2C%20P.%2C%20Da%20Silva%2C%20A.%2C%20Demorti%26%23xE8%3Bre%2C%20S.%2C%20Guillaume%2C%20M.%2C%20Hebant%2C%20B.%2C%20Januel%2C%20E.%2C%20Kerbrat%2C%20A.%2C%20Manchon%2C%20E.%2C%20Moisset%2C%20X.%2C%20Montcuquet%2C%20A.%2C%20Pierret%2C%20C.%2C%20Pique%2C%20J.%2C%20Poupart%2C%20J.%2C%20Prunis%2C%20C.%2C%20Roux%2C%20T.%2C%20Schmitt%2C%20P.%2C%20Androdias%2C%20G.%20and%20Cohen%2C%20M.%20%282024%29%20%26%23x2018%3BCancer%20and%20multiple%20sclerosis%3A%202023%20recommendations%20from%20the%20French%20Multiple%20Sclerosis%20Society%26%23x2019%3B%2C%20%3Ci%3EMultiple%20Sclerosis%20%28Houndmills%2C%20Basingstoke%2C%20England%29%3C%5C%2Fi%3E%2C%20p.%2013524585231223880.%20Available%20at%3A%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F13524585231223880%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F13524585231223880%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cancer%20and%20multiple%20sclerosis%3A%202023%20recommendations%20from%20the%20French%20Multiple%20Sclerosis%20Society%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Collongues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Durand-Dubief%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lebrun-Frenay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Ayrignac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Bensa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%5Cu00e9vin%22%2C%22lastName%22%3A%22Bigaut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clarisse%22%2C%22lastName%22%3A%22Carra-Dalli%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Defer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Kwiatkowski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Leray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Marignier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Mathey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Morel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Thouvenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Z%5Cu00e9phir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Boucher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mence%22%2C%22lastName%22%3A%22Bouti%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Branger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ang%5Cu00e9lique%22%2C%22lastName%22%3A%22Da%20Silva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demorti%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Guillaume%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%22%2C%22lastName%22%3A%22Hebant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edouard%22%2C%22lastName%22%3A%22Januel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Kerbrat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Manchon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Moisset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexis%22%2C%22lastName%22%3A%22Montcuquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chlo%5Cu00e9%22%2C%22lastName%22%3A%22Pierret%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Pique%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Poupart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chlo%5Cu00e9%22%2C%22lastName%22%3A%22Prunis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Roux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Perrine%22%2C%22lastName%22%3A%22Schmitt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%5Cu00e9raldine%22%2C%22lastName%22%3A%22Androdias%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikael%22%2C%22lastName%22%3A%22Cohen%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Epidemiological%20data%20reveal%20that%2045%25%20of%20persons%20with%20multiple%20sclerosis%20%28PwMS%29%20in%20France%20are%20more%20than%2050%5Cu2009years.%20This%20population%20more%20than%2050%20is%20more%20susceptible%20to%20cancer%2C%20and%20this%20risk%20may%20be%20increased%20by%20frequent%20use%20of%20immunosuppressive%20drugs.%20Consequently%2C%20concerns%20have%20arisen%20about%20the%20potential%20increased%20risk%20of%20cancer%20in%20PwMS%20and%20how%20patients%20should%20be%20screened%20and%20managed%20in%20terms%20of%20cancer%20risk.%5CnOBJECTIVE%3A%20To%20develop%20evidence-based%20recommendations%20to%20manage%20the%20coexistence%20of%20cancer%20and%20multiple%20sclerosis%20%28MS%29.%5CnMETHODS%3A%20The%20French%20Group%20for%20Recommendations%20in%20MS%20collected%20articles%20from%20PubMed%20and%20university%20databases%20covering%20the%20period%20January%201975%20through%20June%202022.%20The%20RAND%5C%2FUCLA%20method%20was%20employed%20to%20achieve%20formal%20consensus.%20MS%20experts%20comprehensively%20reviewed%20the%20full-text%20articles%20and%20developed%20the%20initial%20recommendations.%20A%20group%20of%20multidisciplinary%20health%20care%20specialists%20then%20validated%20the%20final%20proposal.%5CnRESULTS%3A%20Five%20key%20questions%20were%20addressed%2C%20encompassing%20various%20topics%20such%20as%20cancer%20screening%20before%20or%20after%20initiating%20a%20disease-modifying%20therapy%20%28DMT%29%2C%20appropriate%20management%20of%20MS%20in%20the%20context%20of%20cancer%2C%20recommended%20follow-up%20for%20cancer%20in%20patients%20receiving%20a%20DMT%2C%20and%20the%20potential%20reintroduction%20of%20a%20DMT%20after%20initial%20cancer%20treatment.%20A%20strong%20consensus%20was%20reached%20for%20all%2031%20recommendations.%5CnCONCLUSION%3A%20These%20recommendations%20propose%20a%20strategic%20approach%20to%20managing%20cancer%20risk%20in%20PwMS.%22%2C%22date%22%3A%222024-02-15%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1177%5C%2F13524585231223880%22%2C%22ISSN%22%3A%221477-0970%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226KPLZTET%22%5D%2C%22dateModified%22%3A%222025-01-16T14%3A01%3A14Z%22%7D%7D%2C%7B%22key%22%3A%22LKL8F93N%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Venet%20et%20al.%22%2C%22parsedDate%22%3A%222024-01-02%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EVenet%2C%20M.%2C%20Lepine%2C%20A.%2C%20Maarouf%2C%20A.%2C%20Biotti%2C%20D.%2C%20Boutiere%2C%20C.%2C%20Casez%2C%20O.%2C%20Cohen%2C%20M.%2C%20Durozard%2C%20P.%2C%20Demorti%26%23xE8%3Bre%2C%20S.%2C%20Giorgi%2C%20L.%2C%20Maillart%2C%20E.%2C%20Mathey%2C%20G.%2C%20Mazzola%2C%20L.%2C%20Rico%2C%20A.%2C%20Camdessanche%2C%20J.-P.%2C%20Deiva%2C%20K.%2C%20Pelletier%2C%20J.%20and%20Audoin%2C%20B.%20%282024%29%20%26%23x2018%3BControl%20of%20disease%20activity%20with%20large%20extended-interval%20dosing%20of%20rituximab%5C%2Focrelizumab%20in%20highly%20active%20pediatric%20multiple%20sclerosis%26%23x2019%3B%2C%20%3Ci%3EMultiple%20Sclerosis%20%28Houndmills%2C%20Basingstoke%2C%20England%29%3C%5C%2Fi%3E%2C%20p.%2013524585231223068.%20Available%20at%3A%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F13524585231223069%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F13524585231223069%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Control%20of%20disease%20activity%20with%20large%20extended-interval%20dosing%20of%20rituximab%5C%2Focrelizumab%20in%20highly%20active%20pediatric%20multiple%20sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Melany%22%2C%22lastName%22%3A%22Venet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Lepine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%22%2C%22lastName%22%3A%22Biotti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Casez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikael%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Durozard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demorti%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%22%2C%22lastName%22%3A%22Giorgi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Mathey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Mazzola%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Camdessanche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kumaran%22%2C%22lastName%22%3A%22Deiva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22Recent%20studies%20in%20adults%20suggested%20that%20extended-interval%20dosing%20of%20rituximab%5C%2Focrelizumab%20%28RTX%5C%2FOCR%29%20larger%20than%2012%20months%20was%20safe%20and%20could%20improve%20safety.%20This%20was%20an%20observational%20cohort%20study%20of%20very%20active%20pediatric-onset%20multiple%20sclerosis%20%28PoMS%29%20%28median%20%28range%29%20age%2C%2016%20%2812-17%29%20years%29%20treated%20with%20RTX%5C%2FOCR%20with%206%20month%20standard-interval%20dosing%20%28n%20%3D%209%29%20or%20early%20extended-interval%20dosing%20%28n%20%3D%2012%2C%20median%20%28range%29%20interval%2018%20months%20%2812-25%29%29.%20Within%20a%20median%20%28range%29%20follow-up%20of%2031%20%2812-63%29%20months%20after%20RTX%5C%2FOCR%20onset%2C%20one%20patient%20%28standard-interval%29%20experienced%20relapse%20and%20no%20patient%20showed%20disability%20worsening%20or%20new%20T2-weighted%20lesions.%20This%20study%20suggests%20that%20the%20effectiveness%20of%20RTX%5C%2FOCR%20is%20maintained%20with%20a%20median%20extended-interval%20dosing%20of%2018%20months%20in%20patients%20with%20very%20active%20PoMS.%22%2C%22date%22%3A%222024-01-02%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1177%5C%2F13524585231223069%22%2C%22ISSN%22%3A%221477-0970%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%5D%2C%22dateModified%22%3A%222024-01-08T09%3A47%3A24Z%22%7D%7D%2C%7B%22key%22%3A%22TBE42JYS%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Attia%20et%20al.%22%2C%22parsedDate%22%3A%222023-11%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EAttia%2C%20R.%2C%20Fitoussi%2C%20R.%2C%20Mairot%2C%20K.%2C%20Demortiere%2C%20S.%2C%20Stellman%2C%20J.-P.%2C%20Tilsley%2C%20P.%2C%20Audoin%2C%20B.%2C%20David%2C%20T.%20and%20Stolowy%2C%20N.%20%282023%29%20%26%23x2018%3BRisk%20factors%20associated%20with%20progression%20from%20papilloedema%20to%20optic%20atrophy%3A%20results%20from%20a%20cohort%20of%20113%20patients%26%23x2019%3B%2C%20%3Ci%3EBMJ%20open%20ophthalmology%3C%5C%2Fi%3E%2C%208%281%29%2C%20p.%20e001375.%20Available%20at%3A%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjophth-2023-001375%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjophth-2023-001375%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Risk%20factors%20associated%20with%20progression%20from%20papilloedema%20to%20optic%20atrophy%3A%20results%20from%20a%20cohort%20of%20113%20patients%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ruben%22%2C%22lastName%22%3A%22Attia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ruben%22%2C%22lastName%22%3A%22Fitoussi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kevin%22%2C%22lastName%22%3A%22Mairot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demortiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan-Patrick%22%2C%22lastName%22%3A%22Stellman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Penelope%22%2C%22lastName%22%3A%22Tilsley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22David%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Natacha%22%2C%22lastName%22%3A%22Stolowy%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20aim%20of%20this%20study%20was%20to%20assess%20the%20risk%20factors%20for%20atrophic%20progression%20of%20patients%20with%20papilloedema%20secondary%20to%20intracranial%20hypertension%2C%20using%20optical%20coherence%20tomography%20parameters.%5CnMETHODS%3A%20A%20retrospective%20study%20was%20conducted%20at%20Marseille%20University%20Hospitals%27%20Ophthalmology%20departments%20between%20December%202015%20and%20December%202021.%20All%20patients%20with%20papilloedema%20resulting%20from%20elevated%20intracranial%20hypertension%20at%20the%20initial%20presentation%20were%20included.%20Ophthalmological%20evaluations%20included%20analysing%20retinal%20nerve%20fibre%20layer%20%28RNFL%29%2C%20ganglion%20cell%20layer%20%28GCL%29%20and%20total%20peripapillary%20retinal%20thickness%20%28RT%29.%5CnRESULTS%3A%20The%20study%20included%20222%20eyes%20from%20113%20patients.%20The%20main%20aetiologies%20of%20intracranial%20hypertension%20were%20idiopathic%20intracranial%20hypertension%20%2849%5C%2F113%29%2C%20intracranial%20tumours%20%2833%5C%2F113%29%20and%20cerebral%20venous%20thrombosis%20%2815%5C%2F113%29.%20The%20initial%20RNFL%20and%20RT%20showed%20significant%20correlations%20with%20optic%20atrophy.%20The%20mean%20RNFL%20was%20199.63%5Cu2009%5Cu00b5m%20in%20the%20%27no%20atrophy%27%20group%20and%20365.28%5Cu2009%5Cu00b5m%20in%20the%20%27atrophy%27%20group%20%28p%3C0.001%29.%20Similarly%2C%20the%20mean%20RT%20was%20483.72%5Cu2009%5Cu00b5m%20in%20the%20%27non-atrophy%27%20group%20and%20796.69%5Cu2009%5Cu00b5m%20in%20the%20%27atrophy%27%20group%20%28p%3C0.001%29.%20The%20presence%20of%20peripapillary%20haemorrhages%20showed%20a%20strong%20correlated%20with%20optic%20atrophy%20with%20an%20OR%3D19.12%20%28p%3C0.001%29.%20Impaired%20initial%20visual%20acuity%20was%20also%20associated%20with%20final%20optic%20atrophy%20with%20an%20OR%3D7.76%20%28p%3D0.020%29.%20Furthermore%2C%20impaired%20initial%20GCL%20was%20a%20major%20predictor%20of%20optic%20atrophy%20%28OR%3D18.25%20%28p%3D0.021%29%29.%5CnCONCLUSION%3A%20Our%20study%20highlights%20the%20risk%20factors%20for%20optic%20atrophy%20in%20papilloedema%2C%20aiming%20to%20facilitate%20the%20early%20detection%20of%20patients%20at%20a%20high%20risk%20of%20vision%20loss%20and%20enable%20more%20aggressive%20medical%20or%20surgical%20management.%22%2C%22date%22%3A%222023-11%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1136%5C%2Fbmjophth-2023-001375%22%2C%22ISSN%22%3A%222397-3269%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226KPLZTET%22%2C%229L2KHJ5X%22%2C%22S58TGFSV%22%5D%2C%22dateModified%22%3A%222024-05-15T04%3A59%3A21Z%22%7D%7D%2C%7B%22key%22%3A%22CBEZGFUB%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Claverie%20et%20al.%22%2C%22parsedDate%22%3A%222023-09%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EClaverie%2C%20R.%2C%20Perriguey%2C%20M.%2C%20Rico%2C%20A.%2C%20Boutiere%2C%20C.%2C%20Demortiere%2C%20S.%2C%20Durozard%2C%20P.%2C%20Hilezian%2C%20F.%2C%20Dubrou%2C%20C.%2C%20Vely%2C%20F.%2C%20Pelletier%2C%20J.%2C%20Audoin%2C%20B.%20and%20Maarouf%2C%20A.%20%282023%29%20%26%23x2018%3BEfficacy%20of%20Rituximab%20Outlasts%20B-Cell%20Repopulation%20in%20Multiple%20Sclerosis%3A%20Time%20to%20Rethink%20Dosing%3F%26%23x2019%3B%2C%20%3Ci%3ENeurology%28R%29%20Neuroimmunology%20%26amp%3B%20Neuroinflammation%3C%5C%2Fi%3E%2C%2010%285%29%2C%20p.%20e200152.%20Available%20at%3A%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200152%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200152%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Efficacy%20of%20Rituximab%20Outlasts%20B-Cell%20Repopulation%20in%20Multiple%20Sclerosis%3A%20Time%20to%20Rethink%20Dosing%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roxane%22%2C%22lastName%22%3A%22Claverie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Perriguey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clemence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demortiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Durozard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Hilezian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clea%22%2C%22lastName%22%3A%22Dubrou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Vely%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20OBJECTIVES%3A%20Patients%20with%20multiple%20sclerosis%20%28PwMS%29%20receiving%20extended%20dosing%20of%20rituximab%20%28RTX%29%20have%20exhibited%20no%20return%20of%20disease%20activity%2C%20which%20suggests%20that%20maintenance%20of%20deep%20depletion%20of%20circulating%20B%20cells%20is%20not%20necessary%20to%20maintain%20the%20efficacy%20of%20RTX%20in%20MS.%5CnMETHODS%3A%20This%20was%20a%20prospective%20monocentric%20observational%20study%20including%20all%20consecutive%20PwMS%20who%20started%20or%20continued%20RTX%20after%202019%2C%20when%20the%20medical%20staff%20decided%20to%20extend%20the%20dosing%20interval%20up%20to%2024%20months%20for%20all%20patients.%20Circulating%20B-cell%20subsets%20were%20monitored%20regularly%20and%20systematically%20in%20case%20of%20relapse.%20The%20first%20extended%20interval%20was%20analyzed.%5CnRESULTS%3A%20We%20included%20236%20PwMS%20%2881%25%20with%20relapsing-remitting%20MS%3B%20mean%20%5BSD%5D%20age%2043%20%5B12%5D%20years%3B%20median%20%5Brange%5D%20EDSS%20score%204%20%5B0-8%5D%3B%20mean%20relapse%20rate%20during%20the%20year%20before%20RTX%20start%201.09%20%5B0.99%5D%3B%2041.5%25%20with%20MRI%20activity%29.%20The%20median%20number%20of%20RTX%20infusions%20before%20extension%20was%204%20%281-13%29.%20At%20the%20time%20of%20the%20analysis%2C%20the%20median%20delay%20in%20dosing%20was%2017%20months%20%288-39%29%3B%20the%20median%20proportion%20of%20circulating%20CD19%2B%20B%20cells%20was%207%25%20%280-25%29%20of%20total%20lymphocytes%20and%20that%20of%20CD27%2B%20memory%20B%20cells%20was%204%25%20%280-16%29%20of%20total%20B%20cells.%20The%20mean%20annual%20relapse%20rate%20did%20not%20differ%20before%20and%20after%20the%20extension%3A%200.03%20%280.5%29%20and%200.04%20%280.15%29%20%28p%20%3D%200.51%29.%20Similarly%2C%20annual%20relapse%20rates%20did%20not%20differ%20before%20and%20after%20extension%20in%20patients%20with%20EDSS%20score%20%5Cu22643%20%28n%20%3D%2079%29%20or%20disease%20duration%20%5Cu22645%20years%20%28n%20%3D%2071%29%20at%20RTX%20onset.%20During%20the%20%5C%22extended%20dosing%5C%22%20period%2C%20MRI%20demonstrated%20no%20lesion%20accrual%20in%20228%20of%20the%20236%20patients%20%2897%25%29.%20Five%20patients%20experienced%20clinical%20relapse%2C%20which%20was%20confirmed%20by%20MRI.%20In%20these%20patients%2C%20the%20level%20of%20B-cell%20subset%20reconstitution%20at%20the%20time%20of%20the%20relapse%20did%20not%20differ%20from%20that%20for%20patients%20with%20the%20same%20extension%20window.%5CnDISCUSSION%3A%20The%20efficacy%20of%20RTX%20outlasted%20substantial%20reconstitution%20of%20circulating%20B%20cells%20in%20PwMS%2C%20which%20suggests%20that%20renewal%20of%20the%20immune%20system%20underlies%20the%20prolonged%20effect%20of%20RTX%20in%20MS.%20These%20findings%20suggest%20that%20extended%20interval%20dosing%20of%20RTX%20that%20leads%20to%20a%20significant%20reconstitution%20of%20circulating%20B%20cells%20is%20safe%20in%20PwMS%2C%20could%20reduce%20the%20risk%20of%20infection%2C%20and%20could%20improve%20vaccine%20efficacy.%22%2C%22date%22%3A%222023-09%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FNXI.0000000000200152%22%2C%22ISSN%22%3A%222332-7812%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%5D%2C%22dateModified%22%3A%222025-01-28T16%3A13%3A09Z%22%7D%7D%2C%7B%22key%22%3A%22HL5B8A5J%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Testud%20et%20al.%22%2C%22parsedDate%22%3A%222023-09%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ETestud%2C%20B.%2C%20Fabiani%2C%20N.%2C%20Demorti%26%23xE8%3Bre%2C%20S.%2C%20Mchinda%2C%20S.%2C%20Medina%2C%20N.L.%2C%20Pelletier%2C%20J.%2C%20Guye%2C%20M.%2C%20Audoin%2C%20B.%2C%20Stellmann%2C%20J.P.%20and%20Callot%2C%20V.%20%282023%29%20%26%23x2018%3BContribution%20of%20the%20MP2RAGE%207T%20Sequence%20in%20MS%20Lesions%20of%20the%20Cervical%20Spinal%20Cord%26%23x2019%3B%2C%20%3Ci%3EAJNR.%20American%20journal%20of%20neuroradiology%3C%5C%2Fi%3E%2C%2044%289%29%2C%20pp.%201101%26%23x2013%3B1107.%20Available%20at%3A%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3174%5C%2Fajnr.A7964%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3174%5C%2Fajnr.A7964%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Contribution%20of%20the%20MP2RAGE%207T%20Sequence%20in%20MS%20Lesions%20of%20the%20Cervical%20Spinal%20Cord%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Testud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Fabiani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Demorti%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Mchinda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%20L.%22%2C%22lastName%22%3A%22Medina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Guye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20P.%22%2C%22lastName%22%3A%22Stellmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Callot%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20PURPOSE%3A%20The%20detection%20of%20spinal%20cord%20lesions%20in%20patients%20with%20MS%20is%20challenging.%20Recently%2C%20the%203D%20MP2RAGE%20sequence%20demonstrated%20its%20usefulness%20at%203T.%20Benefiting%20from%20the%20high%20spatial%20resolution%20provided%20by%20ultra-high-field%20MR%20imaging%20systems%2C%20we%20aimed%20to%20evaluate%20the%20contribution%20of%20the%203D%20MP2RAGE%20sequence%20acquired%20at%207T%20for%20the%20detection%20of%20MS%20lesions%20in%20the%20cervical%20spine.%5CnMATERIALS%20AND%20METHODS%3A%20Seventeen%20patients%20with%20MS%20participated%20in%20this%20study.%20They%20were%20examined%20at%20both%203T%20and%207T.%20The%20MR%20imaging%20examination%20included%20a%20Magnetic%20Imaging%20in%20MS%20%28MAGNIMS%29%20protocol%20with%20an%20axial%20T2%2A-WI%20gradient%20recalled-echo%20sequence%20%28%5C%22optimized%20MAGNIMS%20protocol%5C%22%29%20and%20a%200.9-mm%20isotropic%203D%20MP2RAGE%20sequence%20at%203T%2C%20as%20well%20as%20a%200.7-mm%20isotropic%20and%200.3-mm%20in-plane-resolution%20anisotropic%203D%20MP2RAGE%20sequences%20at%207T.%20Each%20data%20set%20was%20read%20by%20a%20consensus%20of%20radiologists%2C%20neurologists%2C%20and%20neuroscientists.%20The%20number%20of%20lesions%20and%20their%20topography%2C%20as%20well%20as%20the%20visibility%20of%20the%20lesions%20from%20one%20set%20to%20another%2C%20were%20carefully%20analyzed.%5CnRESULTS%3A%20A%20total%20of%2055%20lesions%20were%20detected.%20The%20absolute%20number%20of%20visible%20lesions%20differed%20among%20the%204%20sequences%20%28linear%20mixed%20effect%20ANOVA%2C%20P%20%3D%20.020%29.%20The%20highest%20detection%20was%20observed%20for%20the%20two%207T%20sequences%20with%2051%20lesions%20each%20%2892.7%25%20of%20the%20total%29.%20The%20optimized%203T%20MAGNIMS%20protocol%20and%20the%203T%20MP2RAGE%20isotropic%20sequence%20detected%2041%20%2874.5%25%29%20and%2035%20lesions%20%2863.6%25%29%2C%20respectively.%5CnCONCLUSIONS%3A%20The%207T%20MP2RAGE%20sequences%20detected%20more%20lesions%20than%20the%203T%20sets.%20Isotropic%20and%20anisotropic%20acquisitions%20performed%20comparably.%20Ultra-high-resolution%20sequences%20obtained%20at%207T%20improve%20the%20identification%20and%20delineation%20of%20lesions%20of%20the%20cervical%20spinal%20cord%20in%20MS.%22%2C%22date%22%3A%222023-09%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3174%5C%2Fajnr.A7964%22%2C%22ISSN%22%3A%221936-959X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22ZFC2Q648%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%2C%229L2KHJ5X%22%2C%22XTA6KS7L%22%2C%22PCMV2W5C%22%5D%2C%22dateModified%22%3A%222024-11-26T16%3A01%3A27Z%22%7D%7D%2C%7B%22key%22%3A%22RTM5VRM7%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Demortiere%20et%20al.%22%2C%22parsedDate%22%3A%222023-09%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDemortiere%2C%20S.%2C%20Maarouf%2C%20A.%2C%20Rico%2C%20A.%2C%20Boutiere%2C%20C.%2C%20Hilezian%2C%20F.%2C%20Durozard%2C%20P.%2C%20Pelletier%2C%20J.%20and%20Audoin%2C%20B.%20%282023%29%20%26%23x2018%3BDisease%20Evolution%20in%20Women%20With%20Highly%20Active%20MS%20Who%20Suspended%20Natalizumab%20During%20Pregnancy%20vs%20Rituximab%5C%2FOcrelizumab%20Before%20Conception%26%23x2019%3B%2C%20%3Ci%3ENeurology%28R%29%20Neuroimmunology%20%26amp%3B%20Neuroinflammation%3C%5C%2Fi%3E%2C%2010%285%29%2C%20p.%20e200161.%20Available%20at%3A%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200161%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200161%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Disease%20Evolution%20in%20Women%20With%20Highly%20Active%20MS%20Who%20Suspended%20Natalizumab%20During%20Pregnancy%20vs%20Rituximab%5C%2FOcrelizumab%20Before%20Conception%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demortiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clemence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Hilezian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Durozard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20OBJECTIVES%3A%20In%20women%20with%20highly%20active%20multiple%20sclerosis%20%28MS%29%2C%20suspending%20rituximab%20%28RTX%29%20for%20planning%20pregnancy%20is%20associated%20with%20low%20disease%20reactivation.%20Whether%20this%20strategy%20reduces%20the%20risk%20of%20disease%20reactivity%20as%20compared%20with%20suspending%20natalizumab%20%28NTZ%29%203%20months%20after%20conception%20is%20unclear.%5CnMETHODS%3A%20We%20retrospectively%20included%20women%20with%20MS%20followed%20in%20our%20department%20during%20pregnancy%20and%201%20year%20after%20birth%20who%20suspended%20NTZ%20at%20the%20end%20of%20the%20first%20trimester%20%28option%20mostly%20proposed%20before%202016%29%20or%20suspended%20RTX%5C%2Focrelizumab%20%28RTX%5C%2FOCR%29%20in%20the%20year%20before%20conception%20%28option%20proposed%20since%202016%29.%5CnRESULTS%3A%20In%20women%20who%20suspended%20NTZ%2C%2045%20pregnancies%20resulted%20in%203%20miscarriages%20and%2042%20live%20births%2C%20including%201%20newborn%20with%20major%20malformations.%20In%20women%20who%20suspended%20RTX%5C%2FOCR%2C%2037%20pregnancies%20resulted%20in%203%20miscarriages%20and%2033%20live%20births%3B%201%20pregnancy%20was%20terminated%20for%20malformation.%20During%20pregnancy%2C%20relapse%20occurred%20in%203%5C%2F42%20%287.1%25%29%20patients%20of%20the%20NTZ%20group%20and%201%5C%2F33%20%283%25%29%20of%20the%20RTX%5C%2FOCR%20group%20%28p%20%3D%200.6%29.%20After%20delivery%2C%20relapse%20occurred%20in%209%5C%2F42%20%2821.4%25%29%20patients%20of%20the%20NTZ%20group%20and%200%5C%2F33%20of%20the%20RTX%5C%2FOCR%20group%20%28p%20%3C%200.01%29.%20In%20the%20NTZ%20group%2C%208%5C%2F9%20relapses%20occurred%20in%20patients%20who%20restarted%20NTZ%20less%20than%204%20weeks%20after%20delivery.%20The%20proportion%20of%20patients%20with%20gadolinium-enhanced%20and%5C%2For%20new%20T2%20lesions%20on%20brain%20or%20spinal%20cord%20MRI%20performed%20after%20delivery%20was%20higher%20in%20the%20NTZ%20than%20RTX%5C%2FOCR%20group%20%2814%5C%2F40%20%5B35%25%5D%20vs%201%5C%2F31%20%5B3%25%5D%20patients%2C%20p%20%3D%200.001%29%2C%20the%20proportion%20with%20EDSS%20score%20progression%20during%20the%20period%20including%20pregnancy%20and%20the%20year%20after%20delivery%20was%20higher%20%287%5C%2F42%20%5B17%25%5D%20vs%200%5C%2F33%20patients%2C%20p%20%3D%200.01%29%2C%20and%20the%20proportion%20fulfilling%20NEDA-3%20during%20this%20period%20was%20lower%20%2821%5C%2F40%20%5B53%25%5D%20vs%2030%5C%2F31%20%5B97%25%5D%20patients%2C%20p%20%3C%200.001%29.%5CnDISCUSSION%3A%20Suspending%20RTX%5C%2FOCR%20in%20the%20year%20before%20conception%20in%20women%20with%20highly%20active%20MS%20was%20associated%20with%20no%20disease%20reactivation%20during%20and%20after%20pregnancy.%20As%20previously%20reported%2C%20stopping%20NTZ%20at%20the%20end%20of%20the%20first%20trimester%20was%20associated%20with%20disease%20reactivation.%20In%20women%20receiving%20NTZ%20who%20are%20planning%20pregnancy%2C%20a%20bridge%20to%20RTX%5C%2FOCR%20for%20pregnancy%20or%20continuing%20NTZ%20until%20week%2034%20are%20both%20reasonable%20clinical%20decisions.%20The%20RTX%5C%2FOCR%20option%20is%20more%20comfortable%20for%20women%20and%20reduces%20the%20exposure%20of%20infants%20to%20monoclonal%20antibodies.%22%2C%22date%22%3A%222023-09%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FNXI.0000000000200161%22%2C%22ISSN%22%3A%222332-7812%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%5D%2C%22dateModified%22%3A%222024-11-26T16%3A00%3A58Z%22%7D%7D%2C%7B%22key%22%3A%224MEY9XYY%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Rode%20et%20al.%22%2C%22parsedDate%22%3A%222023-04-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ERode%2C%20J.%2C%20Pique%2C%20J.%2C%20Maarouf%2C%20A.%2C%20Ayrignac%2C%20X.%2C%20Bourre%2C%20B.%2C%20Ciron%2C%20J.%2C%20Cohen%2C%20M.%2C%20Collongues%2C%20N.%2C%20Deschamps%2C%20R.%2C%20Maillart%2C%20E.%2C%20Montcuquet%2C%20A.%2C%20Papeix%2C%20C.%2C%20Ruet%2C%20A.%2C%20Wiertlewski%2C%20S.%2C%20Zephir%2C%20H.%2C%20Marignier%2C%20R.%20and%20Audoin%2C%20B.%20%282023%29%20%26%23x2018%3BTime%20to%20steroids%20impacts%20visual%20outcome%20of%20optic%20neuritis%20in%20MOGAD%26%23x2019%3B%2C%20%3Ci%3EJournal%20of%20Neurology%2C%20Neurosurgery%20%26amp%3B%20Psychiatry%3C%5C%2Fi%3E%2C%2094%284%29%2C%20pp.%20309%26%23x2013%3B313.%20Available%20at%3A%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fjnnp-2022-330360%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fjnnp-2022-330360%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Time%20to%20steroids%20impacts%20visual%20outcome%20of%20optic%20neuritis%20in%20MOGAD%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Rode%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Pique%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Ayrignac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikael%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Collongues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Deschamps%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexis%22%2C%22lastName%22%3A%22Montcuquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Papeix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurelie%22%2C%22lastName%22%3A%22Ruet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Wiertlewski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helene%22%2C%22lastName%22%3A%22Zephir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Marignier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22Background%20To%20characterise%20the%20response%20to%20treatment%20of%20inaugural%20optic%20neuritis%20%28ON%29%20in%20patients%20with%20myelin%20oligodendrocyte%20glycoprotein%20antibody-associated%20disease%20%28MOGAD%29.%5CnMethods%20We%20searched%20the%20French%20MOGAD%20database%20for%20adults%20with%20inaugural%20ON%20with%20a%20detailed%20report%20of%20acute%20treatment%20modalities%20and%20measures%20of%20high-contrast%20best-corrected%20visual%20acuity%20%28BCVA%29%20at%20nadir%20and%20after%203%20months.%20Predictors%20of%20visual%20outcomes%20were%20assessed%20by%20multivariable%20analysis.%5CnResults%20Among%20245%20patients%20with%20at%20least%20one%20episode%20of%20ON%2C%2082%20fulfilled%20all%20criteria%2C%20and%20data%20on%20the%20peripapillary%20retinal%20nerve%20fibre%20layer%20%28pRNFL%29%20were%20available%20for%2044.%20All%20patients%20received%20methylprednisolone%20%28MP%29%2C%20combined%20with%20plasma%20exchange%20in%2018.%20After%203%20months%2C%2075%20of%2082%20%2891%25%29%20patients%20retained%20full%20BCVA%20recovery%2C%20and%20median%20%28range%29%20pRNFL%20of%20the%20affected%20eye%20was%2072%20%5Cu00b5m%20%2840%5Cu2013102%29.%20Failure%20to%20regain%200.0%20logarithmic%20minimum%20angle%20of%20resolution%20vision%20%28Snellen%2020%5C%2F20%29%20at%203%20months%20was%20associated%20with%20time%20to%20first%20MP%20treatment%20%5Cu226510%20days%20%28OR%2016%2C%2095%25%20CI%201.14%20to%20213%2C%20p%3D0.01%29.%20pRNFL%20thickness%20after%203%20months%20was%20related%20to%20better%20BCVA%20at%20nadir%20and%20time%20to%20first%20MP%20treatment%20%3C10%20days%20%28r2%3D19%25%2C%20p%3D0.004%20and%20r2%3D11%25%2C%20p%3D0.03%2C%20respectively%29.%5CnConclusions%20Time%20to%20MP%20affects%20functional%20but%20also%20structural%20visual%20outcomes%20of%20ON%20in%20MOGAD.%22%2C%22date%22%3A%222023%5C%2F04%5C%2F01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1136%5C%2Fjnnp-2022-330360%22%2C%22ISSN%22%3A%220022-3050%2C%201468-330X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fjnnp.bmj.com%5C%2Fcontent%5C%2F94%5C%2F4%5C%2F309%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%226KPLZTET%22%5D%2C%22dateModified%22%3A%222024-11-15T09%3A37%3A08Z%22%7D%7D%2C%7B%22key%22%3A%22M8UHS4XG%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Chen%20et%20al.%22%2C%22parsedDate%22%3A%222023-02-21%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EChen%2C%20J.J.%2C%20Flanagan%2C%20E.P.%2C%20Pittock%2C%20S.J.%2C%20Stern%2C%20N.C.%2C%20Tisavipat%2C%20N.%2C%20Bhatti%2C%20M.T.%2C%20Chodnicki%2C%20K.D.%2C%20Tajfirouz%2C%20D.A.%2C%20Jamali%2C%20S.%2C%20Kunchok%2C%20A.%2C%20Eggenberger%2C%20E.R.%2C%20Nome%2C%20M.A.D.%2C%20Sotirchos%2C%20E.S.%2C%20Vasileiou%2C%20E.S.%2C%20Henderson%2C%20A.D.%2C%20Arnold%2C%20A.C.%2C%20Bonelli%2C%20L.%2C%20Moss%2C%20H.E.%2C%20Navarro%2C%20S.E.V.%2C%20Padungkiatsagul%2C%20T.%2C%20Stiebel-Kalish%2C%20H.%2C%20Lotan%2C%20I.%2C%20Wilf-Yarkoni%2C%20A.%2C%20Danesh-Meyer%2C%20H.%2C%20Ivanov%2C%20S.%2C%20Huda%2C%20S.%2C%20Forcadela%2C%20M.%2C%20Hodge%2C%20D.%2C%20Poullin%2C%20P.%2C%20Rode%2C%20J.%2C%20Papeix%2C%20C.%2C%20Saheb%2C%20S.%2C%20Boudot%20de%20la%20Motte%2C%20M.%2C%20Vignal%2C%20C.%2C%20Hacohen%2C%20Y.%2C%20Pique%2C%20J.%2C%20Maillart%2C%20E.%2C%20Deschamps%2C%20R.%2C%20Audoin%2C%20B.%20and%20Marignier%2C%20R.%20%282023%29%20%26%23x2018%3BVisual%20Outcomes%20Following%20Plasma%20Exchange%20for%20Optic%20Neuritis%3A%20An%20International%20Multicenter%20Retrospective%20Analysis%20of%20395%20Optic%20Neuritis%20Attacks%26%23x2019%3B%2C%20%3Ci%3EAmerican%20Journal%20of%20Ophthalmology%3C%5C%2Fi%3E%2C%20pp.%20S0002-9394%2823%2900066%26%23x2013%3B1.%20Available%20at%3A%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ajo.2023.02.013%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ajo.2023.02.013%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Visual%20Outcomes%20Following%20Plasma%20Exchange%20for%20Optic%20Neuritis%3A%20An%20International%20Multicenter%20Retrospective%20Analysis%20of%20395%20Optic%20Neuritis%20Attacks%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20J.%22%2C%22lastName%22%3A%22Chen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eoin%20P.%22%2C%22lastName%22%3A%22Flanagan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sean%20J.%22%2C%22lastName%22%3A%22Pittock%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicole%20Caroline%22%2C%22lastName%22%3A%22Stern%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nanthaya%22%2C%22lastName%22%3A%22Tisavipat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20Tariq%22%2C%22lastName%22%3A%22Bhatti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kevin%20D.%22%2C%22lastName%22%3A%22Chodnicki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deena%20A.%22%2C%22lastName%22%3A%22Tajfirouz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sepideh%22%2C%22lastName%22%3A%22Jamali%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amy%22%2C%22lastName%22%3A%22Kunchok%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%20R.%22%2C%22lastName%22%3A%22Eggenberger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%20A.%20Di%22%2C%22lastName%22%3A%22Nome%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elias%20S.%22%2C%22lastName%22%3A%22Sotirchos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eleni%20S.%22%2C%22lastName%22%3A%22Vasileiou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amanda%20D.%22%2C%22lastName%22%3A%22Henderson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anthony%20C.%22%2C%22lastName%22%3A%22Arnold%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%22%2C%22lastName%22%3A%22Bonelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Heather%20E.%22%2C%22lastName%22%3A%22Moss%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvia%20Elizabeth%20Villarreal%22%2C%22lastName%22%3A%22Navarro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tanyatuth%22%2C%22lastName%22%3A%22Padungkiatsagul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hadas%22%2C%22lastName%22%3A%22Stiebel-Kalish%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Itay%22%2C%22lastName%22%3A%22Lotan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adi%22%2C%22lastName%22%3A%22Wilf-Yarkoni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helen%22%2C%22lastName%22%3A%22Danesh-Meyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefan%22%2C%22lastName%22%3A%22Ivanov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Saif%22%2C%22lastName%22%3A%22Huda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mirasol%22%2C%22lastName%22%3A%22Forcadela%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Hodge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascale%22%2C%22lastName%22%3A%22Poullin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Rode%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Papeix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samir%22%2C%22lastName%22%3A%22Saheb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Boudot%20de%20la%20Motte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Vignal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yael%22%2C%22lastName%22%3A%22Hacohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Pique%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Deschamps%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Marignier%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20To%20evaluate%20the%20effectiveness%20of%20plasma%20exchange%20%28PLEX%29%20for%20optic%20neuritis%20%28ON%29.%5CnMETHODS%3A%20We%20conducted%20an%20international%20multicenter%20retrospective%20study%20evaluating%20the%20outcomes%20of%20ON%20following%20PLEX.%20Outcomes%20were%20compared%20to%20raw%20data%20from%20the%20Optic%20Neuritis%20Treatment%20Trial%20%28ONTT%29%20using%20a%20matched%20subset.%5CnRESULTS%3A%20A%20total%20of%20395%20ON%20attack%20treated%20with%20PLEX%20from%20317%20patients%20were%20evaluated.%20The%20median%20age%20was%2037%20years%20%28range%209%20to%2075%29%20and%2071%25%20were%20female.%20Causes%20of%20ON%20included%3A%20multiple%20sclerosis%20%28108%29%2C%20myelin-oligodendrocyte-glycoprotein-antibody-associated-disease%20%28MOGAD%29%20%2892%29%2C%20aquaporin-4-IgG-positive-neuromyelitis-optica-spectrum-disorder%20%28AQP4%2BNMOSD%29%20%2875%29%2C%20seronegative-NMOSD%20%2834%29%2C%20idiopathic%20%2883%29%2C%20and%20other%20%283%29.%20Median%20time%20from%20onset%20of%20vision%20loss%20to%20PLEX%20was%202.6%20weeks%20%28IQR%2C%201.4-4.0%29.%20Median%20visual%20acuity%20%28VA%29%20at%20time%20of%20PLEX%20was%20count%20fingers%20%28IQR%2C%2020%5C%2F200-hand%20motion%29%20and%20median%20final%20VA%20was%2020%5C%2F25%20%28IQR%2C%2020%5C%2F20-20%5C%2F60%29%20with%20no%20differences%20among%20etiologies%20except%20MOGAD-ON%20which%20had%20better%20outcomes.%20In%2081%20%2820.5%25%29%20ON%20attacks%2C%20the%20final%20VA%20was%2020%5C%2F200%20or%20worse.%20Patients%20with%20poor%20outcomes%20were%20older%20%28p%3D0.002%29%2C%20had%20worse%20VA%20at%20time%20of%20PLEX%20%28p%3C0.001%29%2C%20and%20longer%20delay%20to%20PLEX%20%28p%3C0.001%29.%20In%20comparison%20with%20the%20ONTT%20subset%20with%20severe%20corticosteroid-unresponsive%20ON%2C%20a%20final%20VA%20of%20worse%20than%2020%5C%2F40%20occurred%20in%206%5C%2F50%20%2812%25%29%20PLEX-treated%20ON%20versus%206%5C%2F18%20%2833%25%29%20from%20the%20ONTT%20treated%20with%20intravenous%20methylprednisolone%20without%20PLEX%20%28p%3D0.04%29.%5CnCONCLUSION%3A%20Most%20ON%20attacks%20improved%20with%20PLEX%2C%20and%20outcomes%20were%20better%20than%20attacks%20with%20similar%20severity%20in%20the%20ONTT.%20The%20presence%20of%20severe%20vision%20loss%20at%20nadir%2C%20older%20age%2C%20and%20longer%20delay%20to%20PLEX%20predicted%20a%20worse%20outcome%20while%20MOGAD-ON%20had%20a%20more%20favorable%20prognosis.%22%2C%22date%22%3A%222023-02-21%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ajo.2023.02.013%22%2C%22ISSN%22%3A%221879-1891%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226KPLZTET%22%5D%2C%22dateModified%22%3A%222023-02-24T07%3A35%3A20Z%22%7D%7D%2C%7B%22key%22%3A%22ZUHKTNY2%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Carra-Dalli%5Cu00e8re%20et%20al.%22%2C%22parsedDate%22%3A%222023-02-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ECarra-Dalli%26%23xE8%3Bre%2C%20C.%2C%20Rollot%2C%20F.%2C%20Deschamps%2C%20R.%2C%20Ciron%2C%20J.%2C%20Vukusic%2C%20S.%2C%20Audoin%2C%20B.%2C%20Ruet%2C%20A.%2C%20Maillart%2C%20E.%2C%20Papeix%2C%20C.%2C%20Zephir%2C%20H.%2C%20Laplaud%2C%20D.%2C%20Cohen%2C%20M.%2C%20Bourre%2C%20B.%2C%20El-Bahi%2C%20I.%2C%20Labauge%2C%20P.%2C%20Casey%2C%20R.%2C%20Ayrignac%2C%20X.%20and%20Marignier%2C%20R.%20%282023%29%20%26%23x2018%3BPregnancy%20and%20post-partum%20in%20patients%20with%20myelin-oligodendrocyte%20glycoprotein%20antibody-associated%20disease%26%23x2019%3B%2C%20%3Ci%3EMultiple%20Sclerosis%20Journal%3C%5C%2Fi%3E%2C%2029%282%29%2C%20pp.%20270%26%23x2013%3B276.%20Available%20at%3A%20%3Ca%20class%3D%27zp-ItemURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F13524585221134214%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F13524585221134214%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Pregnancy%20and%20post-partum%20in%20patients%20with%20myelin-oligodendrocyte%20glycoprotein%20antibody-associated%20disease%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clarisse%22%2C%22lastName%22%3A%22Carra-Dalli%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Rollot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Deschamps%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Ruet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Papeix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Zephir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Laplaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikael%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Illiasse%22%2C%22lastName%22%3A%22El-Bahi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Casey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Ayrignac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Marignier%22%7D%5D%2C%22abstractNote%22%3A%22Background%20and%20objective%3A%20Myelin-oligodendrocyte%20glycoprotein%20%28MOG%29%20antibody-associated%20disease%20%28MOGAD%29%20frequently%20initiates%20during%20childbearing%20years.%20This%20study%20investigated%20the%20impact%20of%20pregnancy%20and%20post-partum%20on%20MOGAD%20activity.%5CnMethods%3A%20Retrospective%20analysis%20of%20clinical%20and%20demographic%20data%20from%20a%20multicenter%20French%20cohort%20of%20adult%20patients%20with%20MOGAD.%20All%20adult%20female%20patients%20who%20had%20a%20pregnancy%20after%20disease%20onset%20or%20in%20the%20year%20before%20disease%20onset%20were%20included.%20The%20annualized%20relapse%20rate%20was%20evaluated%20in%20patients%20who%20had%20a%20pregnancy%20after%20disease%20onset%2C%20to%20evaluate%20the%20impact%20of%20pregnancy%20and%20post-partum%20on%20MOGAD%20course.%5CnResults%3A%20Twenty-five%20informative%20pregnancies%20after%20disease%20onset%20were%20identified.%20No%20relapse%20was%20recorded%20during%20these%20pregnancies%20and%20only%20three%20relapses%20occurred%20during%20the%20first%203%5Cu2009months%20post-partum.%20The%20annualized%20relapse%20rate%20decreased%20from%200.67%20%2895%25%20confidence%20interval%3A%200.40%5Cu20131.10%29%20during%20the%20pre-pregnancy%20period%20to%200%20%2895%25%20confidence%20interval%3A%200%5Cu20130.21%29%20during%20pregnancy%20and%20to%200.22%20%2895%25%20confidence%20interval%3A%200.09%5Cu20130.53%29%20during%20the%20first%20year%20post-partum.%20Among%20144%20female%20patients%20in%20their%20childbearing%20age%20recorded%20in%20the%20database%2C%2018%20%2812.5%25%29%20reported%20their%20first%20symptoms%20during%20pregnancy%20or%20in%20the%2012%5Cu2009months%20post-partum.%5CnDiscussion%3A%20Our%20study%20suggests%20a%20marked%20reduction%20of%20MOGAD%20relapse%20rate%20during%20pregnancy%20and%20the%20post-partum%20period.%20Prospective%20studies%20on%20the%20role%20of%20pregnancy%20and%20delivery%20in%20MOGAD%20course%20are%20needed.%22%2C%22date%22%3A%222023-02-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1177%5C%2F13524585221134214%22%2C%22ISSN%22%3A%221352-4585%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F13524585221134214%22%2C%22collections%22%3A%5B%226KPLZTET%22%5D%2C%22dateModified%22%3A%222024-01-08T12%3A36%3A19Z%22%7D%7D%2C%7B%22key%22%3A%226GQS6B3H%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Maarouf%20et%20al.%22%2C%22parsedDate%22%3A%222022-10-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMaarouf%2C%20A.%2C%20Audoin%2C%20B.%2C%20Gherib%2C%20S.%2C%20El%20Mendili%2C%20M.M.%2C%20Viout%2C%20P.%2C%20Pariollaud%2C%20F.%2C%20Bouti%26%23xE8%3Bre%2C%20C.%2C%20Rico%2C%20A.%2C%20Guye%2C%20M.%2C%20Ranjeva%2C%20J.-P.%2C%20Zaaraoui%2C%20W.%20and%20Pelletier%2C%20J.%20%282022%29%20%26%23x2018%3BGrey-matter%20sodium%20concentration%20as%20an%20individual%20marker%20of%20multiple%20sclerosis%20severity%26%23x2019%3B%2C%20%3Ci%3EMultiple%20Sclerosis%20Journal%3C%5C%2Fi%3E%2C%2028%2812%29%2C%20pp.%201903%26%23x2013%3B1912.%20Available%20at%3A%20%3Ca%20class%3D%27zp-ItemURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F13524585221102587%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F13524585221102587%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Grey-matter%20sodium%20concentration%20as%20an%20individual%20marker%20of%20multiple%20sclerosis%20severity%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Soraya%22%2C%22lastName%22%3A%22Gherib%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mohamed%20Mounir%22%2C%22lastName%22%3A%22El%20Mendili%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Viout%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fanelly%22%2C%22lastName%22%3A%22Pariollaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mence%22%2C%22lastName%22%3A%22Bouti%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Guye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Ranjeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wafaa%22%2C%22lastName%22%3A%22Zaaraoui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%5D%2C%22abstractNote%22%3A%22Objective%3AQuantification%20of%20brain%20injury%20in%20patients%20with%20variable%20disability%20despite%20similar%20disease%20duration%20may%20be%20relevant%20to%20identify%20the%20mechanisms%20underlying%20disability%20in%20multiple%20sclerosis%20%28MS%29.%20We%20aimed%20to%20compare%20grey-matter%20sodium%20abnormalities%20%28GMSAs%29%2C%20a%20parameter%20reflecting%20neuronal%20and%20astrocyte%20dysfunction%2C%20in%20MS%20patients%20with%20benign%20multiple%20sclerosis%20%28BMS%29%20and%20non-benign%20multiple%20sclerosis%20%28NBMS%29.Methods%3AWe%20identified%20never-treated%20BMS%20patients%20in%20our%20local%20MS%20database%20of%201352%20patients.%20A%20group%20with%20NBMS%20was%20identified%20with%20same%20disease%20duration.%20All%20participants%20underwent%2023Na%20magnetic%20resonance%20imaging%20%28MRI%29.%20The%20existence%20of%20GMSA%20was%20detected%20by%20statistical%20analysis.Results%3AIn%20total%2C%20102%20individuals%20were%20included%20%2821%20BMS%2C%2025%20NBMS%20and%2056%20controls%29.%20GMSA%20was%20detected%20in%2010%20BMS%20and%2019%20NBMS%20%2811%5C%2F16%20relapsing-remitting%20multiple%20sclerosis%20%28RRMS%29%20and%208%5C%2F9%20secondary%20progressive%20multiple%20sclerosis%20%28SPMS%29%20patients%29%20%28p%3F%3D%3F0.05%29.%20On%20logistic%20regression%20including%20the%20presence%20or%20absence%20of%20GMSA%2C%20thalamic%20volume%2C%20cortical%20grey-matter%20volume%20and%20T2-weighted%20lesion%20load%2C%20thalamic%20volume%20was%20independently%20associated%20with%20BMS%20status%20%28odds%20ratio%20%28OR%29%3F%3D%3F0.64%20for%20each%20unit%29.%20Nonetheless%2C%20the%20absence%20of%20GMSA%20was%20independently%20associated%20when%20excluding%20patients%20with%20significant%20cognitive%20alteration%20%28n%3F%3D%3F7%29%20from%20the%20BMS%20group%20%28OR%3F%3D%3F4.6%29.Conclusion%3ADetection%20of%20GMSA%20in%20individuals%20and%20thalamic%20volume%20are%20promising%20to%20differentiate%20BMS%20from%20NBMS%20as%20compared%20with%20cortical%20or%20whole%20grey-matter%20atrophy%20and%20T2-weighted%20lesions.%22%2C%22date%22%3A%222022-10-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1177%5C%2F13524585221102587%22%2C%22ISSN%22%3A%221352-4585%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F13524585221102587%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22QU2QXBVV%22%2C%22UP3H3ICX%22%2C%22B4EWFM7E%22%2C%22P66W67T8%22%2C%226KPLZTET%22%2C%22F2AGIUQU%22%2C%22XTA6KS7L%22%5D%2C%22dateModified%22%3A%222024-11-26T16%3A01%3A22Z%22%7D%7D%2C%7B%22key%22%3A%22JMKK2PYJ%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Poullet%20et%20al.%22%2C%22parsedDate%22%3A%222022-07%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EPoullet%2C%20Z.%2C%20Pique%2C%20J.%2C%20Maarouf%2C%20A.%2C%20Boutiere%2C%20C.%2C%20Rico%2C%20A.%2C%20Demortiere%2C%20S.%2C%20Durozard%2C%20P.%2C%20Papeix%2C%20C.%2C%20Maillart%2C%20E.%2C%20Collongues%2C%20N.%2C%20Ayrignac%2C%20X.%2C%20Zephir%2C%20H.%2C%20Deschamps%2C%20R.%2C%20Ciron%2C%20J.%2C%20Pelletier%2C%20J.%2C%20Marignier%2C%20R.%20and%20Audoin%2C%20B.%20%282022%29%20%26%23x2018%3BPure%20Relapsing%20Short%20Myelitis%3A%20Part%20of%20the%20Multiple%20Sclerosis%20Spectrum%20or%20New%20Entity%3F%26%23x2019%3B%2C%20%3Ci%3ENeurology%28R%29%20Neuroimmunology%20%26amp%3B%20Neuroinflammation%3C%5C%2Fi%3E%2C%209%284%29%2C%20p.%20e1167.%20Available%20at%3A%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000001167%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000001167%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Pure%20Relapsing%20Short%20Myelitis%3A%20Part%20of%20the%20Multiple%20Sclerosis%20Spectrum%20or%20New%20Entity%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Z%5Cu00e9lia%22%2C%22lastName%22%3A%22Poullet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Pique%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clemence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demortiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Durozard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Papeix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Collongues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Ayrignac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helene%22%2C%22lastName%22%3A%22Zephir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Deschamps%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Marignier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20OBJECTIVES%3A%20Pure%20relapsing%20short%20myelitis%20with%20clinical%20and%20paraclinical%20features%20suggesting%20multiple%20sclerosis%20%28MS%29%20has%20been%20described%20recently.%20Here%2C%20we%20evaluated%20the%20existence%20of%20this%20potential%20new%20form%20of%20MS%20by%20retrospectively%20searching%20for%20similar%20cases%20in%20the%20databases%20of%20the%20French%20tertiary%20MS%20centers.%5CnMETHODS%3A%20Patients%20were%20included%20based%20on%20the%20present%20criteria%3A%20at%20least%202%20short%20%28%3C3%20vertebral%20segments%29%20myelitis%20episodes%3B%20minimum%20follow-up%20of%203%20years%3B%20no%20MS-like%20brain%20lesion%20during%20all%20the%20follow-up%3B%20tested%20negative%20for%20both%20anti-myelin%20oligodendrocyte%20glycoprotein%20and%20anti-aquaporin%204%20antibodies%20in%20serum%3B%20presence%20of%20oligoclonal%20bands%20in%20CSF%3B%20and%20comprehensive%20workup%20to%20exclude%20alternative%20diagnoses.%5CnRESULTS%3A%20Eighteen%20patients%20fulfilled%20all%20criteria.%20The%20sex%20ratio%20%28females%5C%2Fmales%29%20was%205%5C%2F1%3B%20the%20median%20%28range%29%20age%20at%20first%20relapse%20was%2035.5%20%2825-54%29%20years%2C%20the%20disease%20duration%20was%2080.5%20%2850-308%29%20months%2C%20and%20the%20annualized%20relapse%20rate%20was%200.36%20%280.1-0.5%29.%20The%20median%20%28range%29%20number%20of%20relapses%20per%20patient%20was%202%20%282-5%29%2C%20and%20the%20median%20%28range%29%20Expanded%20Disability%20Status%20Scale%20score%20at%20last%20follow-up%20was%201%20%280-7.5%29.%20In%20CSF%2C%20the%20median%20%28range%29%20protein%20level%20was%200.34%20g%5C%2FL%20%280.18-0.77%29%2C%20and%20the%20median%20%28range%29%20number%20of%20mononuclear%20cells%20was%203%20%280-28%29.%20Spinal%20cord%20MRI%20demonstrated%20a%20median%20%28range%29%20number%20of%202%20%281-5%29%20lesions%20per%20examination%20and%203%20%5B1-7%5D%20on%20the%20last%20examination.%20Fifty-five%20percent%20of%20lesions%20involved%20the%20cervical%20levels.%20Secondary%20progressive%20evolution%20occurred%20in%203%20of%2018%20%2817%25%29%20patients.%5CnDISCUSSION%3A%20Pure%20spinal%20MS%20could%20be%20a%20rare%20entity%20in%20the%20MS%20disease%20spectrum.%20However%2C%20the%20existence%20of%20a%20distinct%20entity%20in%20the%20inflammatory%20CNS%20disorders%20cannot%20be%20excluded.%22%2C%22date%22%3A%222022-07%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FNXI.0000000000001167%22%2C%22ISSN%22%3A%222332-7812%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%2C%22NLCL528K%22%5D%2C%22dateModified%22%3A%222024-11-26T16%3A01%3A02Z%22%7D%7D%2C%7B%22key%22%3A%22BA7BKXEL%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Januel%20et%20al.%22%2C%22parsedDate%22%3A%222022-06-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EJanuel%2C%20E.%2C%20De%20Seze%2C%20J.%2C%20Vermersch%2C%20P.%2C%20Maillart%2C%20E.%2C%20Bourre%2C%20B.%2C%20Pique%2C%20J.%2C%20Moisset%2C%20X.%2C%20Bensa%2C%20C.%2C%20Maarouf%2C%20A.%2C%20Pelletier%2C%20J.%2C%20Vukusic%2C%20S.%2C%20Audoin%2C%20B.%20and%20Louapre%2C%20C.%20%282022%29%20%26%23x2018%3BPost-vaccine%20COVID-19%20in%20patients%20with%20multiple%20sclerosis%20or%20neuromyelitis%20optica%26%23x2019%3B%2C%20%3Ci%3EMultiple%20Sclerosis%20Journal%3C%5C%2Fi%3E%2C%2028%287%29%2C%20pp.%201155%26%23x2013%3B1159.%20Available%20at%3A%20%3Ca%20class%3D%27zp-ItemURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F13524585211049737%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F13524585211049737%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Post-vaccine%20COVID-19%20in%20patients%20with%20multiple%20sclerosis%20or%20neuromyelitis%20optica%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edouard%22%2C%22lastName%22%3A%22Januel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22De%20Seze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Vermersch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Pique%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Moisset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Bensa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Louapre%22%7D%5D%2C%22abstractNote%22%3A%22Introduction%3ARecent%20studies%20suggested%20that%20anti-CD20%20and%20fingolimod%20may%20be%20associated%20with%20lower%20anti-spike%20protein-based%20immunoglobulin-G%20response%20following%20COVID-19%20vaccination.%20We%20evaluated%20if%20COVID-19%20occurred%20despite%20vaccination%20among%20patients%20with%20multiple%20sclerosis%20%28MS%29%20and%20neuromyelitis%20optica%20%28NMO%29%2C%20using%20the%20COVISEP%20registry.Case%20series%3AWe%20report%2018%20cases%20of%20COVID-19%20after%20two%20doses%20of%20BNT162b2-vaccination%2C%2013%20of%20which%20treated%20with%20anti-CD20%20and%20four%20with%20fingolimod.%20COVID-19%20severity%20was%20mild.Discussion%3AThese%20results%20reinforce%20the%20recommendation%20for%20a%20third%20COVID-19%20vaccine%20dose%20among%20anti-CD20%20treated%20patients%20and%20stress%20the%20need%20for%20a%20prospective%20clinical%20and%20biological%20study%20on%20COVID-19%20vaccine%20efficacy%20among%20MS%20and%20NMO%20patients.%22%2C%22date%22%3A%222022-06-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1177%5C%2F13524585211049737%22%2C%22ISSN%22%3A%221352-4585%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F13524585211049737%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%5D%2C%22dateModified%22%3A%222024-11-26T16%3A01%3A22Z%22%7D%7D%2C%7B%22key%22%3A%22N7JR5MZU%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Demuth%20et%20al.%22%2C%22parsedDate%22%3A%222022-03-02%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDemuth%2C%20S.%2C%20Guillaume%2C%20M.%2C%20Bourre%2C%20B.%2C%20Ciron%2C%20J.%2C%20Zephir%2C%20H.%2C%20Sirejacob%2C%20Y.%2C%20Kerbrat%2C%20A.%2C%20Lebrun-Frenay%2C%20C.%2C%20Papeix%2C%20C.%2C%20Michel%2C%20L.%2C%20Laplaud%2C%20D.%2C%20Vukusic%2C%20S.%2C%20Maillart%2C%20E.%2C%20Cohen%2C%20M.%2C%20Audoin%2C%20B.%2C%20Marignier%2C%20R.%2C%20Collongues%2C%20N.%20and%20NOMADMUS%20Study%20Group%20%282022%29%20%26%23x2018%3BTreatment%20regimens%20for%20neuromyelitis%20optica%20spectrum%20disorder%20attacks%3A%20a%20retrospective%20cohort%20study%26%23x2019%3B%2C%20%3Ci%3EJournal%20of%20Neuroinflammation%3C%5C%2Fi%3E%2C%2019%281%29%2C%20p.%2062.%20Available%20at%3A%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12974-022-02420-2%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12974-022-02420-2%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Treatment%20regimens%20for%20neuromyelitis%20optica%20spectrum%20disorder%20attacks%3A%20a%20retrospective%20cohort%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stanislas%22%2C%22lastName%22%3A%22Demuth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Guillaume%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Zephir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yoann%22%2C%22lastName%22%3A%22Sirejacob%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Kerbrat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lebrun-Frenay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Papeix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Laplaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikael%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Marignier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Collongues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22NOMADMUS%20Study%20Group%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Neuromyelitis%20optica%20spectrum%20disorder%20%28NMOSD%29%20attacks%20require%20an%20urgent%20probabilistic%20anti-inflammatory%20therapeutic%20strategy.%20As%20inadequately%20treated%20attacks%20result%20in%20disability%2C%20there%20is%20a%20need%20to%20identify%20the%20optimal%20attack-treatment%20regimen.%20Our%20study%20aimed%20to%20identify%20predictors%20of%20outcome%20after%20a%20first%20attack%20in%20patients%20with%20an%20NMOSD%20presentation%20and%20propose%20the%20best%20treatment%20strategy.%5CnMETHODS%3A%20We%20performed%20a%20retrospective%20cohort%20study%20on%20the%20French%20national%20NMOSD%20registry%20%28NOMADMUS%29%2C%20a%20nested%20cohort%20of%20the%20French%20multiple%20sclerosis%20observatory%20%28OFSEP%29%20recruiting%20patients%20with%20NMOSD%20presentations%20in%20France.%20We%20studied%20the%20first%20attack%20for%20any%20independent%20locations%20of%20clinical%20core%20characteristic%20of%20NMOSD%2C%20in%20treatment-na%5Cu00efve%20patients.%20The%20primary%20outcome%20was%20the%20evolution%20of%20the%20Expanded%20Disability%20Status%20Scale%20%28EDSS%29%20score%20at%206%5Cu00a0months%2C%20stratified%20in%20two%20ways%20to%20account%20for%20recovery%20%28return%20to%20baseline%20EDSS%20score%29%20and%20treatment%20response%20%28classified%20as%20%5C%22good%5C%22%20if%20the%20EDSS%20score%20decreased%20by%20%5Cu2265%5Cu20091%20point%20after%20a%20nadir%20EDSS%20score%5Cu2009%5Cu2264%5Cu20093%2C%20or%20by%20%5Cu2265%5Cu20092%20points%20after%20a%20nadir%20EDSS%20score%5Cu2009%3E%5Cu20093%29.%20We%20used%20ordinal%20logistic%20regression%20to%20infer%20statistical%20associations%20with%20the%20outcome.%5CnRESULTS%3A%20We%20included%20211%20attacks%20among%20183%20patients%20%28104%20with%20anti-AQP4%20antibodies%2C%2060%20with%20anti-MOG%20antibodies%2C%20and%2019%20double%20seronegative%29.%20Attack%20treatment%20regimens%20comprised%20corticosteroids%20%28n%5Cu2009%3D%5Cu2009196%29%2C%20plasma%20exchanges%20%28PE%3B%20n%5Cu2009%3D%5Cu200972%29%20and%20intravenous%20immunoglobulins%20%28n%5Cu2009%3D%5Cu20096%29.%20Complete%20recovery%20was%20reached%20in%2040%20attacks%20%2819%25%29%20at%206%5Cu00a0months.%20The%20treatment%20response%20was%20%5C%22good%5C%22%20in%20134%20attacks%20%2863.5%25%29.%20There%20was%20no%20improvement%20in%20EDSS%20score%20in%2050%20attacks%20%2823.7%25%29.%20MOG-antibody%20seropositivity%20and%20short%20delays%20to%20PE%20were%20significantly%20and%20independently%20associated%20with%20better%20recovery%20and%20treatment%20response.%5CnCONCLUSIONS%3A%20We%20identified%20two%20prognostic%20factors%3A%20serostatus%20%28with%20better%20outcomes%20among%20MOG-Ab-positive%20patients%29%20and%20the%20delay%20to%20PE.%20We%2C%20therefore%2C%20argue%20for%20a%20more%20aggressive%20anti-inflammatory%20management%20of%20the%20first%20attacks%20suggesting%20an%20NMOSD%20presentation%2C%20with%20the%20early%20combination%20of%20PE%20with%20corticosteroids.%22%2C%22date%22%3A%222022-03-02%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12974-022-02420-2%22%2C%22ISSN%22%3A%221742-2094%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226KPLZTET%22%5D%2C%22dateModified%22%3A%222024-05-03T05%3A39%3A51Z%22%7D%7D%2C%7B%22key%22%3A%22JZB2NE65%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Perriguey%20et%20al.%22%2C%22parsedDate%22%3A%222022-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EPerriguey%2C%20M.%2C%20Maarouf%2C%20A.%2C%20Stellmann%2C%20J.-P.%2C%20Rico%2C%20A.%2C%20Boutiere%2C%20C.%2C%20Demortiere%2C%20S.%2C%20Durozard%2C%20P.%2C%20Pelletier%2C%20J.%20and%20Audoin%2C%20B.%20%282022%29%20%26%23x2018%3BHypogammaglobulinemia%20and%20Infections%20in%20Patients%20With%20Multiple%20Sclerosis%20Treated%20With%20Rituximab%26%23x2019%3B%2C%20%3Ci%3ENeurology%28R%29%20Neuroimmunology%20%26amp%3B%20Neuroinflammation%3C%5C%2Fi%3E%2C%209%281%29%2C%20p.%20e1115.%20Available%20at%3A%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000001115%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000001115%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Hypogammaglobulinemia%20and%20Infections%20in%20Patients%20With%20Multiple%20Sclerosis%20Treated%20With%20Rituximab%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Perriguey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan-Patrick%22%2C%22lastName%22%3A%22Stellmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clemence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demortiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Durozard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20OBJECTIVES%3A%20To%20determine%20the%20frequency%20of%20hypogammaglobulinemia%20and%20infections%20in%20patients%20with%20multiple%20sclerosis%20%28PwMS%29%20receiving%20rituximab%20%28RTX%29.%5CnMETHODS%3A%20This%20prospective%20observational%20study%20included%20all%20consecutive%20PwMS%20receiving%20RTX%20at%20the%20university%20hospital%20of%20Marseille%2C%20France%2C%20between%202015%20and%202020.%20Patient%20visits%20occurred%20at%20least%20every%206%20months.%5CnRESULTS%3A%20We%20included%20188%20patients%20%28151%20with%20relapsing-remitting%20MS%3B%20the%20mean%20age%20was%2043.4%20years%20%5BSD%2012.9%5D%2C%20median%20disease%20duration%2010%20years%20%5Brange%200-36%5D%2C%20median%20Expanded%20Disability%20Status%20Scale%205%20%5Brange%200-8%5D%2C%20median%20follow-up%203.5%20years%20%5Brange%201-5.8%5D%2C%20and%20median%20number%20of%20RTX%20infusions%205%20%5Brange%201-9%5D%29.%20Overall%2C%20317%20symptomatic%20infections%20and%2013%20severe%20infections%20occurred%20in%20133%20of%20188%20%2870.7%25%29%20and%2011%20of%20188%20%285.9%25%29%20patients%2C%20respectively.%20After%204%20years%2C%2024.4%25%20of%20patients%20%2895%25%20CI%2018.0-33.1%29%20were%20free%20of%20any%20infection%20and%2092.0%25%20%2895%25%20CI%2087.1-97.1%29%20had%20not%20experienced%20a%20severe%20infection.%20At%20RTX%20onset%2C%20the%20immunoglobulin%20G%20%28IgG%29%20level%20was%20abnormal%20in%2032%20of%20188%20%2817%25%29%20patients.%20After%20RTX%2C%20IgG%20level%20was%20%3C7%2C%20%3C6%2C%20%3C4%20and%20%3C2%20g%5C%2FL%20for%2083%20%2844%25%29%2C%2044%20%2823.4%25%29%2C%208%20%284.2%25%29%20and%201%20%280.53%25%29%20patients%2C%20respectively.%20The%20risk%20of%20infection%20was%20associated%20with%20reduced%20IgG%20levels%20%28multivariate%20Cox%20proportional%20hazards%20hazard%20ratio%20%5BHR%5D%20%3D%200.86%2C%2095%25%20CI%200.75-0.98%2C%20p%20%3D%200.03%29.%20The%20risk%20of%20reduced%20IgG%20level%20%3C6%20g%5C%2FL%20increased%20with%20age%20%28HR%20%3D%201.36%2C%2095%25%20CI%201.05-1.75%2C%20p%20%3D%200.01%29.%5CnDISCUSSION%3A%20In%20PwMS%20receiving%20RTX%2C%20reduced%20IgG%20level%20was%20frequent%20and%20interacted%20with%20the%20risk%20of%20infection.%22%2C%22date%22%3A%222022-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FNXI.0000000000001115%22%2C%22ISSN%22%3A%222332-7812%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%2C%229L2KHJ5X%22%2C%22NLCL528K%22%5D%2C%22dateModified%22%3A%222025-01-28T16%3A13%3A07Z%22%7D%7D%2C%7B%22key%22%3A%22HEUPG3D9%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ringelstein%20et%20al.%22%2C%22parsedDate%22%3A%222022-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ERingelstein%2C%20M.%2C%20Ayzenberg%2C%20I.%2C%20Lindenblatt%2C%20G.%2C%20Fischer%2C%20K.%2C%20Gahlen%2C%20A.%2C%20Novi%2C%20G.%2C%20Hayward-K%26%23xF6%3Bnnecke%2C%20H.%2C%20Schippling%2C%20S.%2C%20Rommer%2C%20P.S.%2C%20Kornek%2C%20B.%2C%20Zrzavy%2C%20T.%2C%20Biotti%2C%20D.%2C%20Ciron%2C%20J.%2C%20Audoin%2C%20B.%2C%20Berthele%2C%20A.%2C%20Giglhuber%2C%20K.%2C%20Zephir%2C%20H.%2C%20K%26%23xFC%3Bmpfel%2C%20T.%2C%20Berger%2C%20R.%2C%20R%26%23xF6%3Bther%2C%20J.%2C%20H%26%23xE4%3Bu%26%23xDF%3Bler%2C%20V.%2C%20Stellmann%2C%20J.-P.%2C%20Whittam%2C%20D.%2C%20Jacob%2C%20A.%2C%20Kraemer%2C%20M.%2C%20Gueguen%2C%20A.%2C%20Deschamps%2C%20R.%2C%20Bayas%2C%20A.%2C%20H%26%23xFC%3Bmmert%2C%20M.W.%2C%20Trebst%2C%20C.%2C%20Haarmann%2C%20A.%2C%20Jarius%2C%20S.%2C%20Wildemann%2C%20B.%2C%20Grothe%2C%20M.%2C%20Siebert%2C%20N.%2C%20Ruprecht%2C%20K.%2C%20Paul%2C%20F.%2C%20Collongues%2C%20N.%2C%20Marignier%2C%20R.%2C%20Levy%2C%20M.%2C%20Karenfort%2C%20M.%2C%20Deppe%2C%20M.%2C%20Albrecht%2C%20P.%2C%20Hellwig%2C%20K.%2C%20Gold%2C%20R.%2C%20Hartung%2C%20H.-P.%2C%20Meuth%2C%20S.G.%2C%20Kleiter%2C%20I.%2C%20Aktas%2C%20O.%20and%20Neuromyelitis%20Optica%20Study%20Group%20%28NEMOS%29%20%282022%29%20%26%23x2018%3BInterleukin-6%20Receptor%20Blockade%20in%20Treatment-Refractory%20MOG-IgG-Associated%20Disease%20and%20Neuromyelitis%20Optica%20Spectrum%20Disorders%26%23x2019%3B%2C%20%3Ci%3ENeurology%28R%29%20Neuroimmunology%20%26amp%3B%20Neuroinflammation%3C%5C%2Fi%3E%2C%209%281%29%2C%20p.%20e1100.%20Available%20at%3A%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000001100%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000001100%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Interleukin-6%20Receptor%20Blockade%20in%20Treatment-Refractory%20MOG-IgG-Associated%20Disease%20and%20Neuromyelitis%20Optica%20Spectrum%20Disorders%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marius%22%2C%22lastName%22%3A%22Ringelstein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ilya%22%2C%22lastName%22%3A%22Ayzenberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gero%22%2C%22lastName%22%3A%22Lindenblatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katinka%22%2C%22lastName%22%3A%22Fischer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Gahlen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giovanni%22%2C%22lastName%22%3A%22Novi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helen%22%2C%22lastName%22%3A%22Hayward-K%5Cu00f6nnecke%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sven%22%2C%22lastName%22%3A%22Schippling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paulus%20S.%22%2C%22lastName%22%3A%22Rommer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barbara%22%2C%22lastName%22%3A%22Kornek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tobias%22%2C%22lastName%22%3A%22Zrzavy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%22%2C%22lastName%22%3A%22Biotti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Achim%22%2C%22lastName%22%3A%22Berthele%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katrin%22%2C%22lastName%22%3A%22Giglhuber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helene%22%2C%22lastName%22%3A%22Zephir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tania%22%2C%22lastName%22%3A%22K%5Cu00fcmpfel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%22%2C%22lastName%22%3A%22Berger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joachim%22%2C%22lastName%22%3A%22R%5Cu00f6ther%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vivien%22%2C%22lastName%22%3A%22H%5Cu00e4u%5Cu00dfler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan-Patrick%22%2C%22lastName%22%3A%22Stellmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Whittam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anu%22%2C%22lastName%22%3A%22Jacob%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Markus%22%2C%22lastName%22%3A%22Kraemer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Gueguen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Deschamps%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonios%22%2C%22lastName%22%3A%22Bayas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%20W.%22%2C%22lastName%22%3A%22H%5Cu00fcmmert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinna%22%2C%22lastName%22%3A%22Trebst%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Axel%22%2C%22lastName%22%3A%22Haarmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sven%22%2C%22lastName%22%3A%22Jarius%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brigitte%22%2C%22lastName%22%3A%22Wildemann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Grothe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadja%22%2C%22lastName%22%3A%22Siebert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Klemens%22%2C%22lastName%22%3A%22Ruprecht%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Friedemann%22%2C%22lastName%22%3A%22Paul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Collongues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Marignier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Levy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Karenfort%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Deppe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philipp%22%2C%22lastName%22%3A%22Albrecht%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kerstin%22%2C%22lastName%22%3A%22Hellwig%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ralf%22%2C%22lastName%22%3A%22Gold%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hans-Peter%22%2C%22lastName%22%3A%22Hartung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sven%20G.%22%2C%22lastName%22%3A%22Meuth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ingo%22%2C%22lastName%22%3A%22Kleiter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Orhan%22%2C%22lastName%22%3A%22Aktas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Neuromyelitis%20Optica%20Study%20Group%20%28NEMOS%29%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20OBJECTIVES%3A%20To%20evaluate%20the%20long-term%20safety%20and%20efficacy%20of%20tocilizumab%20%28TCZ%29%2C%20a%20humanized%20anti-interleukin-6%20receptor%20antibody%20in%20myelin%20oligodendrocyte%20glycoprotein-IgG-associated%20disease%20%28MOGAD%29%20and%20neuromyelitis%20optica%20spectrum%20disorders%20%28NMOSD%29.%5CnMETHODS%3A%20Annualized%20relapse%20rate%20%28ARR%29%2C%20Expanded%20Disability%20Status%20Scale%20score%2C%20MRI%2C%20autoantibody%20titers%2C%20pain%2C%20and%20adverse%20events%20were%20retrospectively%20evaluated%20in%2057%20patients%20with%20MOGAD%20%28n%20%3D%2014%29%2C%20aquaporin-4%20%28AQP4%29-IgG%20seropositive%20%28n%20%3D%2036%29%2C%20and%20seronegative%20NMOSD%20%28n%20%3D%207%3B%2012%25%29%2C%20switched%20to%20TCZ%20from%20previous%20immunotherapies%2C%20particularly%20rituximab.%5CnRESULTS%3A%20Patients%20received%20TCZ%20for%2023.8%20months%20%28median%3B%20interquartile%20range%2013.0-51.1%20months%29%2C%20with%20an%20IV%20dose%20of%208.0%20mg%5C%2Fkg%20%28median%3B%20range%206-12%20mg%5C%2Fkg%29%20every%2031.6%20days%20%28mean%3B%20range%2026-44%20days%29.%20For%20MOGAD%2C%20the%20median%20ARR%20decreased%20from%201.75%20%28range%200.5-5%29%20to%200%20%28range%200-0.9%3B%20p%20%3D%200.0011%29%20under%20TCZ.%20A%20similar%20effect%20was%20seen%20for%20AQP4-IgG%2B%20%28ARR%20reduction%20from%201.5%20%5Brange%200-5%5D%20to%200%20%5Brange%200-4.2%5D%3B%20p%20%3C%200.001%29%20and%20for%20seronegative%20NMOSD%20%28from%203.0%20%5Brange%201.0-3.0%5D%20to%200.2%20%5Brange%200-2.0%5D%3B%20p%20%3D%200.031%29.%20During%20TCZ%2C%2060%25%20of%20all%20patients%20were%20relapse%20free%20%2879%25%20for%20MOGAD%2C%2056%25%20for%20AQP4-IgG%2B%2C%20and%2043%25%20for%20seronegative%20NMOSD%29.%20Disability%20follow-up%20indicated%20stabilization.%20MRI%20inflammatory%20activity%20decreased%20in%20MOGAD%20%28p%20%3D%200.04%3B%20for%20the%20brain%29%20and%20in%20AQP4-IgG%2B%20NMOSD%20%28p%20%3C%200.001%3B%20for%20the%20spinal%20cord%29.%20Chronic%20pain%20was%20unchanged.%20Regarding%20only%20patients%20treated%20with%20TCZ%20for%20at%20least%2012%20months%20%28n%20%3D%2044%29%2C%20ARR%20reductions%20were%20confirmed%2C%20including%20the%20subgroups%20of%20MOGAD%20%28n%20%3D%2011%29%20and%20AQP4-IgG%2B%20patients%20%28n%20%3D%2028%29.%20Similarly%2C%20in%20the%20group%20of%20patients%20treated%20with%20TCZ%20for%20at%20least%2012%20months%2C%2059%25%20of%20them%20were%20relapse%20free%2C%20with%2073%25%20for%20MOGAD%2C%2057%25%20for%20AQP4-IgG%2B%2C%20and%2040%25%20for%20patients%20with%20seronegative%20NMOSD.%20No%20severe%20or%20unexpected%20safety%20signals%20were%20observed.%20Add-on%20therapy%20showed%20no%20advantage%20compared%20with%20TCZ%20monotherapy.%5CnDISCUSSION%3A%20This%20study%20provides%20Class%20III%20evidence%20that%20long-term%20TCZ%20therapy%20is%20safe%20and%20reduces%20relapse%20probability%20in%20MOGAD%20and%20AQP4-IgG%2B%20NMOSD.%22%2C%22date%22%3A%222022-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FNXI.0000000000001100%22%2C%22ISSN%22%3A%222332-7812%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226KPLZTET%22%2C%229L2KHJ5X%22%5D%2C%22dateModified%22%3A%222024-11-21T08%3A40%3A10Z%22%7D%7D%2C%7B%22key%22%3A%22GAIYH54I%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Rico%20et%20al.%22%2C%22parsedDate%22%3A%222021-10%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ERico%2C%20A.%2C%20Ninove%2C%20L.%2C%20Maarouf%2C%20A.%2C%20Boutiere%2C%20C.%2C%20Durozard%2C%20P.%2C%20Demortiere%2C%20S.%2C%20Saba%20Villarroel%2C%20P.M.%2C%20Amroun%2C%20A.%2C%20Fouri%26%23xE9%3B%2C%20T.%2C%20de%20Lamballerie%2C%20X.%2C%20Pelletier%2C%20J.%20and%20Audoin%2C%20B.%20%282021%29%20%26%23x2018%3BDetermining%20the%20best%20window%20for%20BNT162b2%20mRNA%20vaccination%20for%20SARS-CoV-2%20in%20patients%20with%20multiple%20sclerosis%20receiving%20anti-CD20%20therapy%26%23x2019%3B%2C%20%3Ci%3EMultiple%20Sclerosis%20Journal%20-%20Experimental%2C%20Translational%20and%20Clinical%3C%5C%2Fi%3E%2C%207%284%29%2C%20p.%2020552173211062144.%20Available%20at%3A%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F20552173211062142%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F20552173211062142%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Determining%20the%20best%20window%20for%20BNT162b2%20mRNA%20vaccination%20for%20SARS-CoV-2%20in%20patients%20with%20multiple%20sclerosis%20receiving%20anti-CD20%20therapy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%22%2C%22lastName%22%3A%22Ninove%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Durozard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demortiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paola%20Mariela%22%2C%22lastName%22%3A%22Saba%20Villarroel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdennour%22%2C%22lastName%22%3A%22Amroun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Toscane%22%2C%22lastName%22%3A%22Fouri%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22de%20Lamballerie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22We%20studied%20the%20serologic%20response%20to%20the%20BNT162b2%20mRNA%20vaccine%20at%20four%20weeks%20after%20the%20second%20dose%20in%20patients%20with%20RRMS%20treated%20with%20rituximab%20with%20extended-interval%20dosing%20%28n%5Cu2009%3D%5Cu200926%29.%20At%20four%20weeks%2C%2073%25%20of%20patients%20were%20seropositive.%20No%20patient%20without%20B%20cells%20at%20the%20first%20dose%20%28n%5Cu2009%3D%5Cu20094%29%20was%20seropositive.%20Four%20of%20seven%20%2857%25%29%20patients%20with%20B-cell%20proportion%20%3E0%25%20and%20%5Cu22645%25%20were%20seropositive.%20All%20patients%20with%20B-cell%20proportion%20%3E5%25%20%28n%5Cu2009%3D%5Cu200915%29%20were%20seropositive.%20In%20all%20patients%2C%20quantitative%20ELISA%20measures%20after%20vaccination%20were%20correlated%20with%20B-cell%20counts%20measured%20before%20vaccination.%20In%20patients%20receiving%20rituximab%2C%20seropositivity%20after%20BNT162b2%20mRNA%20vaccination%20emerged%20only%20after%20B-cell%20repopulation.%22%2C%22date%22%3A%222021-10%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1177%5C%2F20552173211062142%22%2C%22ISSN%22%3A%222055-2173%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%5D%2C%22dateModified%22%3A%222022-12-03T05%3A53%3A57Z%22%7D%7D%2C%7B%22key%22%3A%22DXZ6FCYF%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Hilezian%20et%20al.%22%2C%22parsedDate%22%3A%222021-08-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EHilezian%2C%20F.%2C%20Maarouf%2C%20A.%2C%20Boutiere%2C%20C.%2C%20Rico%2C%20A.%2C%20Demortiere%2C%20S.%2C%20Kerschen%2C%20P.%2C%20Sene%2C%20T.%2C%20Bensa-Koscher%2C%20C.%2C%20Giannesini%2C%20C.%2C%20Capron%2C%20J.%2C%20Mekinian%2C%20A.%2C%20Camdessanch%26%23xE9%3B%2C%20J.-P.%2C%20Androdias%2C%20G.%2C%20Marignier%2C%20R.%2C%20Collongues%2C%20N.%2C%20Casez%2C%20O.%2C%20Coclitu%2C%20C.%2C%20Vaillant%2C%20M.%2C%20Mathey%2C%20G.%2C%20Ciron%2C%20J.%2C%20Pelletier%2C%20J.%20and%20Audoin%2C%20B.%20%282021%29%20%26%23x2018%3BTNF-%26%23x3B1%3B%20inhibitors%20used%20as%20steroid-sparing%20maintenance%20monotherapy%20in%20parenchymal%20CNS%20sarcoidosis%26%23x2019%3B%2C%20%3Ci%3EJournal%20of%20Neurology%2C%20Neurosurgery%20%26amp%3B%20Psychiatry%3C%5C%2Fi%3E%2C%2092%288%29%2C%20pp.%20890%26%23x2013%3B896.%20Available%20at%3A%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fjnnp-2020-325665%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fjnnp-2020-325665%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22TNF-%5Cu03b1%20inhibitors%20used%20as%20steroid-sparing%20maintenance%20monotherapy%20in%20parenchymal%20CNS%20sarcoidosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Hilezian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clemence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demortiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Kerschen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Sene%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Bensa-Koscher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Giannesini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Capron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arsene%22%2C%22lastName%22%3A%22Mekinian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Camdessanch%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%5Cu00e9raldine%22%2C%22lastName%22%3A%22Androdias%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Marignier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Collongues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Casez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catalina%22%2C%22lastName%22%3A%22Coclitu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathieu%22%2C%22lastName%22%3A%22Vaillant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Mathey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22Objective%20To%20assess%20the%20efficacy%20of%20tumour%20necrosis%20factor-%5Cu03b1%20%28TNF-%5Cu03b1%29%20inhibitors%20used%20as%20steroid-sparing%20monotherapy%20in%20central%20nervous%20system%20%28CNS%29%20parenchymal%20sarcoidosis.%5CnMethods%20The%20French%20Multiple%20Sclerosis%20and%20Neuroinflammation%20Centers%20retrospectively%20identified%20patients%20with%20definite%20or%20probable%20CNS%20sarcoidosis%20treated%20with%20TNF-%5Cu03b1%20inhibitors%20as%20steroid-sparing%20monotherapy.%20Only%20patients%20with%20CNS%20parenchymal%20involvement%20demonstrated%20by%20MRI%20and%20imaging%20follow-up%20were%20included.%20The%20primary%20outcome%20was%20the%20minimum%20dose%20of%20steroids%20reached%20that%20was%20not%20associated%20with%20clinical%20or%20imaging%20worsening%20during%20a%20minimum%20of%203%20months%20after%20dosing%20change.%5CnResults%20Of%20the%20identified%2038%20patients%20with%20CNS%20sarcoidosis%20treated%20with%20TNF-%5Cu03b1%20inhibitors%2C%2023%20fulfilled%20all%20criteria%20%2813%20females%29.%20Treatments%20were%20infliximab%20%28n%3D22%29%20or%20adalimumab%20%28n%3D1%29%20for%20a%20median%20%28IQR%29%20of%2024%20%2817%5Cu201340%29%20months.%20At%20treatment%20initiation%2C%20the%20mean%20%28SD%29%20age%20was%2041.5%20%2810.5%29%20years%20and%20median%20%28IQR%29%20disease%20duration%2022%20%2814%5Cu201349.5%29%20months.%20Overall%2C%2060%25%20of%20patients%20received%20other%20immunosuppressive%20agents%20before%20a%20TNF-%5Cu03b1%20inhibitor.%20The%20mean%20%28SD%29%20minimum%20dose%20of%20steroids%20was%2031.5%20%2833%29%20mg%20before%20TNF-%5Cu03b1%20inhibitor%20initiation%20and%206.5%20%285.5%29%20mg%20after%20%28p%3D0.001%29.%20In%20all%2C%2065%25%20of%20patients%20achieved%20steroids%20dosing%20%3C6%20mg%5C%2Fday%3B%2061%25%20showed%20clinical%20improvement%2C%2030%25%20stability%20and%209%25%20disease%20worsening.%20Imaging%20revealed%20improvement%20in%2074%25%20of%20patients%20and%20stability%20in%2026%25.%5CnConclusion%20TNF-%5Cu03b1%20inhibitors%20can%20greatly%20reduce%20steroids%20dosing%20in%20patients%20with%20CNS%20parenchymal%20sarcoidosis%2C%20even%20refractory.%5CnClassification%20of%20evidence%20This%20study%20provides%20Class%20IV%20evidence%20that%20TNF-%5Cu03b1%20inhibitor%20used%20as%20steroid-sparing%20monotherapy%20is%20effective%20for%20patients%20with%20CNS%20parenchymal%20sarcoidosis.%22%2C%22date%22%3A%222021%5C%2F08%5C%2F01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1136%5C%2Fjnnp-2020-325665%22%2C%22ISSN%22%3A%220022-3050%2C%201468-330X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fjnnp.bmj.com%5C%2Fcontent%5C%2F92%5C%2F8%5C%2F890%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%5D%2C%22dateModified%22%3A%222025-01-16T14%3A01%3A15Z%22%7D%7D%2C%7B%22key%22%3A%229F94JMM9%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Has%20Silemek%20et%20al.%22%2C%22parsedDate%22%3A%222021-08-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EHas%20Silemek%2C%20A.C.%2C%20Ranjeva%2C%20J.-P.%2C%20Audoin%2C%20B.%2C%20Heesen%2C%20C.%2C%20Gold%2C%20S.M.%2C%20K%26%23xFC%3Bhn%2C%20S.%2C%20Weygandt%2C%20M.%20and%20Stellmann%2C%20J.-P.%20%282021%29%20%26%23x2018%3BDelayed%20access%20to%20conscious%20processing%20in%20multiple%20sclerosis%3A%20Reduced%20cortical%20activation%20and%20impaired%20structural%20connectivity%26%23x2019%3B%2C%20%3Ci%3EHuman%20Brain%20Mapping%3C%5C%2Fi%3E%2C%2042%2811%29%2C%20pp.%203379%26%23x2013%3B3395.%20Available%20at%3A%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fhbm.25440%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fhbm.25440%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Delayed%20access%20to%20conscious%20processing%20in%20multiple%20sclerosis%3A%20Reduced%20cortical%20activation%20and%20impaired%20structural%20connectivity%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arzu%20C.%22%2C%22lastName%22%3A%22Has%20Silemek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Ranjeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%22%2C%22lastName%22%3A%22Heesen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefan%20M.%22%2C%22lastName%22%3A%22Gold%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simone%22%2C%22lastName%22%3A%22K%5Cu00fchn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%22%2C%22lastName%22%3A%22Weygandt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan-Patrick%22%2C%22lastName%22%3A%22Stellmann%22%7D%5D%2C%22abstractNote%22%3A%22Although%20multiple%20sclerosis%20%28MS%29%20is%20frequently%20accompanied%20by%20visuo-cognitive%20impairment%2C%20especially%20functional%20brain%20mechanisms%20underlying%20this%20impairment%20are%20still%20not%20well%20understood.%20Consequently%2C%20we%20used%20a%20functional%20MRI%20%28fMRI%29%20backward%20masking%20task%20to%20study%20visual%20information%20processing%20stratifying%20unconscious%20and%20conscious%20in%20MS.%20Specifically%2C%2030%20persons%20with%20MS%20%28pwMS%29%20and%2034%20healthy%20controls%20%28HC%29%20were%20shown%20target%20stimuli%20followed%20by%20a%20mask%20presented%208-150%5Cu2009ms%20later%20and%20had%20to%20compare%20the%20target%20to%20a%20reference%20stimulus.%20Retinal%20integrity%20%28via%20optical%20coherence%20tomography%29%2C%20optic%20tract%20integrity%20%28visual%20evoked%20potential%3B%20VEP%29%20and%20whole%20brain%20structural%20connectivity%20%28probabilistic%20tractography%29%20were%20assessed%20as%20complementary%20structural%20brain%20integrity%20markers.%20On%20a%20psychophysical%20level%2C%20pwMS%20reached%20conscious%20access%20later%20than%20HC%20%2850%20vs.%2016%5Cu2009ms%2C%20p%5Cu00a0%3C%5Cu2009.001%29.%20The%20delay%20increased%20with%20disease%20duration%20%28p%5Cu00a0%3C%5Cu2009.001%2C%20%5Cu03b2%5Cu00a0%3D%5Cu00a0.37%29%20and%20disability%20%28p%5Cu00a0%3C%5Cu2009.001%2C%20%5Cu03b2%5Cu00a0%3D%5Cu00a0.24%29%2C%20but%20did%20not%20correlate%20with%20conscious%20information%20processing%20speed%20%28Symbol%20digit%20modality%20test%2C%20%5Cu03b2%5Cu00a0%3D%5Cu00a0.07%2C%20p%5Cu00a0%3D%5Cu2009.817%29.%20No%20association%20was%20found%20for%20VEP%20and%20retinal%20integrity%20markers.%20Moreover%2C%20pwMS%20were%20characterized%20by%20decreased%20brain%20activation%20during%20unconscious%20processing%20compared%20with%20HC.%20No%20group%20differences%20were%20found%20during%20conscious%20processing.%20Finally%2C%20a%20complementary%20structural%20brain%20integrity%20analysis%20showed%20that%20a%20reduced%20fractional%20anisotropy%20in%20corpus%20callosum%20and%20an%20impaired%20connection%20between%20right%20insula%20and%20primary%20visual%20areas%20was%20related%20to%20delayed%20conscious%20access%20in%20pwMS.%20Our%20study%20revealed%20slowed%20conscious%20access%20to%20visual%20stimulus%20material%20in%20MS%20and%20a%20complex%20pattern%20of%20functional%20and%20structural%20alterations%20coupled%20to%20unconscious%20processing%20of%5C%2Fdelayed%20conscious%20access%20to%20visual%20stimulus%20material%20in%20MS.%22%2C%22date%22%3A%222021-08-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fhbm.25440%22%2C%22ISSN%22%3A%221097-0193%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22UP3H3ICX%22%2C%226KPLZTET%22%2C%229L2KHJ5X%22%5D%2C%22dateModified%22%3A%222024-06-14T08%3A34%3A30Z%22%7D%7D%2C%7B%22key%22%3A%229VNZ397A%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Perez%20et%20al.%22%2C%22parsedDate%22%3A%222021-04%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EPerez%2C%20T.%2C%20Rico%2C%20A.%2C%20Bouti%26%23xE8%3Bre%2C%20C.%2C%20Maarouf%2C%20A.%2C%20Roudot%2C%20M.%2C%20Honor%26%23xE9%3B%2C%20S.%2C%20Pelletier%2C%20J.%2C%20Bertault-Peres%2C%20P.%20and%20Audoin%2C%20B.%20%282021%29%20%26%23x2018%3BComparison%20of%20rituximab%20originator%20%28MabThera%26%23xAE%3B%29%20to%20biosimilar%20%28Truxima%26%23xAE%3B%29%20in%20patients%20with%20multiple%20sclerosis%26%23x2019%3B%2C%20%3Ci%3EMultiple%20Sclerosis%20%28Houndmills%2C%20Basingstoke%2C%20England%29%3C%5C%2Fi%3E%2C%2027%284%29%2C%20pp.%20585%26%23x2013%3B592.%20Available%20at%3A%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F1352458520912170%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F1352458520912170%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Comparison%20of%20rituximab%20originator%20%28MabThera%5Cu00ae%29%20to%20biosimilar%20%28Truxima%5Cu00ae%29%20in%20patients%20with%20multiple%20sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Perez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mence%22%2C%22lastName%22%3A%22Bouti%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marjorie%22%2C%22lastName%22%3A%22Roudot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phane%22%2C%22lastName%22%3A%22Honor%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Bertault-Peres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Rituximab%27s%20originator%20MabThera%5Cu00ae%20or%20Rituxan%5Cu00ae%20has%20demonstrated%20high%20efficacy%20in%20multiple%20sclerosis%20%28MS%29.%20Because%20of%20the%20patent%20expiration%2C%20rituximab%20biosimilars%20have%20been%20developed.%20However%2C%20because%20a%20biosimilar%20is%20not%20the%20exact%20copy%20of%20the%20originator%2C%20the%20efficacy%20and%20safety%20of%20a%20biosimilar%20may%20significantly%20differ.%5CnOBJECTIVES%3A%20To%20compare%20the%20efficacy%20and%20safety%20of%20the%20biosimilar%20Truxima%5Cu00ae%20and%20the%20originator%20MabThera%5Cu00ae%20in%20MS.%5CnMETHODS%3A%20Consecutive%20MS%20patients%20receiving%20MabThera%5Cu00ae%20or%20Truxima%5Cu00ae%20were%20prospectively%20followed%20during%201%5Cu2009year%20after%20treatment%20introduction.%20Allocation%20to%20each%20treatment%20depended%20on%20the%20period%20of%20introduction%20and%20not%20the%20physician%27s%20choice.%20Lymphocyte%20count%2C%20clinical%20and%20magnetic%20resonance%20imaging%20%28MRI%29%20activity%2C%20Expanded%20Disability%20Status%20Scale%20%28EDSS%29%2C%20and%20adverse%20events%20were%20compared.%5CnRESULTS%3A%20In%20total%2C%20105%20and%2040%20patients%20received%20MabThera%5Cu00ae%20and%20Truxima%5Cu00ae%2C%20respectively.%20The%20two%20groups%20did%20not%20differ%20in%20baseline%20characteristics.%20Effect%20on%20CD19%2B%20lymphocytes%20and%20disease%20activity%20were%20similar%20during%20follow-up.%20EDSS%20remained%20stable%2C%20with%20no%20difference%20between%20groups.%20Adverse%20events%20were%20similar%20between%20groups.%5CnCONCLUSION%3A%20The%20efficacy%20and%20safety%20of%20the%20rituximab%20biosimilar%20Truxima%5Cu00ae%20seem%20equivalent%20to%20the%20originator%20MabThera%5Cu00ae%20in%20MS%20patients.%20Truxima%5Cu00ae%20could%20represent%20a%20relatively%20cheap%20and%20safe%20therapeutic%20alternative%20to%20MabThera%5Cu00ae%20and%20could%20improve%20access%20to%20highly%20efficient%20therapy%20for%20MS%20in%20low-%20or%20middle-income%20countries.%22%2C%22date%22%3A%222021-04%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1177%5C%2F1352458520912170%22%2C%22ISSN%22%3A%221477-0970%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%5D%2C%22dateModified%22%3A%222024-11-26T16%3A01%3A24Z%22%7D%7D%2C%7B%22key%22%3A%22NQN42MA5%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Chard%20et%20al.%22%2C%22parsedDate%22%3A%222021-03%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EChard%2C%20D.T.%2C%20Alahmadi%2C%20A.A.S.%2C%20Audoin%2C%20B.%2C%20Charalambous%2C%20T.%2C%20Enzinger%2C%20C.%2C%20Hulst%2C%20H.E.%2C%20Rocca%2C%20M.A.%2C%20Rovira%2C%20%26%23xC0%3B.%2C%20Sastre-Garriga%2C%20J.%2C%20Schoonheim%2C%20M.M.%2C%20Tijms%2C%20B.%2C%20Tur%2C%20C.%2C%20Gandini%20Wheeler-Kingshott%2C%20C.A.M.%2C%20Wink%2C%20A.M.%2C%20Ciccarelli%2C%20O.%2C%20Barkhof%2C%20F.%20and%20MAGNIMS%20Study%20Group%20%282021%29%20%26%23x2018%3BMind%20the%20gap%3A%20from%20neurons%20to%20networks%20to%20outcomes%20in%20multiple%20sclerosis%26%23x2019%3B%2C%20%3Ci%3ENature%20Reviews.%20Neurology%3C%5C%2Fi%3E%2C%2017%283%29%2C%20pp.%20173%26%23x2013%3B184.%20Available%20at%3A%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41582-020-00439-8%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41582-020-00439-8%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Mind%20the%20gap%3A%20from%20neurons%20to%20networks%20to%20outcomes%20in%20multiple%20sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Declan%20T.%22%2C%22lastName%22%3A%22Chard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adnan%20A.%20S.%22%2C%22lastName%22%3A%22Alahmadi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thalis%22%2C%22lastName%22%3A%22Charalambous%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Enzinger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hanneke%20E.%22%2C%22lastName%22%3A%22Hulst%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20A.%22%2C%22lastName%22%3A%22Rocca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%5Cu00c0lex%22%2C%22lastName%22%3A%22Rovira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jaume%22%2C%22lastName%22%3A%22Sastre-Garriga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Menno%20M.%22%2C%22lastName%22%3A%22Schoonheim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Betty%22%2C%22lastName%22%3A%22Tijms%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carmen%22%2C%22lastName%22%3A%22Tur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudia%20A.%20M.%22%2C%22lastName%22%3A%22Gandini%20Wheeler-Kingshott%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alle%20Meije%22%2C%22lastName%22%3A%22Wink%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olga%22%2C%22lastName%22%3A%22Ciccarelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederik%22%2C%22lastName%22%3A%22Barkhof%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22MAGNIMS%20Study%20Group%22%7D%5D%2C%22abstractNote%22%3A%22MRI%20studies%20have%20provided%20valuable%20insights%20into%20the%20structure%20and%20function%20of%20neural%20networks%2C%20particularly%20in%20health%20and%20in%20classical%20neurodegenerative%20conditions%20such%20as%20Alzheimer%20disease.%20However%2C%20such%20work%20is%20also%20highly%20relevant%20in%20other%20diseases%20of%20the%20CNS%2C%20including%20multiple%20sclerosis%20%28MS%29.%20In%20this%20Review%2C%20we%20consider%20the%20effects%20of%20MS%20pathology%20on%20brain%20networks%2C%20as%20assessed%20using%20MRI%2C%20and%20how%20these%20changes%20to%20brain%20networks%20translate%20into%20clinical%20impairments.%20We%20also%20discuss%20how%20this%20knowledge%20can%20inform%20the%20targeting%20of%20MS%20treatments%20and%20the%20potential%20future%20directions%20for%20research%20in%20this%20area.%20Studying%20MS%20is%20challenging%20as%20its%20pathology%20involves%20neurodegenerative%20and%20focal%20inflammatory%20elements%2C%20both%20of%20which%20could%20disrupt%20neural%20networks.%20The%20disruption%20of%20white%20matter%20tracts%20in%20MS%20is%20reflected%20in%20changes%20in%20network%20efficiency%2C%20an%20increasingly%20random%20grey%20matter%20network%20topology%2C%20relative%20cortical%20disconnection%2C%20and%20both%20increases%20and%20decreases%20in%20connectivity%20centred%20around%20hubs%20such%20as%20the%20thalamus%20and%20the%20default%20mode%20network.%20The%20results%20of%20initial%20longitudinal%20studies%20suggest%20that%20these%20changes%20evolve%20rather%20than%20simply%20increase%20over%20time%20and%20are%20linked%20with%20clinical%20features.%20Studies%20have%20also%20identified%20a%20potential%20role%20for%20treatments%20that%20functionally%20modify%20neural%20networks%20as%20opposed%20to%20altering%20their%20structure.%22%2C%22date%22%3A%222021-03%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41582-020-00439-8%22%2C%22ISSN%22%3A%221759-4766%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226KPLZTET%22%5D%2C%22dateModified%22%3A%222024-03-22T09%3A19%3A08Z%22%7D%7D%2C%7B%22key%22%3A%22VNZ9BYWF%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Stellmann%20et%20al.%22%2C%22parsedDate%22%3A%222021-02-24%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EStellmann%2C%20J.-P.%2C%20Wanke%2C%20N.%2C%20Maarouf%2C%20A.%2C%20Gelli%26%23xDF%3Ben%2C%20S.%2C%20Heesen%2C%20C.%2C%20Audoin%2C%20B.%2C%20Gold%2C%20S.M.%2C%20Zaaraoui%2C%20W.%20and%20Poettgen%2C%20J.%20%282021%29%20%26%23x2018%3BCognitive%20performance%20shows%20domain%20specific%20associations%20with%20regional%20cortical%20thickness%20in%20multiple%20sclerosis%26%23x2019%3B%2C%20%3Ci%3ENeuroImage.%20Clinical%3C%5C%2Fi%3E%2C%2030%2C%20p.%20102606.%20Available%20at%3A%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.nicl.2021.102606%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.nicl.2021.102606%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cognitive%20performance%20shows%20domain%20specific%20associations%20with%20regional%20cortical%20thickness%20in%20multiple%20sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan-Patrick%22%2C%22lastName%22%3A%22Stellmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadine%22%2C%22lastName%22%3A%22Wanke%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Susanne%22%2C%22lastName%22%3A%22Gelli%5Cu00dfen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%22%2C%22lastName%22%3A%22Heesen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefan%20M.%22%2C%22lastName%22%3A%22Gold%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wafaa%22%2C%22lastName%22%3A%22Zaaraoui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jana%22%2C%22lastName%22%3A%22Poettgen%22%7D%5D%2C%22abstractNote%22%3A%22Multiple%20Sclerosis%20%28MS%29%20patients%20often%20suffer%20from%20significant%20cognitive%20impairment.%20Earlier%20research%20has%20shown%20relationships%20between%20regional%20cortical%20atrophy%20and%20cognitive%20deterioration.%20However%2C%20due%20to%20a%20large%20number%20of%20neuropsychological%20assessments%20and%20a%20heterogenous%20pattern%20of%20cognitive%20deficits%20in%20MS%20patients%2C%20reported%20associations%20patterns%20are%20also%20heterogenous.%20Using%20an%20extensive%20neuropsychological%20battery%20of%2023%20different%20tasks%2C%20we%20explored%20domain%20%28attention%5C%2Finformation%20processing%2C%20memory%2C%20spatial%20processing%2C%20executive%20functioning%29%20and%20task-specific%20associations%20with%20regional%20cortical%20thickness%20in%20a%20representative%20sample%20of%20MS%20patients%20%28N%5Cu00a0%3D%5Cu00a097%29.%20Cortical%20regions%20associated%20with%20multiple%20cognitive%20tasks%20in%20the%20left%20hemisphere%20were%20predominantly%20located%20in%20the%20inferior%20insula%20%28attention%20p%5Cu00a0%3C%5Cu00a00.001%2C%20memory%20p%5Cu00a0%3D%5Cu00a00.047%2C%20spatial%20processing%20p%5Cu00a0%3D%5Cu00a00.004%2C%20executive%20functioning%20p%5Cu00a0%3D%5Cu00a00.037%29%2C%20the%20gyrus%20frontalis%20superior%20%28attention%20p%5Cu00a0%3D%5Cu00a00.015%2C%20memory%20p%5Cu00a0%3D%5Cu00a00.037%2C%20spatial%20processing%20p%5Cu00a0%3D%5Cu00a00.033%2C%20executive%20functioning%20p%5Cu00a0%3D%5Cu00a00.017%29%20and%20temporal%20medial%20%28attention%20p%5Cu00a0%3C%5Cu00a00.001%2C%20memory%20two%20clusters%20p%5Cu00a0%3D%5Cu00a00.016%20and%20p%5Cu00a0%3C%5Cu00a00.001%2C%20executive%20functioning%20p%5Cu00a0%3D%5Cu00a00.016%29.%20In%20the%20right%20hemisphere%2C%20we%20detected%20the%20strongest%20association%20in%20the%20sulcus%20interparietalis%20with%20five%20cluster%20%28attention%20SDMT%20p%5Cu00a0%3D%5Cu00a00.003%20and%20TAP_DA%20p%5Cu00a0%3C%5Cu00a00.001%3B%20memory%20Rey%20recall%20p%5Cu00a0%3D%5Cu00a00.013%20and%20VLMT%20verbal%20learning%20p%5Cu00a0%3D%5Cu00a00.016%3B%20spatial%20processing%20Rey%20copy%20p%5Cu00a0%3C%5Cu00a00.001%29.%20We%20replicated%20parts%20of%20our%20results%20in%20an%20independent%20sample%20of%2030%20mildly%20disabled%20MS%20patients.%20Moreover%2C%20comparisons%20to%2029%20healthy%20controls%20showed%20that%20the%20regional%20associations%20seemed%20to%20represent%20rather%20pathophysiological%20dependency%20than%20a%20physiological%20one.%20We%20believe%20that%20our%20results%20may%20prove%20useful%20in%20diagnosis%20and%20rehabilitation%20of%20cognitive%20impairments%20and%20may%20serve%20as%20guidance%20in%20future%20magnetic%20resonance%20imaging%20%28MRI%29%20studies.%22%2C%22date%22%3A%222021-02-24%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.nicl.2021.102606%22%2C%22ISSN%22%3A%222213-1582%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22P66W67T8%22%2C%229L2KHJ5X%22%5D%2C%22dateModified%22%3A%222024-11-15T09%3A37%3A22Z%22%7D%7D%2C%7B%22key%22%3A%22PE62KWZP%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Massire%20et%20al.%22%2C%22parsedDate%22%3A%222021-02-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMassire%2C%20A.%2C%20Seiler%2C%20C.%2C%20Troalen%2C%20T.%2C%20Girard%2C%20O.M.%2C%20Lehmann%2C%20P.%2C%20Brun%2C%20G.%2C%20Bartoli%2C%20A.%2C%20Audoin%2C%20B.%2C%20Bartolomei%2C%20F.%2C%20Pelletier%2C%20J.%2C%20Callot%2C%20V.%2C%20Kober%2C%20T.%2C%20Ranjeva%2C%20J.-P.%20and%20Guye%2C%20M.%20%282021%29%20%26%23x2018%3BT1-Based%20Synthetic%20Magnetic%20Resonance%20Contrasts%20Improve%20Multiple%20Sclerosis%20and%20Focal%20Epilepsy%20Imaging%20at%207%20T%26%23x2019%3B%2C%20%3Ci%3EInvestigative%20Radiology%3C%5C%2Fi%3E%2C%2056%282%29%2C%20pp.%20127%26%23x2013%3B133.%20Available%20at%3A%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FRLI.0000000000000718%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FRLI.0000000000000718%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22T1-Based%20Synthetic%20Magnetic%20Resonance%20Contrasts%20Improve%20Multiple%20Sclerosis%20and%20Focal%20Epilepsy%20Imaging%20at%207%20T%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lien%22%2C%22lastName%22%3A%22Massire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Seiler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Troalen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%20M.%22%2C%22lastName%22%3A%22Girard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Lehmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Brun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Axel%22%2C%22lastName%22%3A%22Bartoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Bartolomei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Callot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tobias%22%2C%22lastName%22%3A%22Kober%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Ranjeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Guye%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVES%3A%20Ultra-high%20field%20magnetic%20resonance%20imaging%20%28MRI%29%20%28%5Cu22657%20T%29%20is%20a%20unique%20opportunity%20to%20improve%20the%20clinical%20diagnosis%20of%20brain%20pathologies%2C%20such%20as%20multiple%20sclerosis%20or%20focal%20epilepsy.%20However%2C%20several%20shortcomings%20of%207%20T%20MRI%2C%20such%20as%20radiofrequency%20field%20inhomogeneities%2C%20could%20degrade%20image%20quality%20and%20hinder%20radiological%20interpretation.%20To%20address%20these%20challenges%2C%20an%20original%20synthetic%20MRI%20method%20based%20on%20T1%20mapping%20achieved%20with%20the%20magnetization-prepared%202%20rapid%20acquisition%20gradient%20echo%20%28MP2RAGE%29%20sequence%20was%20developed.%20The%20radiological%20quality%20of%20on-demand%20T1-based%20contrasts%20generated%20by%20this%20technique%20was%20evaluated%20in%20multiple%20sclerosis%20and%20focal%20epilepsy%20imaging%20at%207%20T.%5CnMATERIALS%20AND%20METHODS%3A%20This%20retrospective%20study%20was%20carried%20out%20from%20October%202017%20to%20September%202019%20and%20included%2021%20patients%20with%20different%20phenotypes%20of%20multiple%20sclerosis%20and%2035%20patients%20with%20focal%20epilepsy%20who%20underwent%20MRI%20brain%20examinations%20using%20a%20whole-body%20investigative%207%20T%20magnetic%20resonance%20system.%20The%20quality%20of%202%20proposed%20synthetic%20contrast%20images%20were%20assessed%20and%20compared%20with%20conventional%20images%20acquired%20at%207%20T%20using%20the%20MP2RAGE%20sequence%20by%204%20radiologists%2C%20evaluating%203%20qualitative%20criteria%3A%20signal%20homogeneity%2C%20contrast%20intensity%2C%20and%20lesion%20visualization.%20Statistical%20analyses%20were%20performed%20on%20reported%20quality%20scores%20using%20Wilcoxon%20rank%20tests%20and%20further%20multiple%20comparisons%20tests.%20Intraobserver%20and%20interobserver%20reliabilities%20were%20calculated%20as%20well.%5CnRESULTS%3A%20Radiological%20quality%20scores%20were%20reported%20higher%20for%20synthetic%20images%20when%20compared%20with%20original%20images%2C%20regardless%20of%20contrast%2C%20pathologies%2C%20or%20raters%20considered%2C%20with%20significant%20differences%20found%20for%20all%203%20criteria%20%28P%20%3C%200.0001%2C%20Wilcoxon%20rank%20test%29.%20None%20of%20the%204%20radiologists%20ever%20rated%20a%20synthetic%20image%20%5C%22markedly%20worse%5C%22%20than%20an%20original%20image.%20Synthetic%20images%20were%20rated%20slightly%20less%20satisfying%20for%20only%203%20epileptic%20patients%2C%20without%20precluding%20lesion%20identification.%5CnCONCLUSION%3A%20T1-based%20synthetic%20MRI%20with%20the%20MP2RAGE%20sequence%20provided%20on-demand%20contrasts%20and%20high-quality%20images%20to%20the%20radiologist%2C%20facilitating%20lesion%20visualization%20in%20multiple%20sclerosis%20and%20focal%20epilepsy%2C%20while%20reducing%20the%20magnetic%20resonance%20examination%20total%20duration%20by%20removing%20an%20additional%20sequence.%22%2C%22date%22%3A%222021-02-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FRLI.0000000000000718%22%2C%22ISSN%22%3A%221536-0210%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%2274RX9758%22%2C%22ZFC2Q648%22%2C%226GBQDAVI%22%2C%22UP3H3ICX%22%2C%22B4EWFM7E%22%2C%22HHEPZHEJ%22%2C%226KPLZTET%22%2C%22XTA6KS7L%22%2C%22CXAMISN8%22%5D%2C%22dateModified%22%3A%222024-11-26T16%3A01%3A32Z%22%7D%7D%2C%7B%22key%22%3A%22ZX3JGUA8%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Luciani%20et%20al.%22%2C%22parsedDate%22%3A%222021%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELuciani%2C%20L.%2C%20Ninove%2C%20L.%2C%20Zandotti%2C%20C.%2C%20Chalvignac%2C%20V.%2C%20Lagier%2C%20D.%2C%20Baume%2C%20J.%2C%20M%26%23xE9%3Blade%2C%20J.%2C%20Piorkowski%2C%20G.%2C%20Coutard%2C%20B.%2C%20Lepidi%2C%20H.%2C%20Pelletier%2C%20J.%2C%20Audoin%2C%20B.%2C%20Rico-Lamy%2C%20A.%20and%20Nougair%26%23xE8%3Bde%2C%20A.%20%282021%29%20%26%23x2018%3BFatal%20underhanded%20chronic%20enterovirus%20infection%20associated%20with%20anti-CD20%20monotherapy%20for%20central%20nervous%20system%20demyelinating%20disease%26%23x2019%3B%2C%20%3Ci%3EMultiple%20Sclerosis%20Journal%3C%5C%2Fi%3E%2C%2027%282%29%2C%20pp.%20320%26%23x2013%3B323.%20Available%20at%3A%20%3Ca%20class%3D%27zp-ItemURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F1352458520923978%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F1352458520923978%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Fatal%20underhanded%20chronic%20enterovirus%20infection%20associated%20with%20anti-CD20%20monotherapy%20for%20central%20nervous%20system%20demyelinating%20disease%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%5Cu00e9a%22%2C%22lastName%22%3A%22Luciani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%22%2C%22lastName%22%3A%22Ninove%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Zandotti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Chalvignac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Lagier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Baume%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22M%5Cu00e9lade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%5Cu00e9raldine%22%2C%22lastName%22%3A%22Piorkowski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Coutard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hubert%22%2C%22lastName%22%3A%22Lepidi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico-Lamy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Nougair%5Cu00e8de%22%7D%5D%2C%22abstractNote%22%3A%22We%20report%20a%20fatal%20case%20of%20coxsackievirus%20B4%20chronic%20infection%20in%20a%2030-year-old%20woman%20with%20a%20diagnosis%20of%20myelin%20oligodendrocyte%20glycoprotein%20antibody-associated%20disorder%20controlled%20by%20rituximab%20monotherapy%20for%203%5Cu2009years.%20Initially%20presenting%20as%20self-limited%20meningitis%2C%20the%20infection%20remained%20silent%20for%208%5Cu2009months%20before%20the%20sudden%20onset%20of%20fulminant%20myocarditis.%20Analysis%20of%20the%20complete%20genome%20showed%20that%20the%20same%20virus%20was%20responsible%20for%20both%20episodes.%22%2C%22date%22%3A%22f%5Cu00e9vrier%201%2C%202021%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1177%5C%2F1352458520923978%22%2C%22ISSN%22%3A%221352-4585%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F1352458520923978%22%2C%22collections%22%3A%5B%22B4EWFM7E%22%2C%226KPLZTET%22%5D%2C%22dateModified%22%3A%222024-11-26T16%3A01%3A54Z%22%7D%7D%2C%7B%22key%22%3A%22RTE9AE9D%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Cobo%5Cu2010Calvo%20et%20al.%22%2C%22parsedDate%22%3A%222021%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ECobo%26%23x2010%3BCalvo%2C%20A.%2C%20Ruiz%2C%20A.%2C%20Rollot%2C%20F.%2C%20Arrambide%2C%20G.%2C%20Deschamps%2C%20R.%2C%20Maillart%2C%20E.%2C%20Papeix%2C%20C.%2C%20Audoin%2C%20B.%2C%20L%26%23xE9%3Bpine%2C%20A.F.%2C%20Maurey%2C%20H.%2C%20Zephir%2C%20H.%2C%20Biotti%2C%20D.%2C%20Ciron%2C%20J.%2C%20Durand%26%23x2010%3BDubief%2C%20F.%2C%20Collongues%2C%20N.%2C%20Ayrignac%2C%20X.%2C%20Labauge%2C%20P.%2C%20Meyer%2C%20P.%2C%20Thouvenot%2C%20E.%2C%20Bourre%2C%20B.%2C%20Montcuquet%2C%20A.%2C%20Cohen%2C%20M.%2C%20Horello%2C%20P.%2C%20Tintor%26%23xE9%3B%2C%20M.%2C%20De%20Seze%2C%20J.%2C%20Vukusic%2C%20S.%2C%20Deiva%2C%20K.%2C%20Marignier%2C%20R.%20and%20the%20NOMADMUS%2C%20KidBioSEP%2C%20and%20OFSEP%20study%20groups%20%282021%29%20%26%23x2018%3BClinical%20Features%20and%20Risk%20of%20Relapse%20in%20Children%20and%20Adults%20with%20Myelin%20Oligodendrocyte%20Glycoprotein%20Antibody%26%23x2013%3BAssociated%20Disease%26%23x2019%3B%2C%20%3Ci%3EAnnals%20of%20Neurology%3C%5C%2Fi%3E%2C%2089%281%29%2C%20pp.%2030%26%23x2013%3B41.%20Available%20at%3A%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fana.25909%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fana.25909%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Clinical%20Features%20and%20Risk%20of%20Relapse%20in%20Children%20and%20Adults%20with%20Myelin%20Oligodendrocyte%20Glycoprotein%20Antibody%5Cu2013Associated%20Disease%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alvaro%22%2C%22lastName%22%3A%22Cobo%5Cu2010Calvo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Ruiz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Rollot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Georgina%22%2C%22lastName%22%3A%22Arrambide%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Deschamps%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Papeix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%20Fabienne%22%2C%22lastName%22%3A%22L%5Cu00e9pine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Maurey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helene%22%2C%22lastName%22%3A%22Zephir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%22%2C%22lastName%22%3A%22Biotti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francoise%22%2C%22lastName%22%3A%22Durand%5Cu2010Dubief%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Collongues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Ayrignac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Meyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Thouvenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexis%22%2C%22lastName%22%3A%22Montcuquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikael%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Horello%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mar%22%2C%22lastName%22%3A%22Tintor%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jerome%22%2C%22lastName%22%3A%22De%20Seze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kumaran%22%2C%22lastName%22%3A%22Deiva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Marignier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22the%20NOMADMUS%2C%20KidBioSEP%2C%20and%20OFSEP%20study%20groups%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2201%5C%2F2021%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1002%5C%2Fana.25909%22%2C%22ISSN%22%3A%220364-5134%2C%201531-8249%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fonlinelibrary.wiley.com%5C%2Fdoi%5C%2F10.1002%5C%2Fana.25909%22%2C%22collections%22%3A%5B%226KPLZTET%22%5D%2C%22dateModified%22%3A%222024-12-05T08%3A30%3A11Z%22%7D%7D%2C%7B%22key%22%3A%22CQ4RA535%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Giovannelli%20et%20al.%22%2C%22parsedDate%22%3A%222021%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGiovannelli%2C%20J.%2C%20Ciron%2C%20J.%2C%20Cohen%2C%20M.%2C%20Kim%2C%20H.-J.%2C%20Kim%2C%20S.-H.%2C%20Stellmann%2C%20J.-P.%2C%20Kleiter%2C%20I.%2C%20McCreary%2C%20M.%2C%20Greenberg%2C%20B.M.%2C%20Deschamps%2C%20R.%2C%20Audoin%2C%20B.%2C%20Maillart%2C%20E.%2C%20Papeix%2C%20C.%2C%20Collongues%2C%20N.%2C%20Bourre%2C%20B.%2C%20Laplaud%2C%20D.%2C%20Ayrignac%2C%20X.%2C%20Durand-Dubief%2C%20F.%2C%20Ruet%2C%20A.%2C%20Vukusic%2C%20S.%2C%20Marignier%2C%20R.%2C%20Dauchet%2C%20L.%2C%20Zephir%2C%20H.%20and%20NEMOS%20%28Neuromyelitis%20Optica%20Study%20Group%20in%20Germany%29%2C%20O.%20%28Observatoire%20F.%20de%20la%20S.%20en%20P.%20investigators%2C%20NOMADMUS%20%28Neuromyelitis%20Optica%20study%20Group%20in%20France%29%20%282021%29%20%26%23x2018%3BA%20meta-analysis%20comparing%20first-line%20immunosuppressants%20in%20neuromyelitis%20optica%26%23x2019%3B%2C%20%3Ci%3EAnnals%20of%20Clinical%20and%20Translational%20Neurology%3C%5C%2Fi%3E%2C%208%2810%29%2C%20pp.%202025%26%23x2013%3B2037.%20Available%20at%3A%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Facn3.51451%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Facn3.51451%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22A%20meta-analysis%20comparing%20first-line%20immunosuppressants%20in%20neuromyelitis%20optica%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Giovannelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikael%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ho-Jin%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Su-Hyun%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan-Patrik%22%2C%22lastName%22%3A%22Stellmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ingo%22%2C%22lastName%22%3A%22Kleiter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Morgan%22%2C%22lastName%22%3A%22McCreary%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%20M.%22%2C%22lastName%22%3A%22Greenberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Deschamps%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Papeix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Collongues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Laplaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Ayrignac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Durand-Dubief%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Ruet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Marignier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luc%22%2C%22lastName%22%3A%22Dauchet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Zephir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22OFSEP%20%28Observatoire%20Fran%5Cu00e7ais%20de%20la%20Scl%5Cu00e9rose%20en%20Plaques%29%20investigators%2C%20NOMADMUS%20%28Neuromyelitis%20Optica%20study%20Group%20in%20France%29%22%2C%22lastName%22%3A%22NEMOS%20%28Neuromyelitis%20Optica%20Study%20Group%20in%20Germany%29%22%7D%5D%2C%22abstractNote%22%3A%22Objective%20As%20phase%20III%20trials%20have%20shown%20interest%20in%20innovative%20but%20expensive%20drugs%20in%20the%20treatment%20of%20neuromyelitis%20optica%20spectrum%20disorder%20%28NMOSD%29%2C%20data%20are%20needed%20to%20clarify%20strategies%20in%20the%20treatment%20of%20neuromyelitis%20optica%20%28NMO%29.%20This%20meta-analysis%20compares%20the%20efficacy%20of%20first-line%20strategies%20using%20rituximab%20%28RTX%29%2C%20mycophenolate%20mofetil%20%28MMF%29%2C%20or%20azathioprine%20%28AZA%29%2C%20which%20are%20still%20widely%20used.%20Methods%20Studies%20identified%20by%20the%20systematic%20review%20of%20Huang%20et%20al.%20%282019%29%20were%20selected%20if%20they%20considered%20at%20least%20two%20first-line%20immunosuppressants%20among%20RTX%2C%20MMF%2C%20and%20AZA.%20We%20updated%20this%20review.%20The%20Medline%2C%20Cochrane%20Central%20Register%20of%20Controlled%20Trials%2C%20Embase%2C%20and%20ClinicalTrials%20databases%20were%20queried%20between%20November%202018%20and%20April%202020.%20To%20be%20included%2C%20the%20hazard%20ratio%20%28HR%29%20%5B95%25%20CI%5D%20for%20the%20time%20to%20first%20relapse%20after%20first-line%20immunosuppression%20had%20to%20be%20available%2C%20calculable%2C%20or%20provided%20by%20the%20authors.%20Results%20We%20gathered%20data%20from%20919%20NMO%20patients%20%28232%20RTX-%2C%20294%20MMF-%2C%20and%20393%20AZA-treated%20patients%29.%20The%20risk%20of%20first%20relapse%20after%20first-line%20immunosuppression%20was%201.55%20%5B1.04%2C%202.31%5D%20%28p%20%3D%200.03%29%20for%20MMF%20compared%20with%20RTX%2C%201.42%20%5B0.87%2C%202.30%5D%20%28p%20%3D%200.16%29%20for%20AZA%20compared%20with%20RTX%2C%20and%200.94%20%5B0.58%2C%201.54%5D%20%28p%20%3D%200.08%29%20for%20MMF%20compared%20with%20AZA.%20Interpretation%20The%20findings%20suggest%20that%20RTX%20is%20more%20efficient%20than%20MMF%20as%20a%20first-line%20therapy.%20Even%20if%20the%20results%20of%20our%20meta-analysis%20cannot%20conclude%20that%20RTX%20has%20a%20better%20efficacy%20in%20delaying%20the%20first%20relapse%20than%20AZA%2C%20the%20observed%20effect%20difference%20between%20both%20treatments%20combined%20with%20the%20results%20of%20previous%20studies%20using%20as%20outcome%20the%20annualized%20relapse%20rate%20may%20be%20in%20favor%20of%20RTX.%22%2C%22date%22%3A%222021%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1002%5C%2Facn3.51451%22%2C%22ISSN%22%3A%222328-9503%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fonlinelibrary.wiley.com%5C%2Fdoi%5C%2Fabs%5C%2F10.1002%5C%2Facn3.51451%22%2C%22collections%22%3A%5B%226KPLZTET%22%2C%229L2KHJ5X%22%5D%2C%22dateModified%22%3A%222024-06-14T08%3A34%3A19Z%22%7D%7D%2C%7B%22key%22%3A%22K6ITQQ54%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Roos%20et%20al.%22%2C%22parsedDate%22%3A%222020-09-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ERoos%2C%20I.%2C%20Leray%2C%20E.%2C%20Frascoli%2C%20F.%2C%20Casey%2C%20R.%2C%20Brown%2C%20J.W.L.%2C%20Horakova%2C%20D.%2C%20Havrdova%2C%20E.K.%2C%20Trojano%2C%20M.%2C%20Patti%2C%20F.%2C%20Izquierdo%2C%20G.%2C%20Eichau%2C%20S.%2C%20Onofrj%2C%20M.%2C%20Lugaresi%2C%20A.%2C%20Prat%2C%20A.%2C%20Girard%2C%20M.%2C%20Grammond%2C%20P.%2C%20Sola%2C%20P.%2C%20Ferraro%2C%20D.%2C%20Ozakbas%2C%20S.%2C%20Bergamaschi%2C%20R.%2C%20S%26%23xE1%3B%2C%20M.J.%2C%20Cartechini%2C%20E.%2C%20Boz%2C%20C.%2C%20Granella%2C%20F.%2C%20Hupperts%2C%20R.%2C%20Terzi%2C%20M.%2C%20Lechner-Scott%2C%20J.%2C%20Spitaleri%2C%20D.%2C%20Van%20Pesch%2C%20V.%2C%20Soysal%2C%20A.%2C%20Olascoaga%2C%20J.%2C%20Prevost%2C%20J.%2C%20Aguera-Morales%2C%20E.%2C%20Slee%2C%20M.%2C%20Csepany%2C%20T.%2C%20Turkoglu%2C%20R.%2C%20Sidhom%2C%20Y.%2C%20Gouider%2C%20R.%2C%20Van%20Wijmeersch%2C%20B.%2C%20McCombe%2C%20P.%2C%20Macdonell%2C%20R.%2C%20Coles%2C%20A.%2C%20Malpas%2C%20C.B.%2C%20Butzkueven%2C%20H.%2C%20Vukusic%2C%20S.%2C%20Kalincik%2C%20T.%2C%20the%20MSBase%2C%20Duquette%2C%20P.%2C%20Grand%26%23x2019%3BMaison%2C%20F.%2C%20Iuliano%2C%20G.%2C%20Ramo-Tello%2C%20C.%2C%20Solaro%2C%20C.%2C%20Cabrera-Gomez%2C%20J.A.%2C%20Rio%2C%20M.E.%2C%20Bola%26%23xF1%3Bos%2C%20R.F.%2C%20Shaygannejad%2C%20V.%2C%20Oreja-Guevara%2C%20C.%2C%20Sanchez-Menoyo%2C%20J.L.%2C%20Petersen%2C%20T.%2C%20Altintas%2C%20A.%2C%20Barnett%2C%20M.%2C%20Flechter%2C%20S.%2C%20Fragoso%2C%20Y.%2C%20Amato%2C%20M.P.%2C%20Moore%2C%20F.%2C%20Ampapa%2C%20R.%2C%20Verheul%2C%20F.%2C%20Hodgkinson%2C%20S.%2C%20Cristiano%2C%20E.%2C%20Yamout%2C%20B.%2C%20Laureys%2C%20G.%2C%20Dominguez%2C%20J.A.%2C%20Zwanikken%2C%20C.%2C%20Deri%2C%20N.%2C%20Dobos%2C%20E.%2C%20Vrech%2C%20C.%2C%20Butler%2C%20E.%2C%20Rozsa%2C%20C.%2C%20Petkovska-Boskova%2C%20T.%2C%20Karabudak%2C%20R.%2C%20Rajda%2C%20C.%2C%20Alkhaboori%2C%20J.%2C%20Saladino%2C%20M.L.%2C%20Shaw%2C%20C.%2C%20Shuey%2C%20N.%2C%20Vucic%2C%20S.%2C%20Sempere%2C%20A.P.%2C%20Campbell%2C%20J.%2C%20Piroska%2C%20I.%2C%20Taylor%2C%20B.%2C%20van%20der%20Walt%2C%20A.%2C%20Kappos%2C%20L.%2C%20Roullet%2C%20E.%2C%20Gray%2C%20O.%2C%20Simo%2C%20M.%2C%20Sirbu%2C%20C.-A.%2C%20OFSEP%20investigators%2C%20Brochet%2C%20B.%2C%20Cotton%2C%20F.%2C%20De%20S%26%23xE8%3Bze%2C%20J.%2C%20Dion%2C%20A.%2C%20Douek%2C%20P.%2C%20Guillemin%2C%20F.%2C%20Laplaud%2C%20D.%2C%20Lebrun-Frenay%2C%20C.%2C%20Moreau%2C%20T.%2C%20Olaiz%2C%20J.%2C%20Pelletier%2C%20J.%2C%20Rigaud-Bully%2C%20C.%2C%20Stankoff%2C%20B.%2C%20Marignier%2C%20R.%2C%20Debouverie%2C%20M.%2C%20Edan%2C%20G.%2C%20Ciron%2C%20J.%2C%20Ruet%2C%20A.%2C%20Collongues%2C%20N.%2C%20Lubetzki%2C%20C.%2C%20Vermersch%2C%20P.%2C%20Labauge%2C%20P.%2C%20Defer%2C%20G.%2C%20Cohen%2C%20M.%2C%20Fromont%2C%20A.%2C%20Wiertlewsky%2C%20S.%2C%20Berger%2C%20E.%2C%20Clavelou%2C%20P.%2C%20Audoin%2C%20B.%2C%20Giannesini%2C%20C.%2C%20Gout%2C%20O.%2C%20Thouvenot%2C%20E.%2C%20Heinzlef%2C%20O.%2C%20Al-Khedr%2C%20A.%2C%20Bourre%2C%20B.%2C%20Casez%2C%20O.%2C%20Cabre%2C%20P.%2C%20Montcuquet%2C%20A.%2C%20Cr%26%23xE9%3Bange%2C%20A.%2C%20Camdessanch%26%23xE9%3B%2C%20J.-P.%2C%20Faure%2C%20J.%2C%20Maurousset%2C%20A.%2C%20Patry%2C%20I.%2C%20Hankiewicz%2C%20K.%2C%20Pottier%2C%20C.%2C%20Maubeuge%2C%20N.%2C%20Labeyrie%2C%20C.%20and%20Nifle%2C%20C.%20%282020%29%20%26%23x2018%3BDelay%20from%20treatment%20start%20to%20full%20effect%20of%20immunotherapies%20for%20multiple%20sclerosis%26%23x2019%3B%2C%20%3Ci%3EBrain%3C%5C%2Fi%3E%2C%20143%289%29%2C%20pp.%202742%26%23x2013%3B2756.%20Available%20at%3A%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fbrain%5C%2Fawaa231%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fbrain%5C%2Fawaa231%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Delay%20from%20treatment%20start%20to%20full%20effect%20of%20immunotherapies%20for%20multiple%20sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Izanne%22%2C%22lastName%22%3A%22Roos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Leray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Federico%22%2C%22lastName%22%3A%22Frascoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Casey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20William%20L%22%2C%22lastName%22%3A%22Brown%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dana%22%2C%22lastName%22%3A%22Horakova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eva%20K%22%2C%22lastName%22%3A%22Havrdova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%22%2C%22lastName%22%3A%22Trojano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francesco%22%2C%22lastName%22%3A%22Patti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillermo%22%2C%22lastName%22%3A%22Izquierdo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sara%22%2C%22lastName%22%3A%22Eichau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%22%2C%22lastName%22%3A%22Onofrj%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alessandra%22%2C%22lastName%22%3A%22Lugaresi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22Prat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Girard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Grammond%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrizia%22%2C%22lastName%22%3A%22Sola%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diana%22%2C%22lastName%22%3A%22Ferraro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Serkan%22%2C%22lastName%22%3A%22Ozakbas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roberto%22%2C%22lastName%22%3A%22Bergamaschi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20Jos%5Cu00e9%22%2C%22lastName%22%3A%22S%5Cu00e1%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabetta%22%2C%22lastName%22%3A%22Cartechini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cavit%22%2C%22lastName%22%3A%22Boz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franco%22%2C%22lastName%22%3A%22Granella%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raymond%22%2C%22lastName%22%3A%22Hupperts%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Murat%22%2C%22lastName%22%3A%22Terzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeannette%22%2C%22lastName%22%3A%22Lechner-Scott%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniele%22%2C%22lastName%22%3A%22Spitaleri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Van%20Pesch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aysun%22%2C%22lastName%22%3A%22Soysal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Javier%22%2C%22lastName%22%3A%22Olascoaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Prevost%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduardo%22%2C%22lastName%22%3A%22Aguera-Morales%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%22%2C%22lastName%22%3A%22Slee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tunde%22%2C%22lastName%22%3A%22Csepany%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Recai%22%2C%22lastName%22%3A%22Turkoglu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Youssef%22%2C%22lastName%22%3A%22Sidhom%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Riadh%22%2C%22lastName%22%3A%22Gouider%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bart%22%2C%22lastName%22%3A%22Van%20Wijmeersch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pamela%22%2C%22lastName%22%3A%22McCombe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Macdonell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alasdair%22%2C%22lastName%22%3A%22Coles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%20B%22%2C%22lastName%22%3A%22Malpas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helmut%22%2C%22lastName%22%3A%22Butzkueven%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tomas%22%2C%22lastName%22%3A%22Kalincik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22the%20MSBase%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Duquette%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francois%22%2C%22lastName%22%3A%22Grand%27Maison%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gerardo%22%2C%22lastName%22%3A%22Iuliano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cristina%22%2C%22lastName%22%3A%22Ramo-Tello%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudio%22%2C%22lastName%22%3A%22Solaro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%20Antonio%22%2C%22lastName%22%3A%22Cabrera-Gomez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20Edite%22%2C%22lastName%22%3A%22Rio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ricardo%20Fernandez%22%2C%22lastName%22%3A%22Bola%5Cu00f1os%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vahid%22%2C%22lastName%22%3A%22Shaygannejad%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Celia%22%2C%22lastName%22%3A%22Oreja-Guevara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%20Luis%22%2C%22lastName%22%3A%22Sanchez-Menoyo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thor%22%2C%22lastName%22%3A%22Petersen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ayse%22%2C%22lastName%22%3A%22Altintas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Barnett%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shlomo%22%2C%22lastName%22%3A%22Flechter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yara%22%2C%22lastName%22%3A%22Fragoso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20Pia%22%2C%22lastName%22%3A%22Amato%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fraser%22%2C%22lastName%22%3A%22Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Radek%22%2C%22lastName%22%3A%22Ampapa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Freek%22%2C%22lastName%22%3A%22Verheul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Suzanne%22%2C%22lastName%22%3A%22Hodgkinson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edgardo%22%2C%22lastName%22%3A%22Cristiano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bassem%22%2C%22lastName%22%3A%22Yamout%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guy%22%2C%22lastName%22%3A%22Laureys%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%20Andres%22%2C%22lastName%22%3A%22Dominguez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cees%22%2C%22lastName%22%3A%22Zwanikken%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Norma%22%2C%22lastName%22%3A%22Deri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eniko%22%2C%22lastName%22%3A%22Dobos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlos%22%2C%22lastName%22%3A%22Vrech%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ernest%22%2C%22lastName%22%3A%22Butler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Csilla%22%2C%22lastName%22%3A%22Rozsa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tatjana%22%2C%22lastName%22%3A%22Petkovska-Boskova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rana%22%2C%22lastName%22%3A%22Karabudak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cecilia%22%2C%22lastName%22%3A%22Rajda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jabir%22%2C%22lastName%22%3A%22Alkhaboori%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20Laura%22%2C%22lastName%22%3A%22Saladino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cameron%22%2C%22lastName%22%3A%22Shaw%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Neil%22%2C%22lastName%22%3A%22Shuey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Steve%22%2C%22lastName%22%3A%22Vucic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Angel%20Perez%22%2C%22lastName%22%3A%22Sempere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jamie%22%2C%22lastName%22%3A%22Campbell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Imre%22%2C%22lastName%22%3A%22Piroska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruce%22%2C%22lastName%22%3A%22Taylor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anneke%22%2C%22lastName%22%3A%22van%20der%20Walt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ludwig%22%2C%22lastName%22%3A%22Kappos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Roullet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Orla%22%2C%22lastName%22%3A%22Gray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Magdolna%22%2C%22lastName%22%3A%22Simo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carmen-Adella%22%2C%22lastName%22%3A%22Sirbu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22OFSEP%20investigators%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Brochet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Cotton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22De%20S%5Cu00e8ze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Armelle%22%2C%22lastName%22%3A%22Dion%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Douek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francis%22%2C%22lastName%22%3A%22Guillemin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Laplaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lebrun-Frenay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Javier%22%2C%22lastName%22%3A%22Olaiz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Rigaud-Bully%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Stankoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Marignier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Debouverie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Edan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Ruet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Collongues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Lubetzki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Vermersch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Defer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mika%5Cu00ebl%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agn%5Cu00e8s%22%2C%22lastName%22%3A%22Fromont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Wiertlewsky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Berger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Clavelou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Giannesini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Gout%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Thouvenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Heinzlef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdullatif%22%2C%22lastName%22%3A%22Al-Khedr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Casez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Cabre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexis%22%2C%22lastName%22%3A%22Montcuquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alain%22%2C%22lastName%22%3A%22Cr%5Cu00e9ange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Camdessanch%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Justine%22%2C%22lastName%22%3A%22Faure%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aude%22%2C%22lastName%22%3A%22Maurousset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ivania%22%2C%22lastName%22%3A%22Patry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karolina%22%2C%22lastName%22%3A%22Hankiewicz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%22%2C%22lastName%22%3A%22Pottier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Maubeuge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Labeyrie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chantal%22%2C%22lastName%22%3A%22Nifle%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%20%20In%20multiple%20sclerosis%2C%20treatment%20start%20or%20switch%20is%20prompted%20by%20evidence%20of%20disease%20activity.%20Whilst%20immunomodulatory%20therapies%20reduce%20disease%20activity%2C%20the%20time%20required%20to%20attain%20maximal%20effect%20is%20unclear.%20In%20this%20study%20we%20aimed%20to%20develop%20a%20method%20that%20allows%20identification%20of%20the%20time%20to%20manifest%20fully%20and%20clinically%20the%20effect%20of%20multiple%20sclerosis%20treatments%20%28%5Cu2018therapeutic%20lag%5Cu2019%29%20on%20clinical%20disease%20activity%20represented%20by%20relapses%20and%20progression-of-disability%20events.%20Data%20from%20two%20multiple%20sclerosis%20registries%2C%20MSBase%20%28multinational%29%20and%20OFSEP%20%28French%29%2C%20were%20used.%20Patients%20diagnosed%20with%20multiple%20sclerosis%2C%20minimum%201-year%20exposure%20to%20treatment%2C%20minimum%203-year%20pretreatment%20follow-up%20and%20yearly%20review%20were%20included%20in%20the%20analysis.%20For%20analysis%20of%20disability%20progression%2C%20all%20events%20in%20the%20subsequent%205-year%20period%20were%20included.%20Density%20curves%2C%20representing%20incidence%20of%20relapses%20and%206-month%20confirmed%20progression%20events%2C%20were%20separately%20constructed%20for%20each%20sufficiently%20represented%20therapy.%20Monte%20Carlo%20simulations%20were%20performed%20to%20identify%20the%20first%20local%20minimum%20of%20the%20first%20derivative%20after%20treatment%20start%3B%20this%20point%20represented%20the%20point%20of%20stabilization%20of%20treatment%20effect%2C%20after%20the%20maximum%20treatment%20effect%20was%20observed.%20The%20method%20was%20developed%20in%20a%20discovery%20cohort%20%28MSBase%29%2C%20and%20externally%20validated%20in%20a%20separate%2C%20non-overlapping%20cohort%20%28OFSEP%29.%20A%20merged%20MSBase-OFSEP%20cohort%20was%20used%20for%20all%20subsequent%20analyses.%20Annualized%20relapse%20rates%20were%20compared%20in%20the%20time%20before%20treatment%20start%20and%20after%20the%20stabilization%20of%20treatment%20effect%20following%20commencement%20of%20each%20therapy.%20We%20identified%2011%5Cu2009180%20eligible%20treatment%20epochs%20for%20analysis%20of%20relapses%20and%204088%20treatment%20epochs%20for%20disability%20progression.%20External%20validation%20was%20performed%20in%20four%20therapies%2C%20with%20no%20significant%20difference%20in%20the%20bootstrapped%20mean%20differences%20in%20therapeutic%20lag%20duration%20between%20registries.%20The%20duration%20of%20therapeutic%20lag%20for%20relapses%20was%20calculated%20for%2010%20therapies%20and%20ranged%20between%2012%20and%2030%20weeks.%20The%20duration%20of%20therapeutic%20lag%20for%20disability%20progression%20was%20calculated%20for%20seven%20therapies%20and%20ranged%20between%2030%20and%2070%20weeks.%20Significant%20differences%20in%20the%20pre-%20versus%20post-treatment%20annualized%20relapse%20rate%20were%20present%20for%20all%20therapies%20apart%20from%20intramuscular%20interferon%20beta-1a.%20In%20conclusion%20we%20have%20developed%2C%20and%20externally%20validated%2C%20a%20method%20to%20objectively%20quantify%20the%20duration%20of%20therapeutic%20lag%20on%20relapses%20and%20disability%20progression%20in%20different%20therapies%20in%20patients%20more%20than%203%20years%20from%20multiple%20sclerosis%20onset.%20Objectively%20defined%20periods%20of%20expected%20therapeutic%20lag%20allows%20insights%20into%20the%20evaluation%20of%20treatment%20response%20in%20randomized%20clinical%20trials%20and%20may%20guide%20clinical%20decision-making%20in%20patients%20who%20experience%20early%20on-treatment%20disease%20activity.%20This%20method%20will%20subsequently%20be%20applied%20in%20studies%20that%20evaluate%20the%20effect%20of%20patient%20and%20disease%20characteristics%20on%20therapeutic%20lag.%22%2C%22date%22%3A%222020-09-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Fbrain%5C%2Fawaa231%22%2C%22ISSN%22%3A%220006-8950%2C%201460-2156%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Fbrain%5C%2Farticle%5C%2F143%5C%2F9%5C%2F2742%5C%2F5908734%22%2C%22collections%22%3A%5B%22B4EWFM7E%22%2C%226KPLZTET%22%5D%2C%22dateModified%22%3A%222024-11-26T16%3A00%3A40Z%22%7D%7D%2C%7B%22key%22%3A%22XI5GRQRV%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kerbrat%20et%20al.%22%2C%22parsedDate%22%3A%222020-07-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EKerbrat%2C%20A.%2C%20Gros%2C%20C.%2C%20Badji%2C%20A.%2C%20Bannier%2C%20E.%2C%20Galassi%2C%20F.%2C%20Comb%26%23xE8%3Bs%2C%20B.%2C%20Chouteau%2C%20R.%2C%20Labauge%2C%20P.%2C%20Ayrignac%2C%20X.%2C%20Carra-Dalliere%2C%20C.%2C%20Maranzano%2C%20J.%2C%20Granberg%2C%20T.%2C%20Ouellette%2C%20R.%2C%20Stawiarz%2C%20L.%2C%20Hillert%2C%20J.%2C%20Talbott%2C%20J.%2C%20Tachibana%2C%20Y.%2C%20Hori%2C%20M.%2C%20Kamiya%2C%20K.%2C%20Chougar%2C%20L.%2C%20Lefeuvre%2C%20J.%2C%20Reich%2C%20D.S.%2C%20Nair%2C%20G.%2C%20Valsasina%2C%20P.%2C%20Rocca%2C%20M.A.%2C%20Filippi%2C%20M.%2C%20Chu%2C%20R.%2C%20Bakshi%2C%20R.%2C%20Callot%2C%20V.%2C%20Pelletier%2C%20J.%2C%20Audoin%2C%20B.%2C%20Maarouf%2C%20A.%2C%20Collongues%2C%20N.%2C%20De%20Seze%2C%20J.%2C%20Edan%2C%20G.%20and%20Cohen-Adad%2C%20J.%20%282020%29%20%26%23x2018%3BMultiple%20sclerosis%20lesions%20in%20motor%20tracts%20from%20brain%20to%20cervical%20cord%3A%20spatial%20distribution%20and%20correlation%20with%20disability%26%23x2019%3B%2C%20%3Ci%3EBrain%3A%20A%20Journal%20of%20Neurology%3C%5C%2Fi%3E%2C%20143%287%29%2C%20pp.%202089%26%23x2013%3B2105.%20Available%20at%3A%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fbrain%5C%2Fawaa162%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fbrain%5C%2Fawaa162%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Multiple%20sclerosis%20lesions%20in%20motor%20tracts%20from%20brain%20to%20cervical%20cord%3A%20spatial%20distribution%20and%20correlation%20with%20disability%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Kerbrat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charley%22%2C%22lastName%22%3A%22Gros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Atef%22%2C%22lastName%22%3A%22Badji%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elise%22%2C%22lastName%22%3A%22Bannier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francesca%22%2C%22lastName%22%3A%22Galassi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benoit%22%2C%22lastName%22%3A%22Comb%5Cu00e8s%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rapha%5Cu00ebl%22%2C%22lastName%22%3A%22Chouteau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Ayrignac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clarisse%22%2C%22lastName%22%3A%22Carra-Dalliere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Josefina%22%2C%22lastName%22%3A%22Maranzano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tobias%22%2C%22lastName%22%3A%22Granberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Russell%22%2C%22lastName%22%3A%22Ouellette%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leszek%22%2C%22lastName%22%3A%22Stawiarz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan%22%2C%22lastName%22%3A%22Hillert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jason%22%2C%22lastName%22%3A%22Talbott%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yasuhiko%22%2C%22lastName%22%3A%22Tachibana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Masaaki%22%2C%22lastName%22%3A%22Hori%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kouhei%22%2C%22lastName%22%3A%22Kamiya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lydia%22%2C%22lastName%22%3A%22Chougar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%22%2C%22lastName%22%3A%22Lefeuvre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%20S.%22%2C%22lastName%22%3A%22Reich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Govind%22%2C%22lastName%22%3A%22Nair%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paola%22%2C%22lastName%22%3A%22Valsasina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20A.%22%2C%22lastName%22%3A%22Rocca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Massimo%22%2C%22lastName%22%3A%22Filippi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Renxin%22%2C%22lastName%22%3A%22Chu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rohit%22%2C%22lastName%22%3A%22Bakshi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Callot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Collongues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22De%20Seze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Edan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Cohen-Adad%22%7D%5D%2C%22abstractNote%22%3A%22Despite%20important%20efforts%20to%20solve%20the%20clinico-radiological%20paradox%2C%20correlation%20between%20lesion%20load%20and%20physical%20disability%20in%20patients%20with%20multiple%20sclerosis%20remains%20modest.%20One%20hypothesis%20could%20be%20that%20lesion%20location%20in%20corticospinal%20tracts%20plays%20a%20key%20role%20in%20explaining%20motor%20impairment.%20In%20this%20study%2C%20we%20describe%20the%20distribution%20of%20lesions%20along%20the%20corticospinal%20tracts%20from%20the%20cortex%20to%20the%20cervical%20spinal%20cord%20in%20patients%20with%20various%20disease%20phenotypes%20and%20disability%20status.%20We%20also%20assess%20the%20link%20between%20lesion%20load%20and%20location%20within%20corticospinal%20tracts%2C%20and%20disability%20at%20baseline%20and%202-year%20follow-up.%20We%20retrospectively%20included%20290%20patients%20%2822%20clinically%20isolated%20syndrome%2C%20198%20relapsing%20remitting%2C%2039%20secondary%20progressive%2C%2031%20primary%20progressive%20multiple%20sclerosis%29%20from%20eight%20sites.%20Lesions%20were%20segmented%20on%20both%20brain%20%28T2-FLAIR%20or%20T2-weighted%29%20and%20cervical%20%28axial%20T2-%20or%20T2%2A-weighted%29%20MRI%20scans.%20Data%20were%20processed%20using%20an%20automated%20and%20publicly%20available%20pipeline.%20Brain%2C%20brainstem%20and%20spinal%20cord%20portions%20of%20the%20corticospinal%20tracts%20were%20identified%20using%20probabilistic%20atlases%20to%20measure%20the%20lesion%20volume%20fraction.%20Lesion%20frequency%20maps%20were%20produced%20for%20each%20phenotype%20and%20disability%20scores%20assessed%20with%20Expanded%20Disability%20Status%20Scale%20score%20and%20pyramidal%20functional%20system%20score.%20Results%20show%20that%20lesions%20were%20not%20homogeneously%20distributed%20along%20the%20corticospinal%20tracts%2C%20with%20the%20highest%20lesion%20frequency%20in%20the%20corona%20radiata%20and%20between%20C2%20and%20C4%20vertebral%20levels.%20The%20lesion%20volume%20fraction%20in%20the%20corticospinal%20tracts%20was%20higher%20in%20secondary%20and%20primary%20progressive%20patients%20%28mean%20%3D%203.6%5Cu2009%5Cu00b1%5Cu20092.7%25%20and%202.9%5Cu2009%5Cu00b1%5Cu20092.4%25%29%2C%20compared%20to%20relapsing-remitting%20patients%20%281.6%5Cu2009%5Cu00b1%5Cu20092.1%25%2C%20both%20P%5Cu2009%3C%5Cu20090.0001%29.%20Voxel-wise%20analyses%20confirmed%20that%20lesion%20frequency%20was%20higher%20in%20progressive%20compared%20to%20relapsing-remitting%20patients%2C%20with%20significant%20bilateral%20clusters%20in%20the%20spinal%20cord%20corticospinal%20tracts%20%28P%5Cu2009%3C%5Cu20090.01%29.%20The%20baseline%20Expanded%20Disability%20Status%20Scale%20score%20was%20associated%20with%20lesion%20volume%20fraction%20within%20the%20brain%20%28r%5Cu2009%3D%5Cu20090.31%2C%20P%5Cu2009%3C%5Cu20090.0001%29%2C%20brainstem%20%28r%5Cu2009%3D%5Cu20090.45%2C%20P%5Cu2009%3C%5Cu20090.0001%29%20and%20spinal%20cord%20%28r%5Cu2009%3D%5Cu20090.57%2C%20P%5Cu2009%3C%5Cu20090.0001%29%20corticospinal%20tracts.%20The%20spinal%20cord%20corticospinal%20tracts%20lesion%20volume%20fraction%20remained%20the%20strongest%20factor%20in%20the%20multiple%20linear%20regression%20model%2C%20independently%20from%20cord%20atrophy.%20Baseline%20spinal%20cord%20corticospinal%20tracts%20lesion%20volume%20fraction%20was%20also%20associated%20with%20disability%20progression%20at%202-year%20follow-up%20%28P%5Cu2009%3D%5Cu20090.003%29.%20Our%20results%20suggest%20a%20cumulative%20effect%20of%20lesions%20within%20the%20corticospinal%20tracts%20along%20the%20brain%2C%20brainstem%20and%20spinal%20cord%20portions%20to%20explain%20physical%20disability%20in%20multiple%20sclerosis%20patients%2C%20with%20a%20predominant%20impact%20of%20intramedullary%20lesions.%22%2C%22date%22%3A%22Jul%2001%2C%202020%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Fbrain%5C%2Fawaa162%22%2C%22ISSN%22%3A%221460-2156%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22ZFC2Q648%22%2C%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%5D%2C%22dateModified%22%3A%222024-11-26T16%3A01%3A26Z%22%7D%7D%2C%7B%22key%22%3A%22KZVPYUJD%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A1497928%2C%22username%22%3A%22fkober%22%2C%22name%22%3A%22Frank%20Kober%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Ffkober%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Rasoanandrianina%20et%20al.%22%2C%22parsedDate%22%3A%222020-05-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ERasoanandrianina%2C%20H.%2C%20Demorti%26%23xE8%3Bre%2C%20S.%2C%20Trabelsi%2C%20A.%2C%20Ranjeva%2C%20J.P.%2C%20Girard%2C%20O.%2C%20Duhamel%2C%20G.%2C%20Guye%2C%20M.%2C%20Pelletier%2C%20J.%2C%20Audoin%2C%20B.%20and%20Callot%2C%20V.%20%282020%29%20%26%23x2018%3BSensitivity%20of%20the%20Inhomogeneous%20Magnetization%20Transfer%20Imaging%20Technique%20to%20Spinal%20Cord%20Damage%20in%20Multiple%20Sclerosis%26%23x2019%3B%2C%20%3Ci%3EAmerican%20Journal%20of%20Neuroradiology%3C%5C%2Fi%3E%2C%2041%285%29%2C%20pp.%20929%26%23x2013%3B937.%20Available%20at%3A%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3174%5C%2Fajnr.A6554%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3174%5C%2Fajnr.A6554%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Sensitivity%20of%20the%20Inhomogeneous%20Magnetization%20Transfer%20Imaging%20Technique%20to%20Spinal%20Cord%20Damage%20in%20Multiple%20Sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Rasoanandrianina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Demorti%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Trabelsi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20P.%22%2C%22lastName%22%3A%22Ranjeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%22%2C%22lastName%22%3A%22Girard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Duhamel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Guye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Callot%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20PURPOSE%3A%20The%20inhomogeneous%20magnetization%20transfer%20technique%20has%20demonstrated%20high%20specificity%20for%20myelin%2C%20and%20has%20shown%20sensitivity%20to%20multiple%20sclerosis-related%20impairment%20in%20brain%20tissue.%20Our%20aim%20was%20to%20investigate%20its%20sensitivity%20to%20spinal%20cord%20impairment%20in%20MS%20relative%20to%20more%20established%20MR%20imaging%20techniques%20%28volumetry%2C%20magnetization%20transfer%2C%20DTI%29.%5CnMATERIALS%20AND%20METHODS%3A%20Anatomic%20images%20covering%20the%20cervical%20spinal%20cord%20from%20the%20C1%20to%20C6%20levels%20and%20DTI%2C%20magnetization%20transfer%5C%2Finhomogeneous%20magnetization%20transfer%20images%20at%20the%20C2%5C%2FC5%20levels%20were%20acquired%20in%2019%20patients%20with%20MS%20and%2019%20paired%20healthy%20controls.%20Anatomic%20images%20were%20segmented%20in%20spinal%20cord%20GM%20and%20WM%2C%20both%20manually%20and%20using%20the%20AMU40%20atlases.%20MS%20lesions%20were%20manually%20delineated.%20MR%20metrics%20were%20analyzed%20within%20normal-appearing%20and%20lesion%20regions%20in%20anterolateral%20and%20posterolateral%20WM%20and%20compared%20using%20Wilcoxon%20rank%20tests%20and%20z%20scores.%20Correlations%20between%20MR%20metrics%20and%20clinical%20scores%20in%20patients%20with%20MS%20were%20evaluated%20using%20the%20Spearman%20rank%20correlation.%5CnRESULTS%3A%20AMU40-based%20C1-to-C6%20GM%5C%2FWM%20automatic%20segmentations%20in%20patients%20with%20MS%20were%20evaluated%20relative%20to%20manual%20delineation.%20Mean%20Dice%20coefficients%20were%200.75%5C%2F0.89%2C%20respectively.%20All%20MR%20metrics%20%28WM%5C%2FGM%20cross-sectional%20areas%2C%20normal-appearing%20and%20lesion%20diffusivities%2C%20and%20magnetization%20transfer%5C%2Finhomogeneous%20magnetization%20transfer%20ratios%29%20were%20observed%20altered%20in%20patients%20compared%20with%20controls%20%28P%20%3C%20.05%29.%20Additionally%2C%20the%20absolute%20inhomogeneous%20magnetization%20transfer%20ratio%20z%20scores%20were%20significantly%20higher%20than%20those%20of%20the%20other%20MR%20metrics%20%28P%20%3C%20.0001%29%2C%20suggesting%20a%20higher%20inhomogeneous%20magnetization%20transfer%20sensitivity%20toward%20spinal%20cord%20impairment%20in%20MS.%20Significant%20correlations%20with%20the%20Expanded%20Disability%20Status%20Scale%20%28%5Cu03c1%20%3D%20%5Cu20130.73%5C%2FP%20%3D%20.02%2C%20%5Cu03c1%20%3D%20%5Cu20130.81%5C%2FP%20%3D%20.004%29%20and%20the%20total%20Medical%20Research%20Council%20scale%20%28%5Cu03c1%20%3D%200.80%5C%2FP%20%3D%20.009%2C%20%5Cu03c1%20%3D%20%5Cu20130.74%5C%2FP%20%3D%20.02%29%20were%20observed%20for%20inhomogeneous%20magnetization%20transfer%20and%20magnetization%20transfer%20ratio%20z%20scores%2C%20respectively%2C%20in%20normal-appearing%20WM%20regions%2C%20while%20weaker%20and%20nonsignificant%20correlations%20were%20obtained%20for%20DTI%20metrics.%5CnCONCLUSIONS%3A%20With%20inhomogeneous%20magnetization%20transfer%20being%20highly%20sensitive%20to%20spinal%20cord%20damage%20in%20MS%20compared%20with%20conventional%20magnetization%20transfer%20and%20DTI%2C%20it%20could%20generate%20great%20clinical%20interest%20for%20longitudinal%20follow-up%20and%20potential%20remyelinating%20clinical%20trials.%20In%20line%20with%20other%20advanced%20myelin%20techniques%20with%20which%20it%20could%20be%20compared%2C%20it%20opens%20perspectives%20for%20multicentric%20investigations.%22%2C%22date%22%3A%222020%5C%2F05%5C%2F01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.3174%5C%2Fajnr.A6554%22%2C%22ISSN%22%3A%220195-6108%2C%201936-959X%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.ajnr.org%5C%2Fcontent%5C%2F41%5C%2F5%5C%2F929%22%2C%22collections%22%3A%5B%2274RX9758%22%2C%22ZFC2Q648%22%2C%22UP3H3ICX%22%2C%22XTA6KS7L%22%5D%2C%22dateModified%22%3A%222024-11-26T16%3A01%3A40Z%22%7D%7D%2C%7B%22key%22%3A%22ZQ3S6KZD%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Poupart%20et%20al.%22%2C%22parsedDate%22%3A%222020-04-14%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EPoupart%2C%20J.%2C%20Giovannelli%2C%20J.%2C%20Deschamps%2C%20R.%2C%20Audoin%2C%20B.%2C%20Ciron%2C%20J.%2C%20Maillart%2C%20E.%2C%20Papeix%2C%20C.%2C%20Collongues%2C%20N.%2C%20Bourre%2C%20B.%2C%20Cohen%2C%20M.%2C%20Wiertlewski%2C%20S.%2C%20Outteryck%2C%20O.%2C%20Laplaud%2C%20D.%2C%20Vukusic%2C%20S.%2C%20Marignier%2C%20R.%2C%20Zephir%2C%20H.%20and%20NOMADMUS%20study%20group%20%282020%29%20%26%23x2018%3BEvaluation%20of%20efficacy%20and%20tolerability%20of%20first-line%20therapies%20in%20NMOSD%26%23x2019%3B%2C%20%3Ci%3ENeurology%3C%5C%2Fi%3E%2C%2094%2815%29%2C%20pp.%20e1645%26%23x2013%3Be1656.%20Available%20at%3A%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FWNL.0000000000009245%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FWNL.0000000000009245%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Evaluation%20of%20efficacy%20and%20tolerability%20of%20first-line%20therapies%20in%20NMOSD%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Poupart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Giovannelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Deschamps%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Papeix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Collongues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mickael%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Wiertlewski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Outteryck%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Laplaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Marignier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Zephir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22NOMADMUS%20study%20group%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20To%20compare%20the%20efficacy%20and%20the%20risk%20of%20severe%20infectious%20events%20of%20immunosuppressive%20agents%20used%20early%20as%20first-line%20therapy%20in%20patients%20with%20neuromyelitis%20optica%20spectrum%20disorder%20%28NMOSD%29.%5CnMETHODS%3A%20We%20retrospectively%20included%20patients%20with%20NMOSD%20and%20a%20seropositive%20status%20for%20aquaporin%204%20or%20myelin%20oligodendrocyte%20glycoprotein%20antibodies%20beginning%20first-line%20immunosuppressants%20within%203%20years%20after%20the%20disease%20onset.%20The%20main%20outcome%20was%20occurrence%20of%20relapse%20after%20the%20initiation%20of%20immunosuppressants%3B%20the%20secondary%20outcome%20was%20the%20annual%20relapse%20rate%20%28AAR%29.%5CnRESULTS%3A%20A%20total%20of%20136%20patients%20were%20included%3A%2062%20%2845.6%25%29%20were%20treated%20with%20rituximab%20%28RTX%29%2C%2042%20%2830.9%25%29%20with%20mycophenolate%20mofetil%20%28MMF%29%2C%20and%2023%20%2816.9%25%29%20with%20azathioprine%20%28AZA%29.%20Compared%20with%20RTX-treated%20patients%2C%20the%20risk%20of%20relapse%20was%20higher%20among%20MMF-treated%20patients%20%28hazard%20ratio%20%5BHR%5D%2C%202.74%20%5B1.17-6.40%5D%3B%20p%20%3D%200.020%29%20after%20adjusting%20for%20age%20at%20disease%20onset%2C%20sex%2C%20antibody%20status%2C%20disease%20duration%2C%20ARR%20before%20treatment%2C%20corticosteroid%20intake%2C%20and%20relapse%20location.%20We%20did%20not%20observe%20any%20difference%20between%20RTX-treated%20and%20AZA-treated%20patients%20%28HR%2C%202.13%20%5B0.72-6.28%5D%3B%20p%20%3D%200.17%29.%20No%20interaction%20was%20found%20between%20the%20antibody%20status%20and%20immunosuppressive%20treatments.%20ARR%20was%20lower%20with%20RTX%20than%20with%20MMF%20%28p%20%3D%200.039%29%2C%20but%20no%20difference%20was%20observed%20with%20AZA.%20We%20observed%209%20serious%20infectious%20events%20with%20MMF%2C%206%20with%20RTX%2C%20and%20none%20with%20AZA.%5CnCONCLUSIONS%3A%20The%20use%20of%20first-line%20RTX%20in%20NMOSD%20appears%20more%20effective%20than%20MMF%20in%20suppressing%20clinical%20activity%2C%20independent%20of%20the%20antibody%20status.%5CnCLASSIFICATION%20OF%20EVIDENCE%3A%20That%20study%20provides%20Class%20III%20evidence%20that%20for%20patients%20with%20NMOSD%2C%20first-line%20RTX%20is%20superior%20to%20MMF%20to%20reduce%20the%20risk%20of%20relapse.%22%2C%22date%22%3A%22Apr%2014%2C%202020%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FWNL.0000000000009245%22%2C%22ISSN%22%3A%221526-632X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%229L2KHJ5X%22%5D%2C%22dateModified%22%3A%222024-03-22T08%3A59%3A27Z%22%7D%7D%2C%7B%22key%22%3A%22CQAWPIVJ%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A1497928%2C%22username%22%3A%22fkober%22%2C%22name%22%3A%22Frank%20Kober%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Ffkober%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Demortiere%20et%20al.%22%2C%22parsedDate%22%3A%222020-03-23%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDemortiere%2C%20S.%2C%20Rico%2C%20A.%2C%20Maarouf%2C%20A.%2C%20Boutiere%2C%20C.%2C%20Pelletier%2C%20J.%20and%20Audoin%2C%20B.%20%282020%29%20%26%23x2018%3BMaintenance%20of%20natalizumab%20during%20the%20first%20trimester%20of%20pregnancy%20in%20active%20multiple%20sclerosis%26%23x2019%3B%2C%20%3Ci%3EMultiple%20Sclerosis%20%28Houndmills%2C%20Basingstoke%2C%20England%29%3C%5C%2Fi%3E%2C%20p.%201352458520912637.%20Available%20at%3A%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F1352458520912637%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F1352458520912637%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Maintenance%20of%20natalizumab%20during%20the%20first%20trimester%20of%20pregnancy%20in%20active%20multiple%20sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demortiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Planning%20pregnancy%20in%20patients%20with%20active%20multiple%20sclerosis%20%28MS%29%20is%20highly%20challenging%20because%20treatment%20withdrawn%20may%20be%20associated%20with%20dramatic%20disease%20reactivation.%5CnOBJECTIVE%3A%20To%20compare%20two%20strategies%20for%20women%20with%20active%20MS%20who%20were%20planning%20pregnancy%3A%20stopping%20natalizumab%20%281%29%20at%20the%20end%20of%20the%20first%20trimester%20and%20%282%29%20at%20conception.%5CnMETHODS%3A%20Standardized%20strategy%20for%20women%20with%20active%20MS%20was%20initiated%20in%20our%20department.%20Maintenance%20of%20natalizumab%20until%20the%20end%20of%20first%20trimester%20was%20recommended%20%28%5C%22secured%20first%20trimester%5C%22%20%28SFT%29%29.%20When%20patients%20refused%2C%20they%20were%20advised%20to%20continue%20until%20conception%20%28%5C%22secured%20conception%5C%22%20%28SC%29%29.%20Predictors%20of%20disease%20activity%20during%20pregnancy%20were%20assessed.%5CnRESULTS%3A%20Forty-six%20pregnancies%20were%20prospectively%20followed%20%2830%20with%20SFT%20and%2016%20with%20SC%29.%20One%20congenital%20anomaly%20occurred%20in%20the%20SC%20group.%20The%20proportions%20of%20patients%20with%20relapse%20and%20disability%20progression%20during%20pregnancy%20were%20lower%20in%20the%20SFT%20than%20in%20the%20SC%20group%20%283.6%25%20vs%2038.5%25%2C%20p%5Cu2009%3C%5Cu20090.005%20and%203.6%25%20vs%2030.8%25%2C%20p%5Cu2009%3C%5Cu20090.05%2C%20respectively%29.%20Predictors%20of%20relapse%20and%20disability%20progression%20during%20pregnancy%20were%20the%20time%20when%20natalizumab%20was%20stopped%20%28conception%20vs%20end%20of%20first%20trimester%29%20and%20the%20number%20of%20relapses%20during%20the%20year%20before%20natalizumab.%5CnCONCLUSION%3A%20Maintaining%20natalizumab%20during%20the%20first%20trimester%20may%20reduce%20the%20risk%20of%20disease%20reactivation%20during%20pregnancy%20in%20patients%20with%20active%20MS.%22%2C%22date%22%3A%22Mar%2023%2C%202020%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1177%5C%2F1352458520912637%22%2C%22ISSN%22%3A%221477-0970%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%5D%2C%22dateModified%22%3A%222024-11-26T16%3A01%3A14Z%22%7D%7D%2C%7B%22key%22%3A%22ZGLSTPHS%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Durozard%20et%20al.%22%2C%22parsedDate%22%3A%222020-02%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDurozard%2C%20P.%2C%20Rico%2C%20A.%2C%20Boutiere%2C%20C.%2C%20Maarouf%2C%20A.%2C%20Lacroix%2C%20R.%2C%20Cointe%2C%20S.%2C%20Fritz%2C%20S.%2C%20Brunet%2C%20C.%2C%20Pelletier%2C%20J.%2C%20Marignier%2C%20R.%20and%20Audoin%2C%20B.%20%282020%29%20%26%23x2018%3BComparison%20of%20the%20Response%20to%20Rituximab%20between%20Myelin%20Oligodendrocyte%20Glycoprotein%20and%20Aquaporin-4%20Antibody%20Diseases%26%23x2019%3B%2C%20%3Ci%3EAnnals%20of%20Neurology%3C%5C%2Fi%3E%2C%2087%282%29%2C%20pp.%20256%26%23x2013%3B266.%20Available%20at%3A%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fana.25648%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fana.25648%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Comparison%20of%20the%20Response%20to%20Rituximab%20between%20Myelin%20Oligodendrocyte%20Glycoprotein%20and%20Aquaporin-4%20Antibody%20Diseases%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Durozard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romaric%22%2C%22lastName%22%3A%22Lacroix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvie%22%2C%22lastName%22%3A%22Cointe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shirley%22%2C%22lastName%22%3A%22Fritz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%22%2C%22lastName%22%3A%22Brunet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Marignier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20To%20compare%20response%20to%20rituximab%20%28RTX%29%20between%20adult%20patients%20positive%20for%20myelin%20oligodendrocyte%20glycoprotein%20%28MOG%29%20and%20aquaporin-4%20%28AQP4%29%20antibodies.%5CnMETHODS%3A%20We%20prospectively%20studied%20adult%20patients%20with%20MOG%20or%20AQP4%20antibodies%20who%20received%20RTX%20under%20an%20individualized%20dosing%20schedule%20adapted%20to%20the%20biological%20effect%20of%20RTX%20monitored%20by%20memory%20B-cell%20measurement.%20Memory%20B%20cells%20were%20counted%20monthly%20and%20when%20relapse%20occurred.%20The%20biological%20effect%20of%20RTX%20was%20considered%20significant%20with%20%3C0.05%25%20memory%20B%20cells%20in%20peripheral%20blood%20lymphocytes.%5CnRESULTS%3A%20In%2016%20patients%20with%20MOG%20antibodies%20and%2029%20with%20AQP4%20antibodies%2C%20mean%20follow-up%20was%2019%20%28range%5Cu2009%3D%5Cu20099-38%29%20and%2038%20%2813-79%29%20months.%20Under%20RTX%2C%2010%20relapses%20occurred%20in%206%20of%2016%20%2837.5%25%29%20patients%20with%20MOG%20antibodies%2C%20and%2013%20occurred%20in%207%20of%2029%20%2824%25%29%20with%20AQP4%20antibodies.%20The%20median%20time%20of%20relapse%20after%20the%20most%20recent%20infusion%20was%202.6%20%280.6-5.8%29%20and%207%20%280.8-13%29%20months%2C%20respectively%20%28p%20%3C%5Cu20090.001%29.%20Memory%20B%20cells%20had%20reemerged%20in%202%20of%2010%20%2820%25%29%20relapses%20in%20patients%20with%20MOG%20antibodies%20and%2012%20of%2013%20%2892.5%25%29%20with%20AQP4%20antibodies%20%28p%20%3C%5Cu20090.001%29.%5CnINTERPRETATION%3A%20In%20AQP4%20antibody-associated%20disorder%2C%20relapse%20mostly%20occurs%20when%20the%20biological%20effect%20of%20RTX%20decreases%2C%20which%20argues%20for%20treatment%20efficacy.%20In%20MOG%20antibody-associated%20disorder%2C%20the%20efficacy%20of%20RTX%20is%20not%20constant%2C%20because%20one-third%20of%20patients%20showed%20relapse%20despite%20an%20effective%20biological%20effect%20of%20RTX.%20In%20this%20subpopulation%2C%20memory%20B-cell%20depletion%20was%20unable%20to%20prevent%20relapse%2C%20which%20was%20probably%20caused%20by%20different%20immunological%20mechanisms.%20These%20findings%20should%20be%20used%20to%20improve%20treatment%20strategies%20for%20MOG%20antibody-associated%20disorder.%20ANN%20NEUROL%202020%3B87%3A256-266.%22%2C%22date%22%3A%22Feb%202020%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fana.25648%22%2C%22ISSN%22%3A%221531-8249%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%5D%2C%22dateModified%22%3A%222024-11-26T16%3A01%3A01Z%22%7D%7D%2C%7B%22key%22%3A%22CBLTUG5R%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22on%20behalf%20of%20the%20OFSEP%2C%20SFSEP%2C%20and%20NOMADMUS%20study%20groups%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3Eon%20behalf%20of%20the%20OFSEP%2C%20SFSEP%2C%20and%20NOMADMUS%20study%20groups%2C%20Maillart%2C%20E.%2C%20Durand-Dubief%2C%20F.%2C%20Louapre%2C%20C.%2C%20Audoin%2C%20B.%2C%20Bourre%2C%20B.%2C%20Derache%2C%20N.%2C%20Ciron%2C%20J.%2C%20Collongues%2C%20N.%2C%20de%20S%26%23xE8%3Bze%2C%20J.%2C%20Cohen%2C%20M.%2C%20Lebrun-Frenay%2C%20C.%2C%20Hadhoum%2C%20N.%2C%20Z%26%23xE9%3Bphir%2C%20H.%2C%20Deschamps%2C%20R.%2C%20Carra-Dalli%26%23xE8%3Bre%2C%20C.%2C%20Labauge%2C%20P.%2C%20Kerschen%2C%20P.%2C%20Montcuquet%2C%20A.%2C%20Wiertlewski%2C%20S.%2C%20Laplaud%2C%20D.%2C%20Runavot%2C%20G.%2C%20Vukusic%2C%20S.%2C%20Papeix%2C%20C.%20and%20Marignier%2C%20R.%20%282020%29%20%26%23x2018%3BOutcome%20and%20risk%20of%20recurrence%20in%20a%20large%20cohort%20of%20idiopathic%20longitudinally%20extensive%20transverse%20myelitis%20without%20AQP4%5C%2FMOG%20antibodies%26%23x2019%3B%2C%20%3Ci%3EJournal%20of%20Neuroinflammation%3C%5C%2Fi%3E%2C%2017%281%29%2C%20p.%20128.%20Available%20at%3A%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12974-020-01773-w%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12974-020-01773-w%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Outcome%20and%20risk%20of%20recurrence%20in%20a%20large%20cohort%20of%20idiopathic%20longitudinally%20extensive%20transverse%20myelitis%20without%20AQP4%5C%2FMOG%20antibodies%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22on%20behalf%20of%20the%20OFSEP%2C%20SFSEP%2C%20and%20NOMADMUS%20study%20groups%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Durand-Dubief%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Louapre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Derache%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Collongues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9rome%22%2C%22lastName%22%3A%22de%20S%5Cu00e8ze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikael%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lebrun-Frenay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nawel%22%2C%22lastName%22%3A%22Hadhoum%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Z%5Cu00e9phir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Deschamps%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clarisse%22%2C%22lastName%22%3A%22Carra-Dalli%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Kerschen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexis%22%2C%22lastName%22%3A%22Montcuquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Wiertlewski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Laplaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gwena%5Cu00eblle%22%2C%22lastName%22%3A%22Runavot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Papeix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Marignier%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Background%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Longitudinally%20extensive%20transverse%20myelitis%20%28LETM%29%20is%20classically%20related%20to%20aquaporin%20%28AQP4%29-antibodies%20%28Ab%29%20neuromyelitis%20optica%20spectrum%20disorders%20%28NMOSD%29%20or%20more%20recently%20to%20myelin%20oligodendrocyte%20glycoprotein%20%28MOG%29-Ab%20associated%20disease.%20However%2C%20some%20patients%20remain%20negative%20for%20any%20diagnosis%2C%20despite%20a%20large%20work-up%20including%20AQP4-Ab%20and%20MOG-Ab.%20Data%20about%20natural%20history%2C%20disability%20outcome%2C%20and%20treatment%20are%20limited%20in%20this%20group%20of%20patients.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20We%20aimed%20to%20%281%29%20describe%20clinical%2C%20biological%2C%20and%20radiological%20features%20of%20double%20seronegative%20LETM%20patients%3B%20%282%29%20assess%20the%20clinical%20course%20and%20identify%20prognostic%20factors%3B%20and%20%283%29%20assess%20the%20risk%20of%20recurrence%2C%20according%20to%20maintenance%20immunosuppressive%20therapy.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Retrospective%20evaluation%20of%20patients%20with%20a%20first%20episode%20of%20LETM%2C%20tested%20negative%20for%20AQP-Ab%20and%20MOG-Ab%2C%20from%20the%20French%20nationwide%20observatory%20study%20NOMADMUS.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Fifty-three%20patients%20%28median%20age%2038%5Cu2009years%20%28range%2016%5Cu201380%29%29%20with%20double%20seronegative%20LETM%20were%20included.%20Median%20nadir%20EDSS%20at%20onset%20was%206.0%20%281%5Cu20138.5%29%2C%20associated%20to%20a%20median%20EDSS%20at%20last%20follow-up%20of%204.0%20%280%5Cu20138%29.%20Recurrence%20was%20observed%20in%2024.5%25%20of%20patients%20in%20the%2018%20following%20months%2C%20with%20a%20median%20time%20to%20first%20relapse%20of%205.7%5Cu2009months.%20The%20risk%20of%20recurrence%20was%20lower%20in%20the%20group%20of%20patients%20treated%20early%20with%20an%20immunosuppressive%20drug%20%282%5C%2F22%2C%209%25%29%2C%20in%20comparison%20with%20untreated%20patients%20%2810%5C%2F31%2C%2032%25%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20A%20first%20episode%20of%20a%20double%20seronegative%20LETM%20is%20associated%20to%20a%20severe%20outcome%20and%20a%20high%20rate%20of%20relapse%20in%20the%20following%2018%5Cu2009months%2C%20suggesting%20that%20an%20early%20immunosuppressive%20treatment%20may%20be%20beneficial%20in%20that%20condition.%22%2C%22date%22%3A%2212%5C%2F2020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12974-020-01773-w%22%2C%22ISSN%22%3A%221742-2094%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fjneuroinflammation.biomedcentral.com%5C%2Farticles%5C%2F10.1186%5C%2Fs12974-020-01773-w%22%2C%22collections%22%3A%5B%226KPLZTET%22%5D%2C%22dateModified%22%3A%222024-03-22T08%3A59%3A27Z%22%7D%7D%2C%7B%22key%22%3A%22CTB8FBXW%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Maarouf%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMaarouf%2C%20A.%2C%20Rico%2C%20A.%2C%20Boutiere%2C%20C.%2C%20Perriguey%2C%20M.%2C%20Demortiere%2C%20S.%2C%20Pelletier%2C%20J.%2C%20Audoin%2C%20B.%20and%20Under%20the%20aegis%20of%20OFSEP%20%282020%29%20%26%23x2018%3BExtending%20rituximab%20dosing%20intervals%20in%20patients%20with%20MS%20during%20the%20COVID-19%20pandemic%20and%20beyond%3F%26%23x2019%3B%2C%20%3Ci%3ENeurology%20-%20Neuroimmunology%20Neuroinflammation%3C%5C%2Fi%3E%2C%207%285%29%2C%20p.%20e825.%20Available%20at%3A%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000000825%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000000825%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Extending%20rituximab%20dosing%20intervals%20in%20patients%20with%20MS%20during%20the%20COVID-19%20pandemic%20and%20beyond%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clemence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Perriguey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demortiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Under%20the%20aegis%20of%20OFSEP%22%7D%5D%2C%22abstractNote%22%3A%22Objective%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20To%20evaluate%20disease%20activity%20in%20patients%20with%20relapsing-remitting%20MS%20%28RRMS%29%20receiving%20rituximab%20with%20an%20extended%20dosing%20interval.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20the%20context%20of%20COVID-19%20pandemic%2C%20this%20was%20an%20interim%20analysis%20of%20an%20ongoing%20prospective%20observational%20study%20of%20patients%20who%20were%20stable%20on%20rituximab%20for%20at%20least%206%20months%20and%20who%20had%20a%20planned%20extended%20dosing%20interval%20of%2024%20months.%20Only%20data%20for%20patients%20with%20active%20RRMS%20before%20rituximab%20were%20analyzed.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20Among%20177%20patients%20receiving%20rituximab%2C%2033%20had%20RRMS%20and%20MRI%20activity%20before%20rituximab%20and%20at%20least%208%20months%20of%20follow-up%20after%20the%20last%20infusion.%20The%20mean%20%28SD%29%20age%20was%2040%20%2814%29%20years%2C%2025%20were%20females%2C%20the%20mean%20disease%20duration%20was%2010%20%286.8%29%20years%2C%20the%20mean%20annual%20relapse%20rate%20%28ARR%29%20before%20rituximab%20was%201.7%20%281.3%29%2C%20and%20the%20median%20Expanded%20Disability%20Status%20Scale%20%28EDSS%29%20score%20before%20rituximab%20was%204.5%20%281%5Cu20137%29.%20Before%20extended%20dosing%2C%20when%20rituximab%20was%20infused%20every%206%20months%2C%20the%20mean%20%28SD%29%20ARR%20decreased%20to%200.04%20%280.1%29%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20p%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C%200.0001%29%20and%20the%20EDSS%20score%20to%204%20%280%5Cu20137%29%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20p%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D%200.04%29.%20At%20the%20time%20of%20this%20analysis%2C%20the%20median%20follow-up%20since%20the%20last%20infusion%20was%2011%20%288%5Cu201331%29%20months.%20No%20patient%20showed%20relapse%20or%20disability%20progression.%20In%20total%2C%2030%20patients%20had%20at%20least%201%20MRI%20performed%20since%20the%20last%20infusion%20%28median%20time%20between%20the%20last%20MRI%20and%20the%20last%20infusion%2010%20%5B8%5Cu201331%5D%20months%29.%20No%20MRI%20showed%20activity.%20The%20CD19%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20cell%20proportion%20was%20%3E1%25%20for%2010%20of%2025%20patients%20at%20the%20last%20count%20%28median%20time%208%20%5B6%5Cu201325%5D%20months%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20An%20extended%20dosing%20interval%20for%20rituximab%20for%20patients%20with%20stable%20MS%20during%20the%20COVID-19%20pandemic%20may%20be%20associated%20with%20a%20low%20risk%20of%20disease%20activity.%22%2C%22date%22%3A%2209%5C%2F2020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1212%5C%2FNXI.0000000000000825%22%2C%22ISSN%22%3A%222332-7812%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fnn.neurology.org%5C%2Flookup%5C%2Fdoi%5C%2F10.1212%5C%2FNXI.0000000000000825%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%5D%2C%22dateModified%22%3A%222025-01-28T16%3A13%3A05Z%22%7D%7D%2C%7B%22key%22%3A%22MARUGN69%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Demorti%5Cu00e8re%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDemorti%26%23xE8%3Bre%2C%20S.%2C%20Lehmann%2C%20P.%2C%20Pelletier%2C%20J.%2C%20Audoin%2C%20B.%20and%20Callot%2C%20V.%20%282020%29%20%26%23x2018%3BImproved%20Cervical%20Cord%20Lesion%20Detection%20with%203D-MP2RAGE%20Sequence%20in%20Patients%20with%20Multiple%20Sclerosis%26%23x2019%3B%2C%20%3Ci%3EAJNR.%20American%20journal%20of%20neuroradiology%3C%5C%2Fi%3E%2C%2041%286%29%2C%20pp.%201131%26%23x2013%3B1134.%20Available%20at%3A%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3174%5C%2Fajnr.A6567%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3174%5C%2Fajnr.A6567%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Improved%20Cervical%20Cord%20Lesion%20Detection%20with%203D-MP2RAGE%20Sequence%20in%20Patients%20with%20Multiple%20Sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Demorti%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Lehmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Callot%22%7D%5D%2C%22abstractNote%22%3A%22Spinal%20cord%20lesions%20have%20a%20real%20diagnostic%20and%20prognostic%20role%20in%20multiple%20sclerosis.%20Thus%2C%20optimizing%20their%20detection%20on%20MR%20imaging%20has%20become%20a%20central%20issue%20with%20direct%20therapeutic%20impact.%20In%20this%20study%2C%20we%20compared%20the%203D-MP2RAGE%20sequence%20with%20the%20conventional%20Magnetic%20Resonance%20Imaging%20in%20Multiple%20Sclerosis%20%28MAGNIMS%29%20set%20for%20cervical%20cord%20lesion%20detection%20in%2028%20patients%20with%20multiple%20sclerosis.%203D-MP2RAGE%20allowed%20better%20detection%20of%20cervical%20lesions%20%28%2B62%25%29%20in%20this%20population%2C%20with%20better%20confidence%2C%20due%20to%20optimized%20contrast%20and%20high%20spatial%20resolution.%22%2C%22date%22%3A%2206%202020%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3174%5C%2Fajnr.A6567%22%2C%22ISSN%22%3A%221936-959X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22ZFC2Q648%22%5D%2C%22dateModified%22%3A%222024-11-26T16%3A01%3A48Z%22%7D%7D%2C%7B%22key%22%3A%22L2BUIVM5%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Stellmann%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EStellmann%2C%20J.-P.%2C%20Maarouf%2C%20A.%2C%20Schulz%2C%20K.-H.%2C%20Baquet%2C%20L.%2C%20P%26%23xF6%3Bttgen%2C%20J.%2C%20Patra%2C%20S.%2C%20Penner%2C%20I.-K.%2C%20Gelli%26%23xDF%3Ben%2C%20S.%2C%20Ketels%2C%20G.%2C%20Besson%2C%20P.%2C%20Ranjeva%2C%20J.-P.%2C%20Guye%2C%20M.%2C%20Nolte%2C%20G.%2C%20Engel%2C%20A.K.%2C%20Audoin%2C%20B.%2C%20Heesen%2C%20C.%20and%20Gold%2C%20S.M.%20%282020%29%20%26%23x2018%3BAerobic%20Exercise%20Induces%20Functional%20and%20Structural%20Reorganization%20of%20CNS%20Networks%20in%20Multiple%20Sclerosis%3A%20A%20Randomized%20Controlled%20Trial%26%23x2019%3B%2C%20%3Ci%3EFrontiers%20in%20Human%20Neuroscience%3C%5C%2Fi%3E%2C%2014%2C%20p.%20255.%20Available%20at%3A%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffnhum.2020.00255%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffnhum.2020.00255%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Aerobic%20Exercise%20Induces%20Functional%20and%20Structural%20Reorganization%20of%20CNS%20Networks%20in%20Multiple%20Sclerosis%3A%20A%20Randomized%20Controlled%20Trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan-Patrick%22%2C%22lastName%22%3A%22Stellmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karl-Heinz%22%2C%22lastName%22%3A%22Schulz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lisa%22%2C%22lastName%22%3A%22Baquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jana%22%2C%22lastName%22%3A%22P%5Cu00f6ttgen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefan%22%2C%22lastName%22%3A%22Patra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Iris-Katharina%22%2C%22lastName%22%3A%22Penner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Susanne%22%2C%22lastName%22%3A%22Gelli%5Cu00dfen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gesche%22%2C%22lastName%22%3A%22Ketels%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Besson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Ranjeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Guye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guido%22%2C%22lastName%22%3A%22Nolte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andreas%20K.%22%2C%22lastName%22%3A%22Engel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%22%2C%22lastName%22%3A%22Heesen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefan%20M.%22%2C%22lastName%22%3A%22Gold%22%7D%5D%2C%22abstractNote%22%3A%22Objectives%3A%20Evidence%20from%20animal%20studies%20suggests%20that%20aerobic%20exercise%20may%20promote%20neuroplasticity%20and%20could%2C%20therefore%2C%20provide%20therapeutic%20benefits%20for%20neurological%20diseases%20such%20as%20multiple%20sclerosis%20%28MS%29.%20However%2C%20the%20effects%20of%20exercise%20in%20human%20CNS%20disorders%20on%20the%20topology%20of%20brain%20networks%2C%20which%20might%20serve%20as%20an%20outcome%20at%20the%20interface%20between%20biology%20and%20clinical%20performance%2C%20remain%20poorly%20understood.%20Methods%3A%20We%20investigated%20functional%20and%20structural%20networks%20in%20patients%20with%20relapsing-remitting%20MS%20in%20a%20clinical%20trial%20of%20standardized%20aerobic%20exercise.%20Fifty-seven%20patients%20were%20randomly%20assigned%20to%20moderate-intensity%20exercise%20for%203%20months%20or%20a%20non-exercise%20control%20group.%20We%20reconstructed%20functional%20networks%20based%20on%20resting-state%20functional%20magnetic%20resonance%20imaging%20%28MRI%29%20and%20used%20probabilistic%20tractography%20on%20diffusion-weighted%20imaging%20data%20for%20structural%20networks.%20Results%3A%20At%20baseline%2C%20compared%20to%2030%20healthy%20controls%2C%20patients%20exhibited%20decreased%20structural%20connectivity%20that%20was%20most%20pronounced%20in%20hub%20regions%20of%20the%20brain.%20Vice%20versa%2C%20functional%20connectivity%20was%20increased%20in%20hubs.%20After%203%20months%2C%20we%20observed%20hub%20independent%20increased%20functional%20connectivity%20in%20the%20exercise%20group%20while%20the%20control%20group%20presented%20a%20loss%20of%20functional%20hub%20connectivity.%20On%20a%20structural%20level%2C%20the%20control%20group%20remained%20unchanged%2C%20while%20the%20exercise%20group%20had%20also%20increased%20connectivity.%20Increased%20clustering%20of%20hubs%20indicates%20a%20better%20structural%20integration%20and%20internal%20connectivity%20at%20the%20top%20of%20the%20network%20hierarchy.%20Conclusion%3A%20Increased%20functional%20connectivity%20of%20hubs%20contrasts%20a%20loss%20of%20structural%20connectivity%20in%20relapsing-remitting%20MS.%20Under%20an%20exercise%20condition%2C%20a%20further%20hub%20independent%20increase%20of%20functional%20connectivity%20seems%20to%20translate%20in%20higher%20structural%20connectivity%20of%20the%20whole%20brain.%22%2C%22date%22%3A%222020%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3389%5C%2Ffnhum.2020.00255%22%2C%22ISSN%22%3A%221662-5161%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22UP3H3ICX%22%2C%22FK6KXTMZ%22%2C%229L2KHJ5X%22%2C%22XTA6KS7L%22%5D%2C%22dateModified%22%3A%222024-11-15T09%3A37%3A19Z%22%7D%7D%2C%7B%22key%22%3A%22SEVAC6G5%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Cousyn%20et%20al.%22%2C%22parsedDate%22%3A%222019-08-13%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ECousyn%2C%20L.%2C%20Law-Ye%2C%20B.%2C%20Pyatigorskaya%2C%20N.%2C%20Debs%2C%20R.%2C%20Froissart%2C%20R.%2C%20Piraud%2C%20M.%2C%20Federico%2C%20A.%2C%20Salvatore%2C%20S.%2C%20Cerase%2C%20A.%2C%20Mac%26%23xE1%3Brio%2C%20M.C.%2C%20Dur%26%23xE3%3Bes%2C%20J.%2C%20Kim%2C%20S.H.%2C%20Adachi%2C%20H.%2C%20Audoin%2C%20B.%2C%20Ayrignac%2C%20X.%2C%20Da%2C%20Y.%2C%20Henderson%2C%20R.%2C%20La%20Piana%2C%20R.%2C%20Laule%2C%20C.%2C%20Nakamagoe%2C%20K.%2C%20Raininko%2C%20R.%2C%20Schols%2C%20L.%2C%20Sirrs%2C%20S.M.%2C%20Viader%2C%20F.%2C%20Jastrz%26%23x119%3Bbski%2C%20K.%2C%20Leclercq%2C%20D.%20and%20Nadjar%2C%20Y.%20%282019%29%20%26%23x2018%3BBrain%20MRI%20features%20and%20scoring%20of%20leukodystrophy%20in%20adult-onset%20Krabbe%20disease%26%23x2019%3B%2C%20%3Ci%3ENeurology%3C%5C%2Fi%3E%2C%2093%287%29%2C%20pp.%20e647%26%23x2013%3Be652.%20Available%20at%3A%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FWNL.0000000000007943%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FWNL.0000000000007943%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Brain%20MRI%20features%20and%20scoring%20of%20leukodystrophy%20in%20adult-onset%20Krabbe%20disease%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louis%22%2C%22lastName%22%3A%22Cousyn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Law-Ye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadya%22%2C%22lastName%22%3A%22Pyatigorskaya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rabab%22%2C%22lastName%22%3A%22Debs%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roseline%22%2C%22lastName%22%3A%22Froissart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Monique%22%2C%22lastName%22%3A%22Piraud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonio%22%2C%22lastName%22%3A%22Federico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simona%22%2C%22lastName%22%3A%22Salvatore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alfonso%22%2C%22lastName%22%3A%22Cerase%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20C.%22%2C%22lastName%22%3A%22Mac%5Cu00e1rio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jo%5Cu00e3o%22%2C%22lastName%22%3A%22Dur%5Cu00e3es%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Seung%20H.%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hiroshi%22%2C%22lastName%22%3A%22Adachi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Ayrignac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yuwei%22%2C%22lastName%22%3A%22Da%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%22%2C%22lastName%22%3A%22Henderson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roberta%22%2C%22lastName%22%3A%22La%20Piana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cornelia%22%2C%22lastName%22%3A%22Laule%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kiyotaka%22%2C%22lastName%22%3A%22Nakamagoe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raili%22%2C%22lastName%22%3A%22Raininko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ludger%22%2C%22lastName%22%3A%22Schols%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%20M.%22%2C%22lastName%22%3A%22Sirrs%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fausto%22%2C%22lastName%22%3A%22Viader%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karol%22%2C%22lastName%22%3A%22Jastrz%5Cu0119bski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Delphine%22%2C%22lastName%22%3A%22Leclercq%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yann%22%2C%22lastName%22%3A%22Nadjar%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20To%20perform%20a%20systematic%20analysis%20and%20scoring%20of%20brain%20MRI%20white%20matter%20hyperintensities%20%28WMH%29%20in%20adult-onset%20Krabbe%20disease.%5CnMETHODS%3A%20We%20retrospectively%20collected%20basic%20clinical%20data%20and%20the%20first%20available%20brain%20MRI%20from%20patients%20with%20confirmed%20Krabbe%20disease%20with%20first%20clinical%20manifestations%20beyond%2010%20years%20of%20age.%20Data%20were%20obtained%20from%20our%20reference%20center%20for%20lysosomal%20diseases%20%28n%20%3D%206%29%20and%20from%20contacted%20authors%20of%20published%20articles%20describing%20patients%20with%20adult-onset%20Krabbe%20disease%20%28n%20%3D%2015%29.%20T2-weighted%20fluid-attenuated%20inversion%20recovery%20images%20of%20each%20patient%20were%20analyzed%20and%20scored%20using%20a%20radiologic%20score%20of%20WMH%20in%20a%20single%20center.%5CnRESULTS%3A%20The%20corticospinal%20tract%20was%20always%20affected%20by%20WMH%20%28100%25%20of%20patients%29%2C%20however%2C%20with%20some%20distinctions%20along%20the%20tract%3A%20the%20precentral%20gyrus%20%28100%25%29%2C%20corona%20radiata%20%2895%25%29%2C%20and%20posterior%20internal%20capsule%20%2881%25%29%20were%20highly%20abnormal%2C%20whereas%20the%20mesencephalon%20%2857%25%29%2C%20pons%20%2852%25%29%2C%20and%20medulla%20oblongata%20%285%25%29%20were%20less%20affected.%20WMH%20were%20also%20frequently%20present%20in%20the%20posterior%20lateral%20periventricular%20white%20matter%20%2895%25%29%2C%20optic%20radiations%20%2886%25%29%2C%20postcentral%20gyrus%20%2871%25%29%2C%20medial%20lemniscus%20%2862%25%29%2C%20and%20corpus%20callosum%2C%20especially%20in%20the%20isthmus%20%2871%25%29%2C%20whereas%20the%20genu%20was%20always%20normal.%20A%20few%20patients%20did%20not%20have%20the%20classical%20MRI%20pattern%20but%20extensive%20hyperintensities%20%28n%20%3D%203%29%2C%20or%20patchy%20distribution%20of%20hyperintensities%20mimicking%20an%20acquired%20etiology%20%28n%20%3D%202%29%2C%20or%20very%20subtle%20hyperintensities%20of%20the%20corticospinal%20tract%20%28n%20%3D%201%29.%5CnCONCLUSIONS%3A%20We%20specified%20the%20main%20locations%20of%20WMH%2C%20which%20were%20observed%20in%20the%20earliest%20stages%20of%20the%20disease%20and%20were%20also%20present%20in%20patients%20with%20atypical%20MRI%20pattern%2C%20highlighting%20the%20importance%20of%20radiologic%20features%20to%20guide%20the%20diagnosis.%22%2C%22date%22%3A%22Aug%2013%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FWNL.0000000000007943%22%2C%22ISSN%22%3A%221526-632X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226KPLZTET%22%5D%2C%22dateModified%22%3A%222024-01-08T12%3A36%3A20Z%22%7D%7D%2C%7B%22key%22%3A%22ETKED9VU%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Maarouf%20et%20al.%22%2C%22parsedDate%22%3A%222019-02-20%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMaarouf%2C%20A.%2C%20Stephan%2C%20D.%2C%20Ranjeva%2C%20M.-P.%2C%20Ranjeva%2C%20J.-P.%2C%20Pelletier%2C%20J.%2C%20Audoin%2C%20B.%2C%20Khrestchatisky%2C%20M.%20and%20Desplat-J%26%23xE9%3Bgo%2C%20S.%20%282019%29%20%26%23x2018%3BHigh%20levels%20of%20serum%20soluble%20TWEAK%20are%20associated%20with%20neuroinflammation%20during%20multiple%20sclerosis%26%23x2019%3B%2C%20%3Ci%3EJournal%20of%20Translational%20Medicine%3C%5C%2Fi%3E%2C%2017%281%29%2C%20p.%2051.%20Available%20at%3A%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12967-019-1789-3%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12967-019-1789-3%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22High%20levels%20of%20serum%20soluble%20TWEAK%20are%20associated%20with%20neuroinflammation%20during%20multiple%20sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Delphine%22%2C%22lastName%22%3A%22Stephan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Pierre%22%2C%22lastName%22%3A%22Ranjeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Ranjeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michel%22%2C%22lastName%22%3A%22Khrestchatisky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Desplat-J%5Cu00e9go%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Inflammation%20and%20demyelination%20are%20the%20main%20processes%20in%20multiple%20sclerosis.%20Nevertheless%2C%20to%20date%2C%20blood%20biomarkers%20of%20inflammation%20are%20lacking.%20TWEAK%2C%20a%20transmembrane%20protein%20that%20belongs%20to%20the%20TNF%20ligand%20family%2C%20has%20been%20previously%20identified%20as%20a%20potential%20candidate.%5CnMETHODS%3A%20Twenty-eight%20patients%20%289%20males%2C%2019%20females%29%20were%20prospectively%20included%20after%20a%20first%20clinical%20episode%20suggestive%20of%20multiple%20sclerosis%20and%20clinically%20followed%20during%203%5Cu00a0years.%20Fifty-seven%20healthy%20controls%20were%20also%20included.%20TWEAK%20serum%20levels%20and%20MRI%20exams%20including%20magnetization%20transfer%20imaging%20were%20performed%20at%20baseline%2C%206-%20and%2012-month%20follow-up.%5CnRESULTS%3A%20TWEAK%20serum%20levels%20were%20significantly%20increased%20in%20the%20patient%20group%20%28mean%20baseline%5Cu2009%3D%5Cu20091086%5Cu2009%5Cu00b1%5Cu2009493%5Cu00a0pg%5C%2FmL%2C%20mean%20M6%5Cu2009%3D%5Cu2009624%5Cu2009%5Cu00b1%5Cu2009302%5Cu00a0pg%5C%2FmL%20and%20mean%20M12%5Cu2009%3D%5Cu2009578%5Cu2009%5Cu00b1%5Cu2009245%5Cu00a0pg%5C%2FmL%29%20compared%20to%20healthy%20controls%20%28mean%5Cu2009%3D%5Cu2009467%5Cu2009%5Cu00b1%5Cu2009177%5Cu00a0pg%5C%2FmL%3B%20respectively%20p%5Cu2009%3C%5Cu20090.0001%2C%200.01%20and%200.06%29.%20Serum%20levels%20of%20soluble%20TWEAK%20were%20significantly%20increased%20during%20relapses%2C%20compared%20to%20time%20periods%20without%20any%20relapse%20%28respectively%20935%5Cu2009%5Cu00b1%5Cu2009489%5Cu00a0pg%5C%2FmL%20and%20611%5Cu2009%5Cu00b1%5Cu2009292%5Cu00a0pg%5C%2FmL%2C%20p%5Cu2009%3D%5Cu20090.0005%29.%20Moreover%2C%20patients%20presenting%20at%20least%20one%20gadolinium-enhanced%20CNS%20lesion%20at%20baseline%20%28n%5Cu2009%3D%5Cu20097%29%20displayed%20significantly%20increased%20serum%20TWEAK%20levels%20in%20comparison%20with%20patients%20without%20any%20gadolinium-enhanced%20lesion%20at%20baseline%20%28n%5Cu2009%3D%5Cu200921%29%20%28respectively%201421%5Cu2009%5Cu00b1%5Cu2009657%5Cu00a0pg%5C%2FmL%20vs%20975%5Cu2009%5Cu00b1%5Cu2009382%5Cu00a0pg%5C%2FmL%3B%20p%5Cu2009%3D%5Cu20090.02%29.%20Finally%2C%20no%20correlation%20was%20evidenced%20between%20TWEAK%20serum%20levels%20and%20the%20extent%20of%20brain%20tissue%20damage%20assessed%20by%20magnetization%20transfer%20ratio.%5CnCONCLUSIONS%3A%20The%20present%20study%20showed%20that%20TWEAK%20serum%20levels%20are%20increased%20in%20MS%20patients%2C%20in%20relation%20to%20the%20disease%20activity.%20This%20simple%20and%20reproducible%20serum%20test%20could%20be%20used%20as%20a%20marker%20of%20ongoing%20inflammation%2C%20contributing%20in%20the%20follow-up%20and%20the%20care%20of%20MS%20patients.%20Thus%2C%20TWEAK%20is%20a%20promising%20serum%20marker%20of%20the%20best%20window%20to%20perform%20brain%20MRI%2C%20optimizing%20the%20disease%20control%20in%20patients.%22%2C%22date%22%3A%22Feb%2020%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12967-019-1789-3%22%2C%22ISSN%22%3A%221479-5876%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22UP3H3ICX%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%5D%2C%22dateModified%22%3A%222024-11-26T16%3A01%3A14Z%22%7D%7D%2C%7B%22key%22%3A%22NPRLLNLS%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A1497928%2C%22username%22%3A%22fkober%22%2C%22name%22%3A%22Frank%20Kober%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Ffkober%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Melenotte%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMelenotte%2C%20C.%2C%20Seguier%2C%20J.%2C%20Ebbo%2C%20M.%2C%20Kaphan%2C%20E.%2C%20Bernit%2C%20E.%2C%20Saillier%2C%20L.%2C%20Audoin%2C%20B.%2C%20Feyeux%2C%20D.%2C%20Daniel%2C%20L.%2C%20Roche%2C%20P.-H.%2C%20Graillon%2C%20T.%2C%20Dufour%2C%20H.%2C%20Bouti%26%23xE8%3Bre%2C%20C.%2C%20Girard%2C%20N.%2C%20Closs-Prophette%2C%20F.%2C%20Guillaud%2C%20C.%2C%20Tieuli%26%23xE9%3B%2C%20N.%2C%20Regent%2C%20A.%2C%20Harl%26%23xE9%3B%2C%20J.R.%2C%20Hamidou%2C%20M.%2C%20Mekinian%2C%20A.%2C%20Grados%2C%20A.%20and%20Schleinitz%2C%20N.%20%282019%29%20%26%23x2018%3BClinical%20presentation%2C%20treatment%20and%20outcome%20of%20IgG4-related%20pachymeningitis%3A%20From%20a%20national%20case%20registry%20and%20literature%20review%26%23x2019%3B%2C%20%3Ci%3ESeminars%20in%20Arthritis%20and%20Rheumatism%3C%5C%2Fi%3E%2C%2049%283%29%2C%20pp.%20430%26%23x2013%3B437.%20Available%20at%3A%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.semarthrit.2019.05.003%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.semarthrit.2019.05.003%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Clinical%20presentation%2C%20treatment%20and%20outcome%20of%20IgG4-related%20pachymeningitis%3A%20From%20a%20national%20case%20registry%20and%20literature%20review%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9a%22%2C%22lastName%22%3A%22Melenotte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Seguier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikael%22%2C%22lastName%22%3A%22Ebbo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elsa%22%2C%22lastName%22%3A%22Kaphan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Bernit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Saillier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Delphine%22%2C%22lastName%22%3A%22Feyeux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Daniel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre-Hugues%22%2C%22lastName%22%3A%22Roche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Graillon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Henry%22%2C%22lastName%22%3A%22Dufour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mence%22%2C%22lastName%22%3A%22Bouti%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadine%22%2C%22lastName%22%3A%22Girard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabienne%22%2C%22lastName%22%3A%22Closs-Prophette%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Constance%22%2C%22lastName%22%3A%22Guillaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Tieuli%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexis%22%2C%22lastName%22%3A%22Regent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Robert%22%2C%22lastName%22%3A%22Harl%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mohamed%22%2C%22lastName%22%3A%22Hamidou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ars%5Cu00e8ne%22%2C%22lastName%22%3A%22Mekinian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Grados%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Schleinitz%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2212%5C%2F2019%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.semarthrit.2019.05.003%22%2C%22ISSN%22%3A%2200490172%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2FS0049017218304736%22%2C%22collections%22%3A%5B%22W98NEAUQ%22%2C%22X9AF3XQR%22%5D%2C%22dateModified%22%3A%222024-12-03T08%3A55%3A41Z%22%7D%7D%2C%7B%22key%22%3A%229Y49QGW5%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Durozard%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDurozard%2C%20P.%2C%20Maarouf%2C%20A.%2C%20Boutiere%2C%20C.%2C%20Ruet%2C%20A.%2C%20Brochet%2C%20B.%2C%20Vukusic%2C%20S.%2C%20Carra-Dalliere%2C%20C.%2C%20Labauge%2C%20P.%2C%20Mathey%2C%20G.%2C%20Debouverie%2C%20M.%2C%20Papeix%2C%20C.%2C%20Maillart%2C%20E.%2C%20Lubetzki%2C%20C.%2C%20Bensa%2C%20C.%2C%20Gout%2C%20O.%2C%20Giannesini%2C%20C.%2C%20Stankoff%2C%20B.%2C%20Ciron%2C%20J.%2C%20Brassat%2C%20D.%2C%20Pelletier%2C%20J.%2C%20Rico%20Lamy%2C%20A.%20and%20Audoin%2C%20B.%20%282019%29%20%26%23x2018%3BEfficacy%20of%20rituximab%20in%20refractory%20RRMS%26%23x2019%3B%2C%20%3Ci%3EMultiple%20Sclerosis%20%28Houndmills%2C%20Basingstoke%2C%20England%29%3C%5C%2Fi%3E%2C%2025%286%29%2C%20pp.%20828%26%23x2013%3B836.%20Available%20at%3A%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F1352458518772748%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F1352458518772748%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Efficacy%20of%20rituximab%20in%20refractory%20RRMS%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Durozard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurelie%22%2C%22lastName%22%3A%22Ruet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Brochet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clarisse%22%2C%22lastName%22%3A%22Carra-Dalliere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Mathey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Debouverie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Papeix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Lubetzki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Bensa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Gout%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Giannesini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Stankoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Brassat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%20Lamy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20To%20investigate%20the%20efficacy%20of%20rituximab%20as%20rescue%20therapy%20in%20patients%20with%20relapsing-remitting%20multiple%20sclerosis%20%28RRMS%29%20and%20persistent%20disease%20activity%20confirmed%20by%20magnetic%20resonance%20imaging%20%28MRI%29%20despite%20immunosuppressive%20disease-modifying%20therapy%20%28DMT%29.%5CnMETHODS%3A%20In%20this%20observational%20nationwide%20retrospective%20multicenter%20study%2C%20we%20first%20identified%20351%20off-label%20rituximab-treated%20patients%20through%20a%20cohort%20of%2015%2C984%20RRMS%20patients.%20In%20this%20group%2C%20we%20identified%20patients%20with%20disease%20activity%20prior%20to%20rituximab%20confirmed%20by%20MRI%20%28one%20or%20more%20new%20T2%20lesion%20and%5C%2For%20gadolinium-enhancing%20lesion%29%20despite%20immunosuppressive%20DMT%20%28fingolimod%2C%20natalizumab%2C%20or%20mitoxantrone%29%20with%20a%20follow-up%20after%20rituximab%20initiation%20longer%20than%206%5Cu2009months.%20Outcome%20data%20were%20collected%20from%20the%20French%20Observatory%20of%20Multiple%20Sclerosis%20%28OFSEP%29%20register%20and%20medical%20charts.%5CnRESULTS%3A%20A%20total%20of%2050%20patients%20were%20identified.%20Median%20rituximab%20treatment%20duration%20was%201.1%20%280.5-6.4%29%5Cu2009year.%20Mean%20annualized%20relapse%20rate%20significantly%20decreased%20from%200.8%20during%20last%20immunosuppressive%20DMT%20to%200.18%20after%20rituximab%20%28%20p%5Cu2009%3C%5Cu20090.0001%29.%20While%2072%25%20of%20patients%20showed%20gadolinium-enhancing%20lesions%20on%20the%20last%20MRI%20performed%20during%20last%20immunosuppressive%20DMT%2C%208%25%20of%20them%20showed%20gadolinium-enhancing%20lesions%20on%20the%20first%20MRI%20performed%206.1%20%28range%201.4-18.4%29%5Cu2009months%20after%20rituximab%20%28%20p%5Cu2009%3C%5Cu20090.0001%29.%5CnCONCLUSION%3A%20This%20study%20provides%20level%20IV%20evidence%20that%20rituximab%20reduces%20clinical%20and%20MRI%20disease%20activity%20in%20patients%20with%20active%20RRMS%20despite%20immunosuppressive%20DMT.%22%2C%22date%22%3A%2205%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1177%5C%2F1352458518772748%22%2C%22ISSN%22%3A%221477-0970%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%5D%2C%22dateModified%22%3A%222024-11-26T16%3A00%3A56Z%22%7D%7D%2C%7B%22key%22%3A%22BVXZS6K7%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22The%20OFSEP%20Group%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EThe%20OFSEP%20Group%2C%20The%20REEM%20Group%2C%20Cobo-Calvo%2C%20A.%2C%20Sep%26%23xFA%3Blveda%2C%20M.%2C%20d%26%23x2019%3BIndy%2C%20H.%2C%20Armangu%26%23xE9%3B%2C%20T.%2C%20Ruiz%2C%20A.%2C%20Maillart%2C%20E.%2C%20Papeix%2C%20C.%2C%20Audoin%2C%20B.%2C%20Zephir%2C%20H.%2C%20Biotti%2C%20D.%2C%20Ciron%2C%20J.%2C%20Durand-Dubief%2C%20F.%2C%20Collongues%2C%20N.%2C%20Ayrignac%2C%20X.%2C%20Labauge%2C%20P.%2C%20Thouvenot%2C%20E.%2C%20Montcuquet%2C%20A.%2C%20Deschamps%2C%20R.%2C%20Sol%26%23xE0%3B-Valls%2C%20N.%2C%20Llufriu%2C%20S.%2C%20Blanco%2C%20Y.%2C%20de%20Seze%2C%20J.%2C%20Vukusic%2C%20S.%2C%20Saiz%2C%20A.%20and%20Marignier%2C%20R.%20%282019%29%20%26%23x2018%3BUsefulness%20of%20MOG-antibody%20titres%20at%20first%20episode%20to%20predict%20the%20future%20clinical%20course%20in%20adults%26%23x2019%3B%2C%20%3Ci%3EJournal%20of%20Neurology%3C%5C%2Fi%3E%2C%20266%284%29%2C%20pp.%20806%26%23x2013%3B815.%20Available%20at%3A%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00415-018-9160-9%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00415-018-9160-9%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Usefulness%20of%20MOG-antibody%20titres%20at%20first%20episode%20to%20predict%20the%20future%20clinical%20course%20in%20adults%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22The%20OFSEP%20Group%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22The%20REEM%20Group%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alvaro%22%2C%22lastName%22%3A%22Cobo-Calvo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mar%5Cu00eda%22%2C%22lastName%22%3A%22Sep%5Cu00falveda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hyacintha%22%2C%22lastName%22%3A%22d%5Cu2019Indy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thais%22%2C%22lastName%22%3A%22Armangu%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Ruiz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Papeix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helene%22%2C%22lastName%22%3A%22Zephir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%22%2C%22lastName%22%3A%22Biotti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francoise%22%2C%22lastName%22%3A%22Durand-Dubief%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Collongues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Ayrignac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Thouvenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexis%22%2C%22lastName%22%3A%22Montcuquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Deschamps%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nuria%22%2C%22lastName%22%3A%22Sol%5Cu00e0-Valls%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sara%22%2C%22lastName%22%3A%22Llufriu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yolanda%22%2C%22lastName%22%3A%22Blanco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jerome%22%2C%22lastName%22%3A%22de%20Seze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Albert%22%2C%22lastName%22%3A%22Saiz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Marignier%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%224%5C%2F2019%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00415-018-9160-9%22%2C%22ISSN%22%3A%220340-5354%2C%201432-1459%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Flink.springer.com%5C%2F10.1007%5C%2Fs00415-018-9160-9%22%2C%22collections%22%3A%5B%226KPLZTET%22%5D%2C%22dateModified%22%3A%222024-12-05T08%3A30%3A12Z%22%7D%7D%5D%7D
Guttieres, L., Vannelli, L., Demortiere, S., Perriguey, M., Elziere, M., Durozard, P., Boutiere, C., Rico, A., Hilezian, F., Stellmann, J.-P., Pelletier, J., Maarouf, A., Stolowy, N. and Audoin, B. (2025) ‘Fluorescein Angiography as a Surrogate Marker of Disease Activity in Susac Syndrome’, Neurology(R) Neuroimmunology & Neuroinflammation, 12(2), p. e200379. Available at: https://doi.org/10.1212/NXI.0000000000200379.
Villacieros-Álvarez, J., Espejo, C., Arrambide, G., Dinoto, A., Mulero, P., Rubio-Flores, L., Nieto, P., Alcalá, C., Meca-Lallana, J.E., Millan-Pascual, J., Martínez-García, P., Bernard-Valnet, R., González-Suárez, I., Orviz, A., Téllez, R., Navarro Cantó, L., Presas-Rodríguez, S., Martínez-Yélamos, S., Cuello, J.P., Alonso, A., Piñar Morales, R., Álvarez Bravo, G., Benyahya, L., Trouillet-Assant, S., Dyon-Tafan, V., Froment Tilikete, C., Ruet, A., Bourre, B., Deschamps, R., Papeix, C., Maillart, E., Kerschen, P., Ayrignac, X., Rovira, À., Auger, C., Audoin, B., Montalban, X., Tintore, M., Mariotto, S., Cobo-Calvo, A. and Marignier, R. (2025) ‘Profile and Usefulness of Serum Cytokines to Predict Prognosis in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease’, Neurology(R) Neuroimmunology & Neuroinflammation, 12(2), p. e200362. Available at: https://doi.org/10.1212/NXI.0000000000200362.
Ramdani, R., Pique, J., Deschamps, R., Ciron, J., Maillart, E., Audoin, B., Cohen, M., Zephir, H., Laplaud, D., Ayrignac, X., Collongues, N., Ruet, A., Thouvenot, E., Bourre, B., Papeix, C., Benyahya, L., Marignier, R. and NOMADMUS Study Group (2025) ‘Evaluation of the predictive value of CSF-restricted oligoclonal bands on residual disability and risk of relapse in adult patients with MOGAD: MOGADOC study’, Multiple Sclerosis (Houndmills, Basingstoke, England), p. 13524585241311436. Available at: https://doi.org/10.1177/13524585241311435.
Androdias, G., Lünemann, J.D., Maillart, E., Amato, M.P., Audoin, B., Bruijstens, A.L., Bsteh, G., Butzkueven, H., Ciccarelli, O., Cobo-Calvo, A., Derfuss, T., Di Pauli, F., Edan, G., Enzinger, C., Geraldes, R., Granziera, C., Hacohen, Y., Hartung, H.-P., Hynes, S., Inglese, M., Kappos, L., Kuusisto, H., Langer-Gould, A., Magyari, M., Marignier, R., Montalban, X., Mycko, M.P., Nourbakhsh, B., Oh, J., Oreja-Guevara, C., Piehl, F., Prosperini, L., Sastre-Garriga, J., Sellebjerg, F., Selmaj, K., Siva, A., Tallantyre, E., van Pesch, V., Vukusic, S., Weinstock-Guttman, B., Zipp, F., Tintoré, M., Iacobaeus, E. and Stankoff, B. (2024) ‘De-escalating and discontinuing disease-modifying therapies in multiple sclerosis’, Brain, p. awae409. Available at: https://doi.org/10.1093/brain/awae409.
Durozard, P., Maarouf, A., Zaaraoui, W., Stellmann, J.-P., Boutière, C., Rico, A., Demortière, S., Guye, M., Le Troter, A., Dary, H., Ranjeva, J.-P., Audoin, B. and Pelletier, J. (2024) ‘Cortical Lesions as an Early Hallmark of Multiple Sclerosis: Visualization by 7 T MRI’, Investigative Radiology, 59(11), p. 747. Available at: https://doi.org/10.1097/RLI.0000000000001082.
Maarouf, A., Stellmann, J.P., Rico, A., Boutiere, C., Demortiere, S., Durozard, P., Zaaraoui, W., Ranjeva, J.-P., Pelletier, J. and Audoin, B. (2024) ‘Active and non-active progression independent of relapse activity within the first 20 years of relapsing multiple sclerosis’, Journal of Neurology, Neurosurgery, and Psychiatry, p. jnnp-2024-333597. Available at: https://doi.org/10.1136/jnnp-2024-333597.
Graille-Avy, L., Boutiere, C., Rigollet, C., Perriguey, M., Rico, A., Demortiere, S., Durozard, P., Hilezian, F., Vely, F., Bertault-Peres, P., Pelletier, J., Maarouf, A. and Audoin, B. (2024) ‘Effect of Prior Treatment With Fingolimod on Early and Late Response to Rituximab/Ocrelizumab in Patients With Multiple Sclerosis’, Neurology(R) Neuroimmunology & Neuroinflammation, 11(3), p. e200231. Available at: https://doi.org/10.1212/NXI.0000000000200231.
Demortiere, S., Joubert, B., Benaiteau, M., Hilezian, F., Boutiere, C., Rico, A., Stolowy, N., Dubois, V., Audoin, B., Maarouf, A. and Pelletier, J. (2024) ‘Anti-IgLON5 Disease With Inaugural Bilateral Neuropapillitis’, Neurology, 102(8), p. e209284. Available at: https://doi.org/10.1212/WNL.0000000000209284.
Cruz, E.S., Fortanier, E., Hilezian, F., Maarouf, A., Boutière, C., Demortière, S., Rico, A., Delmont, E., Pelletier, J., Attarian, S. and Audoin, B. (2024) ‘Factors affecting the topography of nitrous oxide-induced neurological complications’, European Journal of Neurology, p. e16291. Available at: https://doi.org/10.1111/ene.16291.
Sole Cruz, E., Stolowy, N., Attia, R., Audoin, B. and Demortière, S. (2024) ‘Acute posterior ischemic optic neuropathy associated with a hypertensive crisis’, Revue Neurologique, 180(3), pp. 218–219. Available at: https://doi.org/10.1016/j.neurol.2023.12.002.
Collongues, N., Durand-Dubief, F., Lebrun-Frenay, C., Audoin, B., Ayrignac, X., Bensa, C., Bigaut, K., Bourre, B., Carra-Dallière, C., Ciron, J., Defer, G., Kwiatkowski, A., Leray, E., Maillart, E., Marignier, R., Mathey, G., Morel, N., Thouvenot, E., Zéphir, H., Boucher, J., Boutière, C., Branger, P., Da Silva, A., Demortière, S., Guillaume, M., Hebant, B., Januel, E., Kerbrat, A., Manchon, E., Moisset, X., Montcuquet, A., Pierret, C., Pique, J., Poupart, J., Prunis, C., Roux, T., Schmitt, P., Androdias, G. and Cohen, M. (2024) ‘Cancer and multiple sclerosis: 2023 recommendations from the French Multiple Sclerosis Society’, Multiple Sclerosis (Houndmills, Basingstoke, England), p. 13524585231223880. Available at: https://doi.org/10.1177/13524585231223880.
Venet, M., Lepine, A., Maarouf, A., Biotti, D., Boutiere, C., Casez, O., Cohen, M., Durozard, P., Demortière, S., Giorgi, L., Maillart, E., Mathey, G., Mazzola, L., Rico, A., Camdessanche, J.-P., Deiva, K., Pelletier, J. and Audoin, B. (2024) ‘Control of disease activity with large extended-interval dosing of rituximab/ocrelizumab in highly active pediatric multiple sclerosis’, Multiple Sclerosis (Houndmills, Basingstoke, England), p. 13524585231223068. Available at: https://doi.org/10.1177/13524585231223069.
Attia, R., Fitoussi, R., Mairot, K., Demortiere, S., Stellman, J.-P., Tilsley, P., Audoin, B., David, T. and Stolowy, N. (2023) ‘Risk factors associated with progression from papilloedema to optic atrophy: results from a cohort of 113 patients’, BMJ open ophthalmology, 8(1), p. e001375. Available at: https://doi.org/10.1136/bmjophth-2023-001375.
Claverie, R., Perriguey, M., Rico, A., Boutiere, C., Demortiere, S., Durozard, P., Hilezian, F., Dubrou, C., Vely, F., Pelletier, J., Audoin, B. and Maarouf, A. (2023) ‘Efficacy of Rituximab Outlasts B-Cell Repopulation in Multiple Sclerosis: Time to Rethink Dosing?’, Neurology(R) Neuroimmunology & Neuroinflammation, 10(5), p. e200152. Available at: https://doi.org/10.1212/NXI.0000000000200152.
Testud, B., Fabiani, N., Demortière, S., Mchinda, S., Medina, N.L., Pelletier, J., Guye, M., Audoin, B., Stellmann, J.P. and Callot, V. (2023) ‘Contribution of the MP2RAGE 7T Sequence in MS Lesions of the Cervical Spinal Cord’, AJNR. American journal of neuroradiology, 44(9), pp. 1101–1107. Available at: https://doi.org/10.3174/ajnr.A7964.
Demortiere, S., Maarouf, A., Rico, A., Boutiere, C., Hilezian, F., Durozard, P., Pelletier, J. and Audoin, B. (2023) ‘Disease Evolution in Women With Highly Active MS Who Suspended Natalizumab During Pregnancy vs Rituximab/Ocrelizumab Before Conception’, Neurology(R) Neuroimmunology & Neuroinflammation, 10(5), p. e200161. Available at: https://doi.org/10.1212/NXI.0000000000200161.
Rode, J., Pique, J., Maarouf, A., Ayrignac, X., Bourre, B., Ciron, J., Cohen, M., Collongues, N., Deschamps, R., Maillart, E., Montcuquet, A., Papeix, C., Ruet, A., Wiertlewski, S., Zephir, H., Marignier, R. and Audoin, B. (2023) ‘Time to steroids impacts visual outcome of optic neuritis in MOGAD’, Journal of Neurology, Neurosurgery & Psychiatry, 94(4), pp. 309–313. Available at: https://doi.org/10.1136/jnnp-2022-330360.
Chen, J.J., Flanagan, E.P., Pittock, S.J., Stern, N.C., Tisavipat, N., Bhatti, M.T., Chodnicki, K.D., Tajfirouz, D.A., Jamali, S., Kunchok, A., Eggenberger, E.R., Nome, M.A.D., Sotirchos, E.S., Vasileiou, E.S., Henderson, A.D., Arnold, A.C., Bonelli, L., Moss, H.E., Navarro, S.E.V., Padungkiatsagul, T., Stiebel-Kalish, H., Lotan, I., Wilf-Yarkoni, A., Danesh-Meyer, H., Ivanov, S., Huda, S., Forcadela, M., Hodge, D., Poullin, P., Rode, J., Papeix, C., Saheb, S., Boudot de la Motte, M., Vignal, C., Hacohen, Y., Pique, J., Maillart, E., Deschamps, R., Audoin, B. and Marignier, R. (2023) ‘Visual Outcomes Following Plasma Exchange for Optic Neuritis: An International Multicenter Retrospective Analysis of 395 Optic Neuritis Attacks’, American Journal of Ophthalmology, pp. S0002-9394(23)00066–1. Available at: https://doi.org/10.1016/j.ajo.2023.02.013.
Carra-Dallière, C., Rollot, F., Deschamps, R., Ciron, J., Vukusic, S., Audoin, B., Ruet, A., Maillart, E., Papeix, C., Zephir, H., Laplaud, D., Cohen, M., Bourre, B., El-Bahi, I., Labauge, P., Casey, R., Ayrignac, X. and Marignier, R. (2023) ‘Pregnancy and post-partum in patients with myelin-oligodendrocyte glycoprotein antibody-associated disease’, Multiple Sclerosis Journal, 29(2), pp. 270–276. Available at: https://doi.org/10.1177/13524585221134214.
Maarouf, A., Audoin, B., Gherib, S., El Mendili, M.M., Viout, P., Pariollaud, F., Boutière, C., Rico, A., Guye, M., Ranjeva, J.-P., Zaaraoui, W. and Pelletier, J. (2022) ‘Grey-matter sodium concentration as an individual marker of multiple sclerosis severity’, Multiple Sclerosis Journal, 28(12), pp. 1903–1912. Available at: https://doi.org/10.1177/13524585221102587.
Poullet, Z., Pique, J., Maarouf, A., Boutiere, C., Rico, A., Demortiere, S., Durozard, P., Papeix, C., Maillart, E., Collongues, N., Ayrignac, X., Zephir, H., Deschamps, R., Ciron, J., Pelletier, J., Marignier, R. and Audoin, B. (2022) ‘Pure Relapsing Short Myelitis: Part of the Multiple Sclerosis Spectrum or New Entity?’, Neurology(R) Neuroimmunology & Neuroinflammation, 9(4), p. e1167. Available at: https://doi.org/10.1212/NXI.0000000000001167.
Januel, E., De Seze, J., Vermersch, P., Maillart, E., Bourre, B., Pique, J., Moisset, X., Bensa, C., Maarouf, A., Pelletier, J., Vukusic, S., Audoin, B. and Louapre, C. (2022) ‘Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica’, Multiple Sclerosis Journal, 28(7), pp. 1155–1159. Available at: https://doi.org/10.1177/13524585211049737.
Demuth, S., Guillaume, M., Bourre, B., Ciron, J., Zephir, H., Sirejacob, Y., Kerbrat, A., Lebrun-Frenay, C., Papeix, C., Michel, L., Laplaud, D., Vukusic, S., Maillart, E., Cohen, M., Audoin, B., Marignier, R., Collongues, N. and NOMADMUS Study Group (2022) ‘Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study’, Journal of Neuroinflammation, 19(1), p. 62. Available at: https://doi.org/10.1186/s12974-022-02420-2.
Perriguey, M., Maarouf, A., Stellmann, J.-P., Rico, A., Boutiere, C., Demortiere, S., Durozard, P., Pelletier, J. and Audoin, B. (2022) ‘Hypogammaglobulinemia and Infections in Patients With Multiple Sclerosis Treated With Rituximab’, Neurology(R) Neuroimmunology & Neuroinflammation, 9(1), p. e1115. Available at: https://doi.org/10.1212/NXI.0000000000001115.
Ringelstein, M., Ayzenberg, I., Lindenblatt, G., Fischer, K., Gahlen, A., Novi, G., Hayward-Könnecke, H., Schippling, S., Rommer, P.S., Kornek, B., Zrzavy, T., Biotti, D., Ciron, J., Audoin, B., Berthele, A., Giglhuber, K., Zephir, H., Kümpfel, T., Berger, R., Röther, J., Häußler, V., Stellmann, J.-P., Whittam, D., Jacob, A., Kraemer, M., Gueguen, A., Deschamps, R., Bayas, A., Hümmert, M.W., Trebst, C., Haarmann, A., Jarius, S., Wildemann, B., Grothe, M., Siebert, N., Ruprecht, K., Paul, F., Collongues, N., Marignier, R., Levy, M., Karenfort, M., Deppe, M., Albrecht, P., Hellwig, K., Gold, R., Hartung, H.-P., Meuth, S.G., Kleiter, I., Aktas, O. and Neuromyelitis Optica Study Group (NEMOS) (2022) ‘Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders’, Neurology(R) Neuroimmunology & Neuroinflammation, 9(1), p. e1100. Available at: https://doi.org/10.1212/NXI.0000000000001100.
Rico, A., Ninove, L., Maarouf, A., Boutiere, C., Durozard, P., Demortiere, S., Saba Villarroel, P.M., Amroun, A., Fourié, T., de Lamballerie, X., Pelletier, J. and Audoin, B. (2021) ‘Determining the best window for BNT162b2 mRNA vaccination for SARS-CoV-2 in patients with multiple sclerosis receiving anti-CD20 therapy’, Multiple Sclerosis Journal - Experimental, Translational and Clinical, 7(4), p. 20552173211062144. Available at: https://doi.org/10.1177/20552173211062142.
Hilezian, F., Maarouf, A., Boutiere, C., Rico, A., Demortiere, S., Kerschen, P., Sene, T., Bensa-Koscher, C., Giannesini, C., Capron, J., Mekinian, A., Camdessanché, J.-P., Androdias, G., Marignier, R., Collongues, N., Casez, O., Coclitu, C., Vaillant, M., Mathey, G., Ciron, J., Pelletier, J. and Audoin, B. (2021) ‘TNF-α inhibitors used as steroid-sparing maintenance monotherapy in parenchymal CNS sarcoidosis’, Journal of Neurology, Neurosurgery & Psychiatry, 92(8), pp. 890–896. Available at: https://doi.org/10.1136/jnnp-2020-325665.
Has Silemek, A.C., Ranjeva, J.-P., Audoin, B., Heesen, C., Gold, S.M., Kühn, S., Weygandt, M. and Stellmann, J.-P. (2021) ‘Delayed access to conscious processing in multiple sclerosis: Reduced cortical activation and impaired structural connectivity’, Human Brain Mapping, 42(11), pp. 3379–3395. Available at: https://doi.org/10.1002/hbm.25440.
Perez, T., Rico, A., Boutière, C., Maarouf, A., Roudot, M., Honoré, S., Pelletier, J., Bertault-Peres, P. and Audoin, B. (2021) ‘Comparison of rituximab originator (MabThera®) to biosimilar (Truxima®) in patients with multiple sclerosis’, Multiple Sclerosis (Houndmills, Basingstoke, England), 27(4), pp. 585–592. Available at: https://doi.org/10.1177/1352458520912170.
Chard, D.T., Alahmadi, A.A.S., Audoin, B., Charalambous, T., Enzinger, C., Hulst, H.E., Rocca, M.A., Rovira, À., Sastre-Garriga, J., Schoonheim, M.M., Tijms, B., Tur, C., Gandini Wheeler-Kingshott, C.A.M., Wink, A.M., Ciccarelli, O., Barkhof, F. and MAGNIMS Study Group (2021) ‘Mind the gap: from neurons to networks to outcomes in multiple sclerosis’, Nature Reviews. Neurology, 17(3), pp. 173–184. Available at: https://doi.org/10.1038/s41582-020-00439-8.
Stellmann, J.-P., Wanke, N., Maarouf, A., Gellißen, S., Heesen, C., Audoin, B., Gold, S.M., Zaaraoui, W. and Poettgen, J. (2021) ‘Cognitive performance shows domain specific associations with regional cortical thickness in multiple sclerosis’, NeuroImage. Clinical, 30, p. 102606. Available at: https://doi.org/10.1016/j.nicl.2021.102606.
Massire, A., Seiler, C., Troalen, T., Girard, O.M., Lehmann, P., Brun, G., Bartoli, A., Audoin, B., Bartolomei, F., Pelletier, J., Callot, V., Kober, T., Ranjeva, J.-P. and Guye, M. (2021) ‘T1-Based Synthetic Magnetic Resonance Contrasts Improve Multiple Sclerosis and Focal Epilepsy Imaging at 7 T’, Investigative Radiology, 56(2), pp. 127–133. Available at: https://doi.org/10.1097/RLI.0000000000000718.
Luciani, L., Ninove, L., Zandotti, C., Chalvignac, V., Lagier, D., Baume, J., Mélade, J., Piorkowski, G., Coutard, B., Lepidi, H., Pelletier, J., Audoin, B., Rico-Lamy, A. and Nougairède, A. (2021) ‘Fatal underhanded chronic enterovirus infection associated with anti-CD20 monotherapy for central nervous system demyelinating disease’, Multiple Sclerosis Journal, 27(2), pp. 320–323. Available at: https://doi.org/10.1177/1352458520923978.
Cobo‐Calvo, A., Ruiz, A., Rollot, F., Arrambide, G., Deschamps, R., Maillart, E., Papeix, C., Audoin, B., Lépine, A.F., Maurey, H., Zephir, H., Biotti, D., Ciron, J., Durand‐Dubief, F., Collongues, N., Ayrignac, X., Labauge, P., Meyer, P., Thouvenot, E., Bourre, B., Montcuquet, A., Cohen, M., Horello, P., Tintoré, M., De Seze, J., Vukusic, S., Deiva, K., Marignier, R. and the NOMADMUS, KidBioSEP, and OFSEP study groups (2021) ‘Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease’, Annals of Neurology, 89(1), pp. 30–41. Available at: https://doi.org/10.1002/ana.25909.
Giovannelli, J., Ciron, J., Cohen, M., Kim, H.-J., Kim, S.-H., Stellmann, J.-P., Kleiter, I., McCreary, M., Greenberg, B.M., Deschamps, R., Audoin, B., Maillart, E., Papeix, C., Collongues, N., Bourre, B., Laplaud, D., Ayrignac, X., Durand-Dubief, F., Ruet, A., Vukusic, S., Marignier, R., Dauchet, L., Zephir, H. and NEMOS (Neuromyelitis Optica Study Group in Germany), O. (Observatoire F. de la S. en P. investigators, NOMADMUS (Neuromyelitis Optica study Group in France) (2021) ‘A meta-analysis comparing first-line immunosuppressants in neuromyelitis optica’, Annals of Clinical and Translational Neurology, 8(10), pp. 2025–2037. Available at: https://doi.org/10.1002/acn3.51451.
Roos, I., Leray, E., Frascoli, F., Casey, R., Brown, J.W.L., Horakova, D., Havrdova, E.K., Trojano, M., Patti, F., Izquierdo, G., Eichau, S., Onofrj, M., Lugaresi, A., Prat, A., Girard, M., Grammond, P., Sola, P., Ferraro, D., Ozakbas, S., Bergamaschi, R., Sá, M.J., Cartechini, E., Boz, C., Granella, F., Hupperts, R., Terzi, M., Lechner-Scott, J., Spitaleri, D., Van Pesch, V., Soysal, A., Olascoaga, J., Prevost, J., Aguera-Morales, E., Slee, M., Csepany, T., Turkoglu, R., Sidhom, Y., Gouider, R., Van Wijmeersch, B., McCombe, P., Macdonell, R., Coles, A., Malpas, C.B., Butzkueven, H., Vukusic, S., Kalincik, T., the MSBase, Duquette, P., Grand’Maison, F., Iuliano, G., Ramo-Tello, C., Solaro, C., Cabrera-Gomez, J.A., Rio, M.E., Bolaños, R.F., Shaygannejad, V., Oreja-Guevara, C., Sanchez-Menoyo, J.L., Petersen, T., Altintas, A., Barnett, M., Flechter, S., Fragoso, Y., Amato, M.P., Moore, F., Ampapa, R., Verheul, F., Hodgkinson, S., Cristiano, E., Yamout, B., Laureys, G., Dominguez, J.A., Zwanikken, C., Deri, N., Dobos, E., Vrech, C., Butler, E., Rozsa, C., Petkovska-Boskova, T., Karabudak, R., Rajda, C., Alkhaboori, J., Saladino, M.L., Shaw, C., Shuey, N., Vucic, S., Sempere, A.P., Campbell, J., Piroska, I., Taylor, B., van der Walt, A., Kappos, L., Roullet, E., Gray, O., Simo, M., Sirbu, C.-A., OFSEP investigators, Brochet, B., Cotton, F., De Sèze, J., Dion, A., Douek, P., Guillemin, F., Laplaud, D., Lebrun-Frenay, C., Moreau, T., Olaiz, J., Pelletier, J., Rigaud-Bully, C., Stankoff, B., Marignier, R., Debouverie, M., Edan, G., Ciron, J., Ruet, A., Collongues, N., Lubetzki, C., Vermersch, P., Labauge, P., Defer, G., Cohen, M., Fromont, A., Wiertlewsky, S., Berger, E., Clavelou, P., Audoin, B., Giannesini, C., Gout, O., Thouvenot, E., Heinzlef, O., Al-Khedr, A., Bourre, B., Casez, O., Cabre, P., Montcuquet, A., Créange, A., Camdessanché, J.-P., Faure, J., Maurousset, A., Patry, I., Hankiewicz, K., Pottier, C., Maubeuge, N., Labeyrie, C. and Nifle, C. (2020) ‘Delay from treatment start to full effect of immunotherapies for multiple sclerosis’, Brain, 143(9), pp. 2742–2756. Available at: https://doi.org/10.1093/brain/awaa231.
Kerbrat, A., Gros, C., Badji, A., Bannier, E., Galassi, F., Combès, B., Chouteau, R., Labauge, P., Ayrignac, X., Carra-Dalliere, C., Maranzano, J., Granberg, T., Ouellette, R., Stawiarz, L., Hillert, J., Talbott, J., Tachibana, Y., Hori, M., Kamiya, K., Chougar, L., Lefeuvre, J., Reich, D.S., Nair, G., Valsasina, P., Rocca, M.A., Filippi, M., Chu, R., Bakshi, R., Callot, V., Pelletier, J., Audoin, B., Maarouf, A., Collongues, N., De Seze, J., Edan, G. and Cohen-Adad, J. (2020) ‘Multiple sclerosis lesions in motor tracts from brain to cervical cord: spatial distribution and correlation with disability’, Brain: A Journal of Neurology, 143(7), pp. 2089–2105. Available at: https://doi.org/10.1093/brain/awaa162.
Rasoanandrianina, H., Demortière, S., Trabelsi, A., Ranjeva, J.P., Girard, O., Duhamel, G., Guye, M., Pelletier, J., Audoin, B. and Callot, V. (2020) ‘Sensitivity of the Inhomogeneous Magnetization Transfer Imaging Technique to Spinal Cord Damage in Multiple Sclerosis’, American Journal of Neuroradiology, 41(5), pp. 929–937. Available at: https://doi.org/10.3174/ajnr.A6554.
Poupart, J., Giovannelli, J., Deschamps, R., Audoin, B., Ciron, J., Maillart, E., Papeix, C., Collongues, N., Bourre, B., Cohen, M., Wiertlewski, S., Outteryck, O., Laplaud, D., Vukusic, S., Marignier, R., Zephir, H. and NOMADMUS study group (2020) ‘Evaluation of efficacy and tolerability of first-line therapies in NMOSD’, Neurology, 94(15), pp. e1645–e1656. Available at: https://doi.org/10.1212/WNL.0000000000009245.
Demortiere, S., Rico, A., Maarouf, A., Boutiere, C., Pelletier, J. and Audoin, B. (2020) ‘Maintenance of natalizumab during the first trimester of pregnancy in active multiple sclerosis’, Multiple Sclerosis (Houndmills, Basingstoke, England), p. 1352458520912637. Available at: https://doi.org/10.1177/1352458520912637.
Durozard, P., Rico, A., Boutiere, C., Maarouf, A., Lacroix, R., Cointe, S., Fritz, S., Brunet, C., Pelletier, J., Marignier, R. and Audoin, B. (2020) ‘Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibody Diseases’, Annals of Neurology, 87(2), pp. 256–266. Available at: https://doi.org/10.1002/ana.25648.
on behalf of the OFSEP, SFSEP, and NOMADMUS study groups, Maillart, E., Durand-Dubief, F., Louapre, C., Audoin, B., Bourre, B., Derache, N., Ciron, J., Collongues, N., de Sèze, J., Cohen, M., Lebrun-Frenay, C., Hadhoum, N., Zéphir, H., Deschamps, R., Carra-Dallière, C., Labauge, P., Kerschen, P., Montcuquet, A., Wiertlewski, S., Laplaud, D., Runavot, G., Vukusic, S., Papeix, C. and Marignier, R. (2020) ‘Outcome and risk of recurrence in a large cohort of idiopathic longitudinally extensive transverse myelitis without AQP4/MOG antibodies’, Journal of Neuroinflammation, 17(1), p. 128. Available at: https://doi.org/10.1186/s12974-020-01773-w.
Maarouf, A., Rico, A., Boutiere, C., Perriguey, M., Demortiere, S., Pelletier, J., Audoin, B. and Under the aegis of OFSEP (2020) ‘Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?’, Neurology - Neuroimmunology Neuroinflammation, 7(5), p. e825. Available at: https://doi.org/10.1212/NXI.0000000000000825.
Demortière, S., Lehmann, P., Pelletier, J., Audoin, B. and Callot, V. (2020) ‘Improved Cervical Cord Lesion Detection with 3D-MP2RAGE Sequence in Patients with Multiple Sclerosis’, AJNR. American journal of neuroradiology, 41(6), pp. 1131–1134. Available at: https://doi.org/10.3174/ajnr.A6567.
Stellmann, J.-P., Maarouf, A., Schulz, K.-H., Baquet, L., Pöttgen, J., Patra, S., Penner, I.-K., Gellißen, S., Ketels, G., Besson, P., Ranjeva, J.-P., Guye, M., Nolte, G., Engel, A.K., Audoin, B., Heesen, C. and Gold, S.M. (2020) ‘Aerobic Exercise Induces Functional and Structural Reorganization of CNS Networks in Multiple Sclerosis: A Randomized Controlled Trial’, Frontiers in Human Neuroscience, 14, p. 255. Available at: https://doi.org/10.3389/fnhum.2020.00255.
Cousyn, L., Law-Ye, B., Pyatigorskaya, N., Debs, R., Froissart, R., Piraud, M., Federico, A., Salvatore, S., Cerase, A., Macário, M.C., Durães, J., Kim, S.H., Adachi, H., Audoin, B., Ayrignac, X., Da, Y., Henderson, R., La Piana, R., Laule, C., Nakamagoe, K., Raininko, R., Schols, L., Sirrs, S.M., Viader, F., Jastrzębski, K., Leclercq, D. and Nadjar, Y. (2019) ‘Brain MRI features and scoring of leukodystrophy in adult-onset Krabbe disease’, Neurology, 93(7), pp. e647–e652. Available at: https://doi.org/10.1212/WNL.0000000000007943.
Maarouf, A., Stephan, D., Ranjeva, M.-P., Ranjeva, J.-P., Pelletier, J., Audoin, B., Khrestchatisky, M. and Desplat-Jégo, S. (2019) ‘High levels of serum soluble TWEAK are associated with neuroinflammation during multiple sclerosis’, Journal of Translational Medicine, 17(1), p. 51. Available at: https://doi.org/10.1186/s12967-019-1789-3.
Melenotte, C., Seguier, J., Ebbo, M., Kaphan, E., Bernit, E., Saillier, L., Audoin, B., Feyeux, D., Daniel, L., Roche, P.-H., Graillon, T., Dufour, H., Boutière, C., Girard, N., Closs-Prophette, F., Guillaud, C., Tieulié, N., Regent, A., Harlé, J.R., Hamidou, M., Mekinian, A., Grados, A. and Schleinitz, N. (2019) ‘Clinical presentation, treatment and outcome of IgG4-related pachymeningitis: From a national case registry and literature review’, Seminars in Arthritis and Rheumatism, 49(3), pp. 430–437. Available at: https://doi.org/10.1016/j.semarthrit.2019.05.003.
Durozard, P., Maarouf, A., Boutiere, C., Ruet, A., Brochet, B., Vukusic, S., Carra-Dalliere, C., Labauge, P., Mathey, G., Debouverie, M., Papeix, C., Maillart, E., Lubetzki, C., Bensa, C., Gout, O., Giannesini, C., Stankoff, B., Ciron, J., Brassat, D., Pelletier, J., Rico Lamy, A. and Audoin, B. (2019) ‘Efficacy of rituximab in refractory RRMS’, Multiple Sclerosis (Houndmills, Basingstoke, England), 25(6), pp. 828–836. Available at: https://doi.org/10.1177/1352458518772748.
The OFSEP Group, The REEM Group, Cobo-Calvo, A., Sepúlveda, M., d’Indy, H., Armangué, T., Ruiz, A., Maillart, E., Papeix, C., Audoin, B., Zephir, H., Biotti, D., Ciron, J., Durand-Dubief, F., Collongues, N., Ayrignac, X., Labauge, P., Thouvenot, E., Montcuquet, A., Deschamps, R., Solà-Valls, N., Llufriu, S., Blanco, Y., de Seze, J., Vukusic, S., Saiz, A. and Marignier, R. (2019) ‘Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults’, Journal of Neurology, 266(4), pp. 806–815. Available at: https://doi.org/10.1007/s00415-018-9160-9.